Ira D. Glick, MD

8/6/2019 Ira D. Glick, MD

http://slidepdf.com/reader/full/ira-d-glick-md 1/97

STATE OF MINNESOTA ISTRICT COURT

COUNTY OF HENNEPIN OURTH JUDICIAL DISTRICTMedical Malpractice/Wrongful Dea

Court File No. 27-CV-07-1679Judge John L. Holahan

Mary W eiss, on her own behalf, and asnext of kin and Trustee of the estate ofDan Markingson, deceased,

Plaintiff,

VS .

Board of Regents For the University ofMinnesota; Dr. Stephen Olson; Dr. CharlesSchultz; Institutional Review B oard for theUniversity of Minnesota; AstrazenecaPharmaceuticals LP; Astrazeneca LP;and Zeneca,

Defendants.

DEFENDANTS DR. STEPHENOLSON'S AND DR. CHARLESSCHULZ'S AND THE UNIVERSITYOF MINNESOTA PHYSICIANS'

DISCLOSURE OF FINDINGS ANDOPINIONS OF EXPERT WITNESSIRA D. GLICK, M.D.

It is expected that Ira D. Glick, M.D., a medical doctor and psychiatrist duly li

practice medicine in the States of New York, California and M aryland, will be calledan expert witness at the time of trial. A copy of his Curriculum Vitae is attached as Exhibit "Awhich sets forth information pertaining to his background, education, training, hospiappointments, board certification, licensure, professional affiliations, honors/awardspublications and presentations.

Dr. Glick has reviewed the following docum ents and case-related materials:

1 . opies of the medical charts and records of Dan Markingson, also knowDaniel Weiss, deceased, from the following healthcare providers:

a. Fairview University Medical Center;b. Minnesota Regional Coroner's Office;c. Regions Hospital;d. Theodore I Residence/Boston Health Care Systems;e. Dr. Victor Amira;f. Children's Health of St. Paul;g. Group Health/HealthPartners;h. Dr. Joseph Gryskiewicz;



i. University Health Service, Ann Arbor;j. University of Minnesota, Department of Psychiatry;k. Dakota County;1 . agan Counseling Clinic;m. Pharmerica;

2. n addition to medical records, Dr. Glick has reviewed the following minformation regarding this matter:

n. Deposition transcript of Dr. Olson;o. Deposition transcript of Dr. Schulz;P. eposition transcript of Mary Weiss;q. Deposition transcript of Mike Howard;r. Deposition transcript of Dr. Arlow Andersen;s. Deposition transcript of David Pettit;t. Deposition transcript of Stacy Hohler;

u. Deposition transcript of April Arnold;v. Deposition transcript of Daniel Buse;w. Expert Disclosures of James I. Hudson, M.D. and Harrison G. Po

Keith A. Horton, M.D., Paul Root Wolpe, Ph.D., and Donald L.Frankenfeld, Economist.

x. E-mails written by Dan Markingson to his mother, Mary Weiss;y. Investigative report of the Office of the Ombudsman; andz. Report of Department of Health & Human Services.aa. uly 22, 2005 Establishment and Inspection Report by the FDA w

Sharon L. Matson, Investigator.bb. nformed Consent Document.cc. re-petition Screening Team Recommendations dated November

2003.dd. rder to Confine, to Transport for Examination, Hearing, Appoin

Attorney, Examiner and Notice by Judge Edward Lynch dated No17, 2003.

ee. dult Consent Form for CAFÉ Study Participation signed on Nov21, 2003.

ff. indings of Fact, Conclusions of Law, and Order for Stay of Comby Judge Robert F. Carolan dated November 20, 2003.

gg. arious correspondences written by Mary Weiss.hh. etters written back to Mary Weiss from a variety of individuals.

Journals kept by Mr. Markingson.11. he Am erican Journal of Psychiatry July 2007, published results

Café Study.

Dr. Glick is expected to testify at trial on issues of the standard of care, causatdamages, and the nature, extent and duration of Dan Markingson's medical conditialso respond to any and all findings and opinions expressed by each and every one oPlaintiff's medical experts.

2



Dr. Glick's testimony will be based upon his education, training and experience, as welas his understanding of the m edical teachings and practices which pertain to the issuin this case. In formulating his findings and opinions, he has reviewed and taken intoconsideration Mr. Markingson's medical records, information and additional discovery materiprovided to him for his review as listed above. All of Dr. Glick's opinions will be stated to areasonable degree of m edical and psychiatric certainty, unless otherwise specified.

Dr. Glick is expected to testify that that Dr. Stephen Olson and Dr. Charles Schprovided reasonable and appropriate care and treatment to Mr. Markingson. He will opine thateach one of them satisfied the standard of care applied to them as physicians in theirroles, as study investigators, and in the case of Dr. Schulz, as the head of the Department ofPsychiatry at the University of Minnesota. Dr. Glick will testify that Mr. Markingson'sparticipation in the CAFE Study in conjunction with all of the additional care and trewas receiving through Theodore I House, adult group therapy at the Fairview Day TCenter, individual therapy with Dr. Arlow Andersen, and monitoring by David Pettit

County was reasonable and appropriate care and treatment for Mr. Markingson. Dr. Glick is alexpected to testify that the care and treatment rendered to Mr. Markingson by Dr. OlSchulz did not cause or con tribute to Mr. Markingson's suicide and ultimate death.

Factual Background

Daniel Weiss was born on November 25, 1976. He was the only son of Mary Weiss andTom Rosner, who never married. Ms. Weiss raised her son as a single parent. Mr. Markingsondid not have a relationship with his biological father. It does not appear that Mr. Markingsonhad a strong male influence in his life during his formative years.

Beginning in approximately 1983, Mr. Markingson was seen repeatedly throughout hischildhood for complaints of headaches. His medical records reflect the fact that the source of hheadaches may have been stress-related. On October 3, 1984, counseling was recommended toMs. Weiss for her son's ongoing headache complaints. The same recommendation againoccurred on January 29, 1985. It does not appear that Mr. Markingson received the counselingthat was recommended.

From A pril 1986 through 1992, Ms. Weiss had her son seen many times for hecomplaints. He received neurology, relaxation therapy, chiropractic care, saw anophthalmologist and also saw allergists to determine the source of the headaches. A neurologissuggested to Ms. Weiss that the source of the headaches were muscle contraction, i.e

In August 1989, Mr. Markingson was placed on amitriptyline, brand name Elavil. Elaviis often prescribed for the relief of symptoms of mental depression. It is a member of the groupof drugs called tricyclic antidepressants. It is unclear, based on the records, why Mr.Markingson was placed on this medication. It appears that Mr. Markingson may have remaineon E lavil throughout his high school years.

3



Mr. Markingson completed his high school education and then took one year off to writa book and/or screenplay. Thereafter, he attended Hamline University for his freshman andsophomore years. He transferred to the University of Michigan where he completed his studiein 2000, and received a B.A. in English. In the late summer or early fall of 2000, Mr.Markingson m oved to Los Angeles, California.

The records reflect that Mr. Markingson's intended career path was to become an actorand/or writer. When he first arrived in Los Angeles, he worked a series of odd jobs, whichincluded selling papers for the L.A. Times and doing office work in an accountant's office. Theonly steady job he held was at Star Line Tours as a tour guide. He was employed there fromFebruary 15, 2002 through August 2003. Initially, he worked full time at Star Line Tours, butchanged his status to part time in early 2003. It is believed Mr. Markingson unexpectedlyresigned from that position in August 2003.

Ms. Weiss visited her son shortly after he moved to California in 2000. However,according to Ms. Weiss, their relationship completely changed after that visit. Ms. Weiss

described the fact that her relationship with Mr. Markingson "totally deteriorated." He stoppedcalling her and he stopped writing to her. She described the fact that after that visit,coim-nunication between herself and her son completely ended. During Mr. Markingson'sresidency in California, he changed his last name from Weiss to Markingson. It is unknown whMr. Markingson chose to change his last name.

Ms. Weiss went to California in August 2003 to attempt to reconnect with her son. Wheshe went out to Los Angeles, she had difficulty finding him and had to contact his emdiscern his whereabouts. Ultimately, Ms. Weiss was able to find her son and, after some time,convince him to return to Minnesota. Ms. Weiss testified that upon seeing her son during thisinitial visit to Los Angeles, she believed that he was mentally ill. He made comments about th

fact that there would be an event that was go ing to occur, that people were watching that there were aliens present in his home. He also commented that he may be called upon toharm people prior to his return to Minnesota

Upon his return to Minnesota, Ms. Weiss arranged for her son to be seen at GroupHealth/HealtliPartners, This visit occurred on September 4, 2003. Prior to the visit, Ms. Weisshad called the office to report that her son had been experiencing memory loss and wA physical examination was conducted which appeared to be normal. Mr. Markingson alsounderwent laboratory tests. Those results showed a slightly underactive thyroid. Mr.Markingson's mental health was not specifically addressed at that visit. Mr. Markingson did notsee a psychiatrist, psychologist, therapist, or any other mental healthcare prov ider at

The records reflect that on or about September 9, 2003, M r. Markingson returnCalifornia. After his return to California, Mr. Markingson began exchanging e-mails with"Guardian Angel Daisy@ hotmail.com" and "Michael the [email protected]." These e-mails were exchanged from September 19 through September 23, 2003. Ms. Weiss assumed thidentity of "Guardian Angel Daisy" and "Michael the Archangel" and exchanged these e-mailswith Mr. Markingson. It is unknown whether or not Mr. Markingson knew that his mother wasthe author of these e-mails. In the context of these e-mails, Mr. Markingson discussed an event

4



that was purportedly going to occur in Duluth where he may be called upon to kill certainindividuals. It was the promise of this "big event" that prompted Mr. Markingson to return toMinnesota.

Mr. Markingson returned to Minnesota and moved into his mother's home, where sheresided with a male companion. Purportedly, Mr. Markingson spent the majority of his daysalone in his childhood room. According to his mother and her companion, he continued toexhibit what they believed to be delusional and paranoid behavior. He would repeatedly makereference to the "big event," "being the chosen one," and his belief that there were referencesbeing made about him on television. From the time of Mr. Markingson's return to Minnesota inlate September 2003 , up until November 12, 2003 , he did not see a psychologist, psytherapist, or a physician for his mental health condition.

Purportedly, on November 12, 2003, Mr. Markingson told Ms. Weiss' companion,Michael Howard, that he intended to slit his mother's throat. This threat prompted Ms. Weissand Mr. Howard to contact the police via 911. Mr. Markingson was transported in handcuffs

from Ms. Weiss's home to Regions Hospital. The police report indicates that Mr. Markingsonwas aggressive verbally at his mother's home and indicated that he was unwilling to go to thehospital. However, Mr. Markingson calmed down prior to his arrival at Regions Hospital.

Hospitalization

Mr. Markingson was originally transported to Regions Hospital emergently. A historywas taken from his mother by a social worker about Mr. Markingson's current mental healthcondition and history. She reported that Mr. Markingson had been discussing a "big event" thawas satanic in nature. She reported that he had made threats to cause her harm on the day of hitransport to the hospital. Mr. Markingson originally denied making these threats, but later

acknowledged that he may be contacted in the future to do so as a result of the upcomevent." He stated that he would decide whether or not to follow through. He also denied anysuicidal ideation or thoughts of harming others. The initial intake at Regions Hospital was donby Dr. Darren Manthey and Dr. Bradley Hernandez. They determined that Mr. Markingson waparanoid, delusional, grandiose and threatening to harm others. Due to a space issue and a statefamily preference, Mr. Markingson was transferred to Fairview University Medical C("FUMC").

Mr. Markingson was admitted to FUMC on a 72-hour hold by resident, Dr. JohPrior to his admission to the psychiatric ward at FUMC, Drs. Darling and Olson took a historyand performed an examination of Mr. Markingson. Dr. Olson verified Dr. Darling's findings and

signed off on them as the attending psychiatrist. Drs. Darling and Olson found that the patient'eye contact was good, but intense at times. His mood was noted to be "good," and his affect wbright, and at times expansive. Drs. Darling and Olson found that his thought process wascoherent and linear. Drs. Darling and Olson also found that the patient's thought content waspositive for delusions, paranoia and ideas of reference. Mr. Markingson's insight and judgmentwere noted to be impaired by his significant delusional framework. Drs. Darling's and Olson'sinitial impression was that Mr. Markingson had a recent onset of multiple delusions andpsychotic symptoms that had been developing in recent months. Drs. Darling's and Olson's

5



diagnosis was psychosis and mood disorder, to rule out bipolar affective disorder, psschizophrenia.

On November 13, 2003, Dr. Olson wrote his admission note for Mr. Markingson. Thebasis of the information contained in that note came from both M r. Markingson him

as his mother. Mr. Markingson acknowledged at that time that he did have some unusual beliebut attributed them to a lack of sleep and anxiety. Ms. Weiss advised Dr. Olson that she had havery little contact with her son over the last year and a half Ms. Weiss also informed Dr. Olsonshe recently exchanged e-mails with her son using false identities. Dr. Olson's notes reflect thaMr. Markingson appeared to be downplaying his psychosis and trying to present himbest possible light. Dr. Olson's diagnosis for Axis I. was Psychosis NOS, and a differentialdiagnosis to include paranoid schizophrenia, schizoaffective disorder, and b ipolar dimanic psychosis. Dr. Olson noted that the patient had an extended period of deterioration andelaborate, disorganized and fragmentary delusional thinking suggestive of paranoidschizophrenia. However, Dr. Olson could not rule out bipolar disorder given the patient's claimof a sleep disorder and increased level of self-esteem. The 72-hour hold was to remain in place

and Dr. Olson prescribed Risperdal for the patient. Mr. Markingson initially refused to takeRisperdal.

On November 14, 2003, Mr. Markingson met with the pre-petition screening team. Atthat point in time, it was noted that the patient did not have the capacity to make decregarding neuroleptic medication, and a Jarvis petition was being considered. During theinterview, Mr. Markingson advised the screening team that he would be willing to be a voluntapatient and follow his physician's recommendations, but that he did not want to take anyneuroleptic medication. Dr. Olson also spoke to the pre-petition screening team, and advisedthem that the patient had bizarre beliefs and lacked insight into the cause of those beliefs. Therwas also concern about whether the patient would follow through without patient car

an admission to an inpatient facility would be necessary. Commitment was ultimatelyrecommended by the screening team and Dr. Olson.

In conjunction with the recomm endation of the screening team for commitmenOlson wrote an examiner's statement in support of the petition for commitment. This waswritten on November 14, 2003. Dr. Olson described the history of the bizarre thinking of thepatient and his threats to harm his mother. Dr. Olson advised the court that the development ofthe delusional thinking appeared to have occurred in the last 6-18 months and that the patientlacked a prior history of psychosis. He also reported to the court that the patient lacked insightinto the causation of his delusional thinking. Dr. Olson advised the court that his diagnosticimpressions and conclusions were that the patient had psychosis NOS; paranoid schizophreniaversus psychiatric mania versus psychosis due to a medical condition. In Dr. Olson's opinion atthat time, Mr. Markingson was at high risk for acting on his delusions. This was submitted to tcourt, along with the pre-petition screening team's recommendation for commitment.

According to a progress note written by Dr. Olson at 5:00 p.m. on November 14, he mewith Mr. Markingson and filled out the examiner's statement in support of the petition forcommitment. This note reflects that on the evening of November 13, 2003, Mr. Markingsonagreed to take the prescribed anti-psychotic medication Risperdal. Thus, his medication use

6



started at that time. Also, during Dr. Olson's meeting with Mr. Markingson, he admitted that hunusual beliefs had gone on longer than he had originally acknowledged, but would for how long. He also continued to deny some of the history that had been reported by hismother. However, he did admit that he had been concerned about a satanic cult, his mother'sidentity, being "the one," and having Angelina Jolie as his sister. Overall, Dr. Olson noted that

the patient appeared to be minimizing his past thoughts, and that his insight and judgimpaired. Dr. Olson questioned whether or not Mr. Markingson was sincere about voluntarilyagreeing to seek treatment. Thus, he was of the opinion that going forward with the commitmewould be appropriate and that a Jarvis hearing may be necessary if the patient did nobe medication compliant.

On November 17, 2003, a Dakota County District Court Judge set forth an OrConfine, to Transport for Exam ination, Hearing, Appointment of Attorney, ExamineNotice. The petition was brought by Kathryn Knight for judicial commitment of DanielMarkingson as a mentally ill person. The judge ordered that FUMC was to retain custody of MMarkingson for observation, evaluation, diagnosis and emergency treatment. A Jarvis petition

was not sought because Mr. Markingson had remained compliant and was taking his Risperdalprescribed.

After taking the medication for several days, Mr. Markingson's case manager andtherapist, Kathleen Bernhaft, wrote the treating physician's recommendations to the court. Therecommendation of FUMC and Dr. Olson was that a stay of commitment would be aThe reason being that Mr. Markingson had been cooperative with his inpatient treatmin the process of developing an aftercare plan. Further, Mr. Markingson had been medicationcompliant. The diagnosis at that time was psychosis NOS, mood disorder NOS, rule out bipolaaffective disorder with psychosis and schizophrenia.

Erin Holker, Ph.D. LP at FUMC performed a neuropsychological evaluation oMarkingson on November 18, 2003. Testing was done to determine Mr. Markingson'sintellectual functioning level and his cognitive impairment, if any. The testing revealed that MMarkingson's overall intellectual functioning was in the superior range. Moreover, no cognitivedifficulties were noted which could potentially interfere with Mr. Markingson's ability toactively participate in his own care and treatment. Mr. Markingson told Dr. Holker of his desirto continue the use of Risperdal and that he was comm itted to participating in his cartreatment.

On November 19, 2003, Dr. Olson discussed the CAFE Study with Mr. Markingson andhis mother. According to his November 19 note, both Mr. Markingson and his mother wereinterested in the Study. Dr. Olson provided them both with materials for their review andconsideration. Assessment of informed consent was not limited to this single session. This wasan ongoing process during Mr. Markingson's hospitalization. Dr. Olson continued to assess hisability to understand the information presented to him. Dr. Olson also continued to presentinformation to Mr. Markingson about alternative care options.

Dr. James Jacobson conducted an examination of Mr. Markingson on November 19,2003, pursuant to the court's order. Dr. Jacobson's diagnosis for Axis I of Markingson was

7



psychosis, NOS, rule out mood disorder, NOS, rule out bipolar disorder with psyrule out schizophrenia. Dr. Jacobson took a history and performed an exam on MrDr. Jacobson found that Mr. Markingson was fully oriented and that his thinking wgoal directed. He did not appear to be delusional, but did admit having peculiar thpast. He expressed to Dr. Jacobson his consent to the stay of commitment. Drrecommendation to the court was that Mr. Markingson remain hospitalized foevaluation to ensure that his recent mental health improvements continued. He alsorecommended that a commitment or a stay of commitment would be approprMarkingson. A Jarvis hearing was not recommended by Dr. Jacobson because Mwas compliant with his medication and he agreed to continue to take his medication

On November 20, 2003, Mr. Markingson appeared in court. During this procwas represented by an attorney. At that time, Mr. Markingson indicated that he volagreeing to a stay of commitment. He admitted to being mentally ill and in need ofThe commitment was to be stayed for six months with a list of terms that includedrespondent remain hospitalized, cooperative with the treatment plan at Fairview Uni

Medical Center until medically discharged, and follow all of the aftercare recommethe treatment team; (b) that the respondent enter, participate in and satisfactorily cominpatient/outpatient treatment program and aftercare recommendations as determinesocial worker; (c) that the respondent cooperate with the treatment plan and follow tany living facility as arranged by his social worker; (d) that the respondent consent tor re-admission to a hospital or other appropriate care facility as determined by the rsocial worker in the event of a relapse; (e) that the respondent take drugs or medicatprescribed, and abstain from the use of any non-prescribed drugs or alcohol; (f) thatrespondent see a psychiatrist and/or therapist as frequently as recommended; (g) tharespondent engage in no behavior which is threatening or injurious to self or others;respondent participate in any day treatment program or community support services

respondent participate in family therapy if recommended; (j) that the respondent siginformation authorizing his social worker and the various service providers to exchainformation; and (k) that the respondent cooperate with his social worker as determi

On November 21, 2003, Mr. Markingson agreed to participate in the Cafe Stsigning the informed consent, he underwent an evaluation with Jeanne Kenny, a Stucoordinator, and Liz Lemke, an assistant working on the Study. Mr. Markingson paevaluation and was able to provide information about potential side effects, things him, and his right to withdraw from the Study at any point in time. Thereafter, Mr. read the consent form, had the consent form read to him, and signed the consent formpresence of Dr. Olson and Ms. Kenney. The informed consent set forth the purposethe Study sponsor, Mr. Markingson's right to withdraw from the Study at any time, alternative care and treatment available to Mr. Markingson, Mr. Markingson had thto ask any questions and raise any concerns prior to signing the information consenhe agreed to participate and signed.

Despite signing the informed consent to participate in the CAFÉ Study, Mr. Mdid not begin the medication for that Study until December 5 , 2003. He continued He was slowly tapered off the Risperdal after December 5, 2003 .

8



Mr. Markingson's first screening visit for the CAFÉ Study occurred on November 24,2003. A history of Mr. Markingson's onset of his mental illness was taken at that point in time.It was noted that the medication he was taking at the time of that visit was Risperdalpm. The diagnosis was schizophrenia paranoid type, to rule out psychosis NOS and

schizophreniform. It was noted that the patient did in fact meet the criteria for schizophrenia,and therefore did meet the diagnostic criteria for the trial.

By November 25, 2005, Mr. Markingson was noted to be tolerating his Risperdal withodifficulty. He also appeared to be gaining more insight into his prior delusional and paranoidbehavior. Mr. Markingson reported at that point in time that he was having tension with hismother and was noted to be upset with her for her decision to not allow him to reside in her hopost discharge.

On November 26, 2003, Mr. Markingson met for the first time with his case mand/or assigned social worker from Dakota County, David Pettit. During this meeting, Mr. Pet

met with Dr. Olson, Ms. Weiss and Mr. Markingson. At that point in time, Dr. Olson presentedthe CAFE Study to Mr. Pettit for his review and consideration. Mr. Pettit acknowledged that hbelieved that the care and treatment provided in the CAFE S tudy was reasonable andappropriate. He also stated that in his opinion, this provided Mr. Markingson with moreinteraction with his medical care providers than if he was discharged in the normal fUltimately, Mr. Pettit agreed to allow Mr. Markingson to participate in the CAFE Study.

On December 3 , 2003, Dr. Olson did an additional assessment of Mr. MarkingCAFE Study. Mr. Markingson indicated that he was working on being comfortable with the fathat he had psychosis. He also indicated a willingness to move to a group home. Once again,Mr. Markingson consented to treatment and to his participation in the CAFE Study.

On December 8, 2003, Mr. Markingson was discharged from FUMC. He was beingtransferred to Theodore I House run by Boston Health Care Systems. The Theodore I House("Theo House") at the time was a Rule 36 facility with around-the-clock staff. The decision tohave Mr. Markingson at this facility was based upon the recommendations of Mr. Pe

Dr. Olson's discharge diagnosis on December 8, 2003, was psychosis NOS, probableschizophrenia, and questionable history of alcohol abuse versus dependence. Mr. Markingsonwas noted to have mild hypothyroidism and had been placed on Synthroid. Over the course ofMr. Markingson's hospitalization, Dr. Olson became aware of the fact that he and his mother ha stressful relationship. Further, according to the history provided by Ms. Weiss, she and her so

had not had contact for a substantial period of time. Dr. Olson noted that throughout Mr.Markingson's hospitalization, he remained guarded and superficial, although he did admit tohaving unusual and delusional thoughts. Dr. Olson also noted that Mr. Markingson continued tminimize his mental illness and the events leading up to his hospitalization.

9



CAFÉ Study

The CAFÉ Study was a 52 week randomized, double-blind, flexible dose mustudy to evaluate the overall effectiveness, as measured by discontinuation rates ofOlanzapine, Quetiapine and Risperidone in patients early in the course of psychotic

There were 24 sites throughout the United States where the CAFE Study was conduP. McE voy and Jeffrey Lieberman served as the head research physicians of the StuStudy was sponsored by Astrazeneca Pharmaceutical Company. A total of 400 patierandomly assigned to treatment with one of the three drugs. The University of Minnone of the site locations. Dr. Olson served as the principal investigator at the UniveMinnesota site, with Dr. S. Charles Schulz and Dr. John Vuchetich serving as co-inv

The CAFÉ Study was modeled after the CATIE Study that had been conducteNational Institute of Mental Health (NIMH). That Study was conducted to determinterms effects and usefulness of antipsychotic medications in persons with schizophrStudy tested the anti-psychotic medications Olanzapine, Quetiapine, Risperidone, C

Ziprasidone, as well as Perphenazine and Fluphenazine Decanoate. The CATIE Stuapproximately 18 months. The majority of sites which conducted the CAFE Study, participated in the CATIE Study. The CAFE Study was set up to mimic real-world cThat is a distinct difference in the CAFE Study from other types of clinical research.

Mr. Markingson attended 11 visits during his participation in the Café Study. summary of assessment ratings for the CAFE visits, was as follows:

SUMMARY OF ASSESSMENT RADate and Visit # Screen

11/24/03Baseline12/5/03

Visit 112/11/03

Visit 212/19/03

Visit 312124103

Visit 412/31/03

Visit 51/8/04

Visit 61/16/04

Visit 71/30/04

Visit 82/13/04

Visit 93/2/04

Visit 103/31/04

Visit 114/28/04

ANSSositive Symptoms

Negative Symptoms

1 3

11

7

1 1

1 2

10

10

7

7

9

7

7

7

9

7

10

1 3

20

1 0

1 8

Calgary Depression Ratingcale

Suicide Sub-rating

10 9 - absent

I

9

1

9

1

9

I

9

1

9

1

9

1

9

1

9

1

ositive and Negativeyndrome Scale

23 — notcomplete

44 40 45 40 35 32 35 36 52 55

linical Global Impressions5 4 3 3 2 2 2 2 2 2 4 3dverse Event/Side Effects None None None 3 -

sleepiness3 -sleepiness

None None 2 — sleepiness2- insomnia

None None None None

bnormal InvoluntaryMovement Scale

0 0 0 0 0 0 0 0 0

arnes Rating for Drugnduced Akathisia

0 0 0 0 0 0 0 0

impson Angus Abbrev 0 0 0 0 0 0 0 1Medication Adherence 9 8 9 8 9 8 9 8 8 8 8

lcohol/Drug Use Scale 1 -abstinent

1 -abstinent

2 -alcohol

1 —

abstinent1-

abstinent2 —alcohol

ealth Care Servicetilization

32 30 32 30 34 27

einrich Carpenter Qualityf Life

98 92

nsight and Treatmentttitude

16 22

10



These rating scales demonstrate an improvem ent in the positive symptoms ofschizophrenia seen with treatment and the low level of schizophrenia and depressivethroughout the duration of the Study. The positive and negative scales have 30 items groupedinto positive, negative and general subscales. The November 24, 2003 screening retrospectiverating of 5 selected positive symptom items totaled 23, indicative of moderately seve

symptomology (23/5 = 4.6; 4 = moderate, 5=moderate severe). However, by the time of thebaseline ratings, Mr. Markingson's score on the full 7-item subscale had dropped to 13 andremained in the range of 7-13 for the entire six months prior to his death. His scores of 7-13represent a near total resolution of psychosis showing a marked improvement. Further, thesescores reflect that Mr. Markingson's delusional thoughts, hallucinations and paranoia werenearly totally absent.

The PANSS Ratings had minimum scores of 7 for positive and negative subscfor the general symptom subscale. Mr. Markingson's negative subscales scores increased from11 at his baseline visit to 18-20 by visits 10 and 11; his general scores went from 20 to 26-28 at visits 10 and 11. These scores are in the minimal to mild range, and as reflected in

the clinical notes, a moderate deterioration in self-care and grooming. In general, antipsychoticmedications exert their therapeutic benefit almost exclusively on positive symptoms, and thereno requirement to change medication due to an increase in negative symptoms.

The medication that Mr. Markingson was assigned in the Study was learned afdeath to be Seroquel, also known as Quetiapine. Each capsule of the Study medication contain100 mg of Quetiapine. The maximal dose was 8 capsules per day, corresponding to a totalmaximum dose of 800 mg. From December 5, 2003 to December 10, 2003, Mr. Markingsonwas taking two pills per day. From December 11, 2003 to December 13, 2003, he was taking atotal of four pills per day. From December 14, 2003 to December 19, 2003, he was taking a totof five pills per day. From December 20, 2003 through March 31, 2004, Mr. Markingson was

taking a total of 7 pills per day. From April 1, 2004 onward, he was taking a total of 8 pills perday. At that point, he reached the maximum dose of 800 mg. of Seroquel.

1. r. Olson

Dr. Olson provided care and treatment to Mr. Markingson throughout the courhospitalization. In addition, Dr. Olson saw Mr. Markingson after his discharge. His documentedvisits with Mr. Markingson occurred on December 11 and 19, March 2 and 31, and April 9. Alof these visits were very lengthy; 30 minutes to one hour. Dr. Olson also recalled speaking witMr. Markingson at his January 30, 2004 visit. This meeting lasted 15 minutes to one-half hour.Therein, Dr. Olson addressed concerns about Mr. Markingson's medication compliance. Headvised Mr. Markingson about the importance of medication and what could happen if hestopped. In addition, Dr. Olson was present at several visits that were conducted by JeanneKenney. Ms. Kenney was the Study coordinator who had been trained to do the necessarytesting for the Study.

At those visits where Mr. Markingson was evaluated by Ms. Kenney, she performedsymptom ratings, side effect assessments, psychosocial education sessions, and othercomponents of the Study. Dr. Olson testified that he often came in midway through those visits

1 1



with Ms. Kenney and Mr. Markingson. When this occurred, Dr. Olson would examine Mr.Markingson and assess his condition. He would provide appropriate direction to Ms. Kenneyabout Mr. Markingson's assessment, medication and ongoing needs.

In addition, Dr. Olson and Ms. Kenney would discuss all of her findings and the progre

of Mr. Markingson. This would occur while Mr. Markingson was still at FUMC/ARC. Ms.Kenney and Dr. Olson would discuss whether or not Mr. Markingson was showing signs ofrelapse, possible side effects, or if there was any other major problem that had presented. Dr.Olson noted that he was available at all times to see Mr. M arkingson if such a proble

Mr. Markingson was also participating in a day treatment program at FUMC. Themultidisciplinary team at the day treatment facility met monthly to discuss clients. Dr. Olsonparticipated in those monthly meetings. During those monthly meetings, Dr. Olson and the daytreatment team would discuss Mr. Markingson's behavior and progress. Dr. Olson also recallshaving 2-3 private conversations with Dan Buse, Mr. Markingson's primary therapist in the datreatment program, regarding Mr. Markingson's mental state, progress and his mother's concer

about his ongoing alleged psychosis.2. r. Charles Schulz

Dr. Schulz saw Dr. Markingson on one occasion during his hospitalization at FThat visit occurred on November 29, 2003. Dr. Schulz had reviewed Mr. Markingson's medicalchart and interviewed him. Mr. Markingson was also examined by Dr. Schulz. Dr. Schulz foundthat the patient's thought process was logical, his mood was pleasant, and that his affect wasappropriate.

Dr. Schulz, as a co-investigator in the CAFÉ Study, did not have any one-on-one visits

evaluations with Mr. Markingson. He received one letter from the patient's mother, Mary Weisalthough she claims to have sent him a total of three letters. After receiving that letter from MsWeiss, Dr. Schulz investigated her concerns. Dr. Schulz met with Dr. Olson and Jeanne Kenneto discuss Mr. Markingson's involvement in the CAFE Study. That conversation included areview of Mr. Markingson's progress, medication use, and overall mental health. Dr. Schulzthen crafted a response to Ms. W eiss addressing each of her concerns.

Dr. Schulz, as a co-investigator on the Study, gave 10% of his overall time to tIn addition to serving as a co-investigator on the Study , Dr. Schulz is also the head oDepartment of Psychiatry at the University of Minnesota. His role as a co-investigator was to bavailable as a backup rater for Dr. Olson if that was necessary. In addition, he was alwaysavailable to Dr. Olson to answer any questions he might have, to discuss the progresstudy, or to d iscuss individual patients participating in the Study .

As previously indicated, Dr. Schulz is also the head of the Department of Psycthe University of Minnesota. The majority of his duties are administrative in nature. He alsodoes clinical work each year for 2-4 weeks working as an attending psychiatrist in thservice. He also sees outpatients for about four hours per week. During that timeframe, he willbe teaching residents and conducting supervision over his entire staff. Dr. Schulz also monitor

12



all of the physicians, fellows, residents, and other staff members working in the Department ofPsychiatry at the University of Minnesota.

3. Eakan Counselink Center

For individual therapy, Mr. Markingson was seen by Dr. Arlow Andersen, Ph.D. LP, ofthe Eagan Counseling Clinic located in Eagan, Minnesota. Dr. Andersen saw Mr. Markingsonon December 11, 2003, January 12, 2004, February 16, 2004, March 29, 2004, and April 26,2004. Each of Dr. Andersen's visits with Mr. Markingson lasted approximately one hour. Thisone-on-one therapy was a part of Mr. Markingson's discharge plan from the hospital. It was alsopart of the outpatient work suggested by Mr. Pettit as a part of Mr. Markingson's stay ofcommitment.

Dr. Andersen was aware of Mr. Markingson's participation in the CAFÉ Study. Thatinformation was learned from Mr. Markingson. In each of Dr. Andersen's visits, he found Mr.Markingson's thought process to be logical and coherent. Dr. Andersen also found Mr.

Markingson to have good insight and good judgment. In each of Dr. Andersen's visits, heassessed whether or not IVIr. Markingson was showing signs of harm to himself or oeach of his visits, he noted that this was either low without plan or absent. In fact, on his lastvisit with Mr. Markingson on April 26, 2004, he noted that any risk to self was absen

Dr. Andersen testified that he did not believe that Mr. Markingson showed signs of beinsuicidal during their last visit. They also discussed the fact that Mr. Markingson's stay ofcommitment had been extended at his last visit. Mr. Markingson reported to Dr. Anderson thathe did not object to the extension because he realized he was not prepared to return t

4. Day Treatment

Mr. Markingson participated in adult mental health day treatment at FUMC. Thisprogram was recommended by his social worker, David Pettit, as well as Dr. Olson. Hisparticipation was from January 14, 2004 through May 5, 2004. He was seen by Daniel Buse,HSW LLCSW, and Len I3ennati, OTR/L. Mr. Markingson attended day treatment on Monday,Wednesday and Friday each week for three hours per day. Two hours of the visits were in groutherapy, and one hour was dedicated to occupational group therapy.

Mr. Markingson had been referred to day treatment to provide structure, suppoeducation about his mental illness. The medical records of Mr. Buse indicate that throughoutMr. Markingson's stay in day treatment, he presented as stable and denied any psychotic

symptoms. Mr. Markingson also willingly acknowledged past delusional thoughts, andrecognized that his thoughts were bizarre in nature and content. Mr. Buse acknowledged that ooccasion, Mr. Markingson presented with some negative symptoms which included some effecflattening, social withdrawal and avoidance. Mr. Buse noted that Mr. Markingson had excellenattendance throughout the course of his participation in day treatment.

Mr. Buse noted in his discharge summary that Mr. Markingson indicated a willingness tbe discharged from day treatment as of May 5, 2004. Similarly, Mr. Bennati, in charge of his

13



occupational therapy, found that Mr. Markingson acknowledged his diagnosis of schand was receptive to continuing his medication use. Mr. Markingson's presentationoccupational therapy was noted throughout to be reserved and quiet. Some negativenoted by Mr. Bennati were that Mr. Markingson had a blunted affect, on occasion apdisheveled in his appearance, and at times was withdrawn. However, Mr. Buse and

both thought Mr. Markingson was mentally stable enough to be discharged from daMr. Markingson graduated from his day treatment program on or about May 5

rarely missed his scheduled appointments. The records from all of his providers seeindicate that he was ready for his transition into independent living, and that he wasto seeking further care and treatment for his ongoing mental illness.

5. heodore I House

After being discharged from FUMC, Mr. Markingson resided in a group homhome was a Rule 36 facility known as TheodoreI House ("Theo House") run by Boston Heal

Care. This facility was comprised of clients who were mentally ill, but not developdisabled. The group home provided 24 hours a day, 7 days a week staff care and moThe staff notes and depositions from staff members indicate that Mr. Markingson wreserved, but never exhibited delusions, hallucinations, or paranoid thinking. Mr. Mwas a resident of Theo House from December 8, 2003 until the time of his death onearly morning hours of May 8, 2004.

On or about January 23, 2004, the staff at Theo House became somewhat susMr. Markingson may be cheeking or palming his medication. In an effort to stop thathe staff put into a place a protocol where Mr. Markingson was required to take his straight from a cup, not allowing him to place it in his hand; he had to consume his

staff presence, and had to stay in the presence of staff for several minutes to ensure tswallowed the medication. This protocol began shortly after January 23, 2005, and until the time of Mr. Markingson's death. Staff believed Mr. Markingson continuedmedication as prescribed up until the time of his death.

According to the staff notes from Theo House, Mr. Markingson accepted extestay of commitment. Further, the staff notes reflect that Mr. Markingson was lookintransitioning into his own apartment and living independently. Staff notes and depoindicate that no one had any reason to believe that Mr. Markingson was consideringexhibiting behavior which would demonstrate he had suicidal ideation.

Assessment and Opinions

1. r. Stephen Olson

In the opinion of Dr. Glick, Dr. Olson did not violate the standard of care by hsimultaneous roles in regard to the care and treatment he rendered to Dan Markingsupon the training, experience, and knowledge of Dr. Glick, it is reasonable and apprindividual to serve as a principal investigator in a clinical trial, to be the personal ps

14



clinical trial, and also to be the primary care psychiatrist for a patient. However, Dr. Glick willclarify that there are truly only two roles that Dr. Olson assumed in this case. Those two rolesare principal investigator and treating clinician. According to Dr. Glick, it is standard practice clinical research for one psychiatrist to assume these roles. Dr. Glick believes Dr. Olson wasaware of a potential conflict and undertook necessary steps to avoid these conflicts. ThereforeDr. Olson satisfied the standard of care in each of these roles according to Dr. Glick. Dr. Olsonin no way violated the ethical code of conduct nor did he violate the applicable standaccording to Dr. Glick.

Dr. Glick will opine that regardless of his role, Dr. Olson's primary concern throughoutwas providing care that was in the best interests of his patient, Dan Markingson. Dr. Glick willacknowledge that some may view a conflict of interest amongst these roles. However, the onlytime these potential conflicts become concerning, is if the best interests of a patient are lost sigof, or if a psychiatrist does something wrong. Dr. Glick will testify that Dr. Olson never lostsight of the best interests of Dan Markingson, nor did he do anything wrong. In Dr. Glick'sopinion, Dr. Olson also made the appropriate efforts to safeguard against conflicts of

interfering w ith his care.Dr. Glick will also offer the opinion that it is a standard practice when doing clinical

research in the psychiatric research community for a psychiatrist to assume all three roles. It ismore common than not that a psychiatrist will serve as the principal investigator of the study, tprimary research psychiatrist of the study, and the primary care psychiatrist for the patient. Dr.Glick will testify this is the accepted m ethod of do ing clinical research and results infor patients.

It is the opinion of Dr. Glick that the Nuremburg Code, Declaration of Helsinki, theInternational Conference on Harmonization Good Clinical Practice Guideline, and FDA

Regulations and Guidelines are guidelines. These guidelines do not set forth the standard of caby which to judge clinical care. These guides set forth ethical considerations which, in someinstances, must be reviewed and accounted for in clinical trials. However, these guidelinescaimot be conclusively considered the standard of care req uired for clinical care.

Dr. Glick will opine that in obtaining informed consent from Mr. Markingson toparticipate in the CAFE Study, reasonable and appropriate methods were utilized. In hisopinion, the standard of care was satisfied when obtaining informed consent from MMarkingson. Informed consent is a process and is not limited to the signature on a singledocument. Dr. Olson followed all of the steps necessary to ensure that Mr. Markingson was noonly competent to give informed consent, but actually willingly agreed to participate

CAFE Study.As previously indicated, Mr. Markingson had been hospitalized since November 12,

2003. On or about November 13, Mr. Markingson began taking Risperdal. The notes reflect thatthe Risperdal had the desired effect on Mr. Markingson by helping him control his psychoticsymptoms. Risperdal was an appropriate antipsychotic medication for Dr. Olson to prescribe.He remained on Risperdal from November 13 until December 5, 2003, when he began to taperoff of the Risperdal and began the CAFE Study medication, later learned to be Seroquel. Durin

15



that timeframe, Mr. Markingson's psychotic symptoms began to stabilize, he was no longerhaving active hallucinations or delusions, and his thought processes were described tand organized. Further, he had coherent and clear thoughts.

In the opinion of Dr. Glick, Mr. Markingson's medical records revealed that he was

competent to give informed consent on November 21, 2003. A neuropsychological examinatioperformed by E rin Holker, Ph.D. LP on Novem ber 18, 2003, indicates that by that daMarkingson did not have cognitive impairments. Specifically, Dr. Holker's report indicates thatMr. Markingson's overall intellectual functioning was in the superior range. Further, Dr. Holkenoted that Mr. Markingson did not have cognitive difficulties that would interfere with his abilto actively participate in his own treatment. In the opinion of Dr. Glick, Mr. Markingson wasable to provide informed consent.

The informed consent form was signed by Mr. Markingson on November 21, 2; Inthe opinion of Dr. Glick, Mr. Markingson was competent and able to understand the CAFEStudy, and also to understand the informed consent process at that time. Mr. Markingson

remained competent throughout his participation in the CAFE Study, and according twas able to give ongoing informed consent which satisfied the applicable standard of

Dr. Glick will testify that it was reasonable and appropriate to have Jeanne K enLiz Lemke participate in the informed consent process. They had been adequately trainedthrough the CAFE Study on competence as well as doing the competency evaluation. Further,Ms. K enney had extensive knowledge about the CAFE Study, and therefore, was a reand appropriate person to participate in the informed consent process.

Dr. Glick will also opine that Dr. Olson's participation in obtaining informed consentfrom M r. Markingson was reasonable, appropriate and was within accepted standard

care. Dr. Olson followed every precaution to ensure that Mr. Markingson was competent toparticipate in giving informed consent. Further, Dr. Glick will opine that Dr. Olson reasonablypresented the CAFE Study as alternative care and treatment and did not coerce Mr. Minto participating. In the opinion of Dr. Glick, the informed consent process in no way caused ocontributed to Mr. Markingson's death.

Dr. Glick will testify that there was nothing about Mr. Markingson's being under a stayof commitment which barred his participation in the CAFE Study. Dr. Glick will opine thathaving Mr. Markingson placed under a stay of commitment, demonstrated Dr. Olson'scommitment to putting Mr. Markingson's best interests at the forefront of his care. There wereno legal limits that would have prohibited Dr. Olson from having a person under a stay ofcommitment participate in a clinical trial. Dr. Glick will opine it was reasonable and appropriatfor Dr. Olson to ask Mr. Markingson to voluntarily participate in the CAFE Study. Dr. Olson'sactions were within accepted standards of medical practice.

Dr. Glick will testify that Mr. Markingson was not coerced into participating in the CAFStudy. Further, Dr. Glick will testify that the stay of commitment did not order Mr. Markingsonto participate in the CAFE Study. Rather, Dr. Olson simply presented the CAFE Study asalternative care and treatment for Mr. Markingson. Ultimately, it was up to Mr. Markingson an

16



his county case manager to determine if they wanted to participate in the Study. They bothvoluntarily concluded it was appropriate for Mr.rMarkingson to participate. Dr. Glick will opinethat Mr. Markingson's participation in the CAFE Study was reasonable and appropriate care, anthat Mr. Markingson was not in any way forced or coerced into participating in the S

Dr. Glick is also supportive of the informed consent document utilized in the CStudy. In his opinion, this document reasonably set forth the risks and benefits of participatingin the CAFE Study. It stated the names and roles of all of the study investigators. It also setforth the study sponsor, Astrazeneca. More importantly, it set forth information that Mr.Markingson's participation in the Study was voluntary and that he could withdraw from theStudy at any point in time. Dr. Glick will opine that the document set forth a reasonable andappropriate amount of alternative care which Mr. Markingson could have sought. Dr. Glick wilalso testify that the document did no t exaggerate nor unduly em phasize any benefits Markingson's participation in the Study. Thus, in the opinion of Dr. Glick, the informed consentdocument in and of itself was reasonable and appropriate and satisfied the standard o

Dr. Glick will testify that it was reasonable and appropriate for Mr. Markingsonparticipate in the CAFE Study. The CAFE Study utilized three FDA-approved antipsychoticmedications. No placebo was involved in the Study. In the opinion of Dr. Glick, this is anexceptionally important aspect of the CAFE Study. At no point in time was Mr. Markingson atrisk of having his psychotic symptoms go unmedicated. Instead, the CAFE Study involved threantipsychotic medication which have a marked impact on the positive symptoms, somsymptoms, and cognition. Thus, in the opinion of Dr. Glick, Mr. Markingson's participation inthe CAFE Study was reasonable, appropriate and satisfied the standard of care.

In Dr. Glick's opinion, it is absolutely clear that Mr. Markingson suffered fromschizophrenia. The medical records also reflect that Mr. Markingson appeared to have a

substance abuse issue. There is absolutely no basis to deduce any other diagnosis of the patientDr. Glick believes that Dr. Olson took the appropriate amount of time to assess the padetermine his diagnosis. Dr. Glick is supportive of the diagnosis reached by Dr. Olson for Mr.Markingson.

Dr. Glick will opine that there is no evidence that Mr. Markingson was bipolar orsuffered from any other mental illness. He will concede that it was appropriate to rule outbipolar as a potential diagnosis for Mr. Markingson. However, in his opinion, under nouncertain terms, Mr. Markingson was not bipolar. Thus, Mr. Markingson met the Studyinclusion/exclusion criteria and was appropriately enrolled in the S tudy.

Dr. Glick will also opine that Mr. Markingson had substantially more monitoring andinvolvement with mental healthcare professionals than he would have received had hin the standard method. The standard method of care called for antipsychotic medication andsome support, i.e., one-on-one psychiatric visits or some form of therapy. In a standard caresetting, Mr. Markingson would have had long periods of time without being seen by psychiatrist. Further, he would have been responsible for taking his own medication with verylimited monitoring. Due to Mr. Markingson's involvement in the CAFE Study, he was receivingsubstantially more m onitoring that he would have received in standard private practi

17



In addition to the greater amount of m onitoring he was receiving because of hiparticipation in the CAFE Study, he was also receiving a great deal of care through hparticipation in the adult day treatment program at FUMC, by being seen by an individualtherapist one time a month, living at Theo House and having 24 hour around the clock care, an

the additional monitoring of his county case manager. According to Dr. Glick, the standard ofcare and level of monitoring Mr. Markingson received, was above and beyond reasonable andappropriate care. Dr. Glick will opine that the level of monitoring involvement with mentalhealthcare professionals Mr. Markingson had, did not in any way cause or contribute to hisdeath.

The evidence throughout the medical records indicate that Mr. Markingson wawell aware of his opportunity to seek alternative care and treatment, to seek a secondand to withdraw from the CAFE Study. Providing Mr. Markingson with this vital informationwas reasonable and appropriate according to Dr. Glick. Mr. Markingson was a competent adultand was the only one who could make that decision. Further, his county case manager never

requested alternative care for him. Dr. Glick will opine that providing Mr. Markingson with allof this information satisfied the standard of care. This did not cause or contribute to his death.

Dr. Olson also testified that he provided information to Mr. Markingson aboutalternatives to his participation in the CAFE Study. According to Dr. Olson, he described forMr. Markingson his right to seek standard medical care. Providing verbal information, inaddition to the written information received by Mr. Markingson, was reasonable and according to Dr. Glick. Dr. Glick will testify that providing this information to Mr. Markingsonin no way caused or contributed to Mr. Markingson's cause of death.

Dr. Glick is of the opinion that it was reasonable and appropriate to seek an extension oMr. Markingson's stay of commitment in May 2004. According to the medical records, as wellas the deposition testimony, in March and April 2004, Mr. Markingson began to comment upohis desire to return to California. He indicated that he was going to travel there without anyrealistic financial planning to get there, and he did not have in place any healthcare system whcould continue to address and assist him with his ongoing mental illness.

Dr. Glick will opine that there is absolutely no evidence that the stay of com misought for any other reason than to ensure appropriate care and treatment for Mr. MaThere is absolutely no evidence that the stay of commitment was sought based upon retain Mr. Markingson in the CAFE Study. Further, Dr. Glick will opine that there was nocoercion by Dr. Olson to have M r. Markingson continue to participate in the stay ofcommitment. The decision to extend the stay of commitment was reasonable and appropriateand satisfied the standard of care according to D r. Glick.

Dr. Glick will opine that based upon his review of the PANS S scores and recoopinion, Mr. Markingson was experiencing sporadic signs of demoralization. However, Dr.Glick does not believe that there was a gradual deterioration over time that ultimatelMarkingson's death. Dr. Glick believes that Mr. Markingson experienced sporadic ups anddowns which would be typical for a person suffering from schizophrenia and dealing with that

18



mental health disorder. Dr. Glick does not agree that Mr. Markingson was in a gradual spiraldown in his mental health condition which caused or contributed to his death. Therefore, Dr.Glick will opine that Dr. Olson reasonably and appropriately monitored Mr. MarkingTherefore, Dr. Olson's care and treatment to Mr. Markingson was in accord with acceptedstandards of medical practice.

Dr. Glick is also prepared to address the assertion that Dr. Olson should have pMarkingson on a different antipsychotic medication. The use of Seroquel, or any of theantipsychotic medication in the Study, was reasonable and appropriate care and treatment. In thopinion of Dr. Glick, the use of Seroquel did stabilize Mr. Markingson and substantially reducand minimized his psychotic symptoms. The ongoing problems experienced by Mr. Markingsowere negative symptoms from his underlying condition. Dr. Glick will testify and explain thatnegative symptom s generally are not easily treated through the use of medication.

Dr. Olson did provide good clinical care both as Mr. Markingson's inpatient psychiatristas well as the principal investigator and Study physician for the CAFE S tudy, accord

Glick. Dr. Olson saw Mr. Markingson on a consistent and regular basis throughout hishospitalization at FUMC. Further, Dr. Olson saw Mr. Markingson on December 11 and 19,2003. Thereafter, he saw him on January 30, March 2 and 31, and April 9. Dr. Olson testifiedthat there were several visits from December through Febmary where he saw Mr. Markingson the end of his CAFE visits during which time he met with Mr. Markingson and evaluated him

In addition, Dr. Olson was m eeting once a month with the day treatment staff tMr. Markingson's progress and overall wellbeing. Dr. Olson would also have regular interactionwith Jeanne Kenney and would discuss her observations of Mx. Markingson, as wellassessments of his progress. Dr. Olson interacted with Mr. Markingson and evaluated him asubstantial amount according to Dr. Glick. The care and treatment rendered by Dr. Olson was

reasonable and appropriate care. By taking the additional steps to interact with other personsproviding care to Mr. Markingson, Dr. Olson took an additional step above and beyonecessary standard of care. In the opinion of Dr. Glick, in no way did his care and treatmentcause or contribute to Mr. Markingson's death.

According to Dr. Glick, there is absolutely no validity to the allegation that Dr. Olsonwas a "absent" principal investigator, Study psychiatrist, or individual psychiatrist. Dr. Olsontook his role as Mr. Markingson's primary care psychiatrist, the principal investigator of theCAFE Study, and the psychiatrist for the CAFE Study very seriously. The care and treatment hprovided to Mr. Markingson was at all times reasonable and appropriate. In no way did the carand treatment rendered by Dr. Olson as the principal investigator of the Study, the Stphysician, nor as Mr. Markingson's primary caregiver, in any way cause or contribute to Mr.Markingson's death.

Dr. Glick will also opine that it was reasonable and appropriate to have Jeanneparticipate in the evaluations and diagnostic interviews with Mr. Markingson. Ms. Kenneyreceived the appropriate training and experience to do that testing. Further, she consulted withDr. Olson on each of her visits with Mr. Markingson. According to Dr. Glick, this was areasonable and appropriate method of assessing this patient. Further, he is of the opinion that

19



this satisfied the standard of care and in no way caused or contributed to Mr. Markingson'sdeath.

Dr. Olson also reasonably and appropriately considered the concerns being raisWeiss. The record reflects that Ms. Weiss sent Dr. Olson two letters in November 2003. Those

letters set forth some concerns she had about her son's participation in the CAFE Study, andalleged ongoing psychotic symptoms. He also on occasion received messages from Ms. Weissraising her concerns.

Dr. Olson took into consideration these concerns. He would consider that informationagainst the presentation that Mr. Markingson made at his CAFE Study visits. In addition, hewould weigh these concerns against information being received from the Theo House and theobservations of Mr. Markingson being made during adult day treatment. In all instances, Mr.Markingson presented as being stable and no one could verify the concerns raised byThus, Dr. Olson reasonably and appropriately assessed and evaluated the concerns raWeiss. When those were determined to be without verification from other sources, Dr. Olson d

not disregard those comm ents, but continued to consider them as a part of his ongointreatment of IVIr. M arkingson. These assessments were reasonable, appropriate and sapplicable standard of care. In no way did this cause or contribute to Mr. Markingson's cause ofdeath.

Dr. Glick will opine that it takes anywhere between six to eighteen months of pcare and consistent antipsychotic medication use before the symptoms of first episodes ofpsychosis fully stabilize. Mr. Markingson was still in the early stages of receiving care for hisdisease, and was continuing to have ongoing problematic symptoms. According to Dr. Glick,this was expected and appropriately accounted for by Dr. Olson and the rest of Mr. Markingsontreatment team.

Dr. Glick will testify that in his opinion there was a significant amount o f confturmoil between Mr. Markingson and Ms. Weiss. Ms. Weiss was Mr. Markingson's only closerelative as he had no father in his life and no siblings. Thus, his only source of family supportwas someone who did not understand his disease, was not being patient with his recovery, andwith whom he had trust issues. These factors created a great deal of stress for Mr. Markingsonand hindered his ability to work toward stabilization of his disease.

Dr. Glick will also offer the opinion that the majority of persons diagnosed witschizophrenia have difficulty accepting care. Approximately 80% will either decline care or fato follow through with the prescribed care in the first few months. In this case, Mr. Markingsonhad been compliant with all of his care for almost six months at the time of his death. In theopinion of Dr. Glick, this demonstrates what excellent care and monitoring Mr. Markingson wareceiving in the CAFE Study.

Dr. Glick will testify there was no reason for Dr. Olson to withdraw Mr. Markingsonfrom the Study. Dr. Glick will opine there were no clear warning signs that Mr. Markingson wapotentially suicidal. He was not exhibiting signs of psychosis nor was he deteriorating. Thebehavioral assessment of suicide ideation consistently showed no evidence of suicide

20



Furthermore, none of his multiple clinicians, staff at Theo H ouse, or apparently, residTheo House were aware of Mr. Markingson's being suicidal. Dr. Glick ,will opine that it wasreasonable and appropriate to have Mr. Markingson remain in the CAFE Study. The CAFEStudy provided reasonable and appropriate care and was w ithin the accepted standardmedical practice. Remaining in the CAFE Study did not in any way cause or contribute to Mr.

Markingson's cause of death.Dr. Glick w ill testify that those with schizophrenia have a greater rate of suicid

average population. Individuals who are schizophrenic have the capability of committing suicideven if they are hospitalized in a locked ward. In the case of Mr. Markingson, he was receivingan exceptional amount of care and close monitoring. His decision to take his own life was notcaused or contributed to by the care and treatment rendered by Dr. Olson as the princinvestigator of the CAFE S tudy, Dr. Olson as primary care psychiatrist of the CAFE as Mr. Markingson's individual primary care psychiatrist.

According to Dr. Glick the toxicology report indicated Mr. Markingson had sto

taking his Café Study medication (quetiapine). The fact that there was no presence of themedication in his blood indicates that Mr. Markingson had not been taking his medication for afew days prior to his suicide. The ability to follow through with care and medication compliancis a significant concern for people diagnosed with schizophrenia. Despite all efforts to ensureMr. Markingson took his medication, it appears he did stop taking it. Mr. Markingson's non-adherence to treatment in the few days prior to his death likely caused or contributed suicide.

Dr. Glick will testify that he did review the Department of Health and Human Sreport regarding their review of the death of Mr. Markingson. In his opinion, there wereabsolutely no adverse findings related to Dr. Olson, the University of Minnesota, the CAFE

Study, nor Dr. Schulz.Dr. Glick has also reviewed the investigation conducted by the Food and Drug

Administration by Sharon L. Matson, Investigator, in January of 2005. Dr. Glick will testify thathe investigation conducted by the FDA found no adverse care and treatment by Dr. OSchulz, or any other person involved in Mr. Markingson's care and treatment. The FDA foundthat Mr. Markingson's diagnosis of schizophrenia was reasonable and appropriate. Dr. Glickalso noted that the FDA found that the court order did not require Mr. Markingson's participatioin the CAFE Study. Thus, there was no evidence of inappropriate coercion.

The FDA investigator found that Mr. Markingson received more care than he wreceived in standard medical care by his participation in the CAFE Study. The FDA also foundthat Mr. Markingson was in a state to give voluntary, informed consent on November 21, 2003The FDA also noted in their report that Mr. Markingson's continued participation in the CaféStudy was appropriate and there was no clinical evidence of deterioration. According to Dr.Glick, the FDA report is proof of the excellent care and treatment Dr. Olson and the Cafforded to Mr. Markingson.

21



Dr. Glick will point out that not one of the other care providers involved in M rMarkingson's care and treatment ever attempted to contact Dr. Olson. Dr. Glick will opine thatif Dr. Andersen, Mr. Pettit, the Theo House staff, or the day treatment staff, had any qconcerns about Mr. Markingson's progress or stability in the CAFE Study, it would have beenincumbent upon them to contact Dr. Olson. According to Dr. Glick, it is very telling that at no

point in time did any of these care providers contact Dr. Olson with concerns about MMarkingson. Instead, individuals from each one of these facilities have indicated that theybelieved that Mr. Markingson was stable and did not need additional assessment by Dr. Olson.This reiterates that the care and treatment received by Mr. Markingson was reasonablappropriate.

Dr. Glick is of the opinion that the standard of care did not call for Dr. Olson toblood tests to verify Mr. Markingson's medication level. According to Dr. Glick it is highlyunusual — almost never clinically done - for blood tests to be obtained. It appeared tMarkingson was compliant with taking his Café medication. Mr. Markingson was regularlyattending all of his appointments with his various medical providers. He was not reporting

having any active hallucinations or delusions. Mr. Markingson also did appear to exhibit anysigns of significant deterioration. Given these circumstances, Dr. Glick does not believe thistype of case would call for an extreme measure like blood testing. Thus, the standard of care dinot require Dr. Olson to acquire blood tests, urine tests or other laboratory testing to Mr. Markingson's medication level.

In the opinion of Dr. Glick, Dr. Olson at all times provided reasonable and appcare and treatment to Mr. Markingson. In his role as principal investigator of the CAFE Study,CAFE Study physician, and primary care psychiatrist to Mr. Markingson, he provided reasonaand appropriate care and treatment, all of which satisfied the standard of care. Further, in hisopinion, in no way did the care and treatment provided by Dr. Olson cause or contribute to Mr.

Markingson's death. Dr. Glick will opine that the care provided by Dr. Olson, Dr. Schulz, theUniversity of Minnesota Physicians, nurses, all other physicians, psychiatrists, psychologists,social workers, day treatment personnel, and Theo I staff was reasonable and appropriate. In hopinion, none of their care caused or contributed to Mr. Markingson's death.

2. r. S. Charles Schulz

During Mr. Markingson's hospitalization, he saw Dr. Schulz on one occasion on or abouNovember 29, 2003. Dr. Schulz was covering rounds at the hospital for Dr. Olson during thattimeframe. Dr. Schulz performed a history and examination of Mr. Markingson during this visiDr. Schulz found Mr. Markingson's thought process to be logical and that his mood was pleasaand his affect was appropriate. He was noted to be on Risperdal at that time and Dr. Schulzcontinued the patient's use of that medication.

In the opinion of Dr. Glick, the care and treatment rendered by Dr. Schulz to MMarkingson on this single visit was reasonable, appropriate, and satisfied the standarHis examination and assessment of this patient, along with the continuation of Mr. Markingsonmedication, was appropriate care. Dr. Glick will opine that Dr. Schulz's care and treatment ofthis patient did not cause or contribute to his death.

22



Dr. Glick is also expected to testify and opine that Dr. Schulz did not violate thof care for a co-investigator of a clinical trial, nor as the head of the Department of PDr. Glick will opine that Dr. Schulz's activities in those capacities was within accepted medicalpractice. Further, Dr. Glick will provide the opinion that Dr. Schulz neither caused norcontributed to Mr. Markingson's death.

According to Dr. Glick, the evidence will show that Dr. Olson and the CAFÉ Streatment team were involved in obtaining informed consent from Mr. Markingson. Dr. Schulzdid not interact with Mr. Markingson after his single visit with him, in the hospital. Dr. Schulzdid not present to Mr. Markingson any information about the CAFE Study. Dr. Schulz did notmake an assessment of Mr. Markingson's competence at any point in time during hishospitalization. Further, all of the evidence will show that Dr. Schulz in no way participated inthe informed consent process conducted on November 21, 2003. In the opinion of Dr. Glick, DSchulz could not have violated the standard of care requirements for obtaining informwhen he was not in any way involved in that process. Thus, Dr. Schulz's lack of involvement in

the informed consent process, could not have been a component or a causal factor in Markingson's death. Dr. Glick will testify that the standard of care did not require Dr. Schulz toparticipate in the informed consent process.

As a co-investigator of the CAFÉ Study, Dr. Schulz was aware of the informatcontained in the informed consent document. That document had been reviewed by theInstitutional Review Board at the University of Minnesota. That Board took into considerationthe reasonableness and appropriateness of that document for use amongst human subjects. Aftmaking several changes to the document, the Institutional Review Board approved thdocument which had been utilized to enroll other subjects in the CAFE Study for themore that it had been conducted at the University of Minnesota site prior to Mr. Markingson's

involvement. Dr. Glick is of the opinion that the information contained in the CAFE Studyinformed consent document was reasonable and appropriate. It is his opinion that that documenfully set forth information about Mr. Markingson's right to withdraw from the Study, alternativtreatment, the risks of the Study, and the benefits. To a reasonable degree of psychiatric andmedical certainty, Dr. Glick will opine that this document was reasonable, appropriatsatisfied the standard of care. In no way w as the document exploitive nor coercive.

Dr. Glick will also testify that as a co-investigator on the S tudy, Dr. Schulz w aresponsible for the care provided to those patients he was seeing. Only the principal investigatoon a study is responsible for the care of all of the patients. Dr. Schulz never saw Mr. Markingsoas a participant in the CAFE Study.

Dr. Glick will also opine that Dr. Schulz was not involved in Mr. Markingson's stay ofcommitment. Nevertheless, Dr. Glick will opine that regardless of Mr. Markingson's stay ofcomm itment, he was still a reasonable and appropriate candidate to participate in theStudy. Further, regardless of the fact that he was functioning under a stay of commitment, didnot negate the fact that,Mr. Markingson was competent and able to voluntarily agree toparticipate in the CAFE Study. Dr. Glick will opine that it was reasonable and appropriate forDr. Schulz, as a co-investigator of the CAFE Study and as the head of the Department of

23



Psychiatry at the University of Minnesota, to allow Mr. Markingson to participate inStudy given h is competence, voluntary choice to participate in the study, and approvMarkingson's case manager/social worker, David Pettit.

Dr. Glick will opine that given his role in Mr. Markingson's care and treatment, Dr.Schulz was not obligated to ensure that Mr. Markingson obtained a second opinion. The medicrecords reflect that Mr. M arkingson was satisfied with the care he was receiving fromand in the CAFE Study. The records also reflect that Dr. Olson, on several occasions, expresseto Mr. Markingson that he had the right to seek a second opinion, yet each time Mr. Markingsorefused. The standard of care did not require Dr. Schulz to force or even suggest to Mr.Markingson that a second opinion was necessary.

As previously stated in his opinions on Dr. Olson, Dr. Glick will opine that acquiring ablood test to discern the level of antipsychotic medication in Mr. Markingson's blood was notrequired. Dr. Schulz had no reason to personally conduct such a test or to request that Dr. Olsoor the CAFE Study staff perform such testing. Dr. Glick will opine that blood level testing is

done in the rarest of circumstances and certainly would not have been called for in this case. DSchulz's position as co-investigator and department head did not require him to seek blood levtesting for Mr. Markingson. Dr. Schulz did not violate the standard of care and did not cause orcontribute to Mr. Markingson's death in this regard.

Dr. Glick will also address the suggestion that there was a conflict of interest ban alleged financial gain that Dr. Schulz would receive as a result of Mr. Markingson'sparticipation in the CAFE Study. Dr. Glick will opine that he has reviewed the records and doenot see any evidence of a financial motivation which would have in any way impaired orhindered Dr. Schulz's judgment in regard to the care and treatment provided to Mr. MarkingsonFurther, there is no evidence of any financial misconduct in how Astrazeneca paid fo

performance of the Study.Dr. Schulz took very seriously his role as the head of the Department of Psych

a co-investigator of the CAFE Study to ensure that all staff, including Dr. Olson, providedappropriate care to all patients and/or Study subjects. In the opinion of Dr. Glick, Dr. Schulzreasonably and appropriately monitored the CAFE Study and was available to assist in anymanner necessary if issues arose. He allowed Dr. Olson, a seasoned, skilled and highlyknowledgeable member of his staff, to serve as the principal investigator of the CAF

Dr. Glick will opine that Dr. Olson's skill and knowledge level called for Dr. Schulz toallow Dr. Olson to conduct this Study independently. Dr. Schulz was, in the opinion of Dr.

Glick, right in that assessment as Dr. Olson did provide appropriate care. Therefore, Dr. Schulzsatisfied the standard of care by allowing the CAFE Study to be conducted in the mawhich it was at the University of Minnesota. There is nothing about the way the CAFE Studywas conducted that caused or contributed to Mr. Markingson's death. The way the Study wasimplemented at the University of Minnesota by Dr. Schulz and Dr. Olson under the direction othe IRB was reasonable and appropriate.

24



According to Dr. Glick, Dr. Schulz knew that Dr. Olson was a conscientious prinvestigator, CAFE Study physician, and primary caregiver. Further, he knew he would dowhatever was necessary to provide reasonable and appropriate care to Mr. Markingson. Dr.Olson did have reasonable and appropriate contact with Mr. Markingson throughout of his hospitalization, and his aftercare prior to his death. Dr. Schulz reasonably andr

appropriately monitored Dr. Olson's contact with Mr. Markingson, and all of the CAFE Studyparticipants, both as a co-investigator and as the head of the D epartment of PsychiatrUniversity of Minnesota.

Dr. Glick is of the opinion that Dr. Schulz did reasonably and appropriately invand consider the information he received from Ms. Weiss. Further, Dr. Glick will opine that DrSchulz's investigation of the subject matter was reasonable, appropriate and satisfied thestandard of care. Dr. Glick will also testify that the timely response by Dr. Schulz to Ms. Weissconcerns about her son's participation in the CAFE Study satisfied the standard of care and didnot in any way cause or contribute to Mr. Markingson's death.

When Dr. Schulz received Ms. Weiss's correspondence, he contacted Jeanne Kenney anDr. Olson to review Mr. Markingson's participation in the CAFE Study. Dr. Schulz testified thathe spent more than one hour talking to them to discern whether or not there was any the concerns she was making about Mr. Markingson's behavior, progress, and continuedparticipation in the CAFE Study. Dr. Schulz extensively questioned both Ms. Kenney and Dr.Olson about her concerns, and after investigating that matter, felt satisfied that Mr. Mwas progressing appropriately, his condition had stabilized, and that he was an appropriatecandidate to be a participant in the CAFE Study.

Dr. Schulz addressed each and every one of Ms. Weiss's concerns. He discussed Mr.Markingson's change in behavior and improvement in his condition since his participation in th

CAFE Study. He also reiterated to Ms. Weiss that if Mr. Markingson was not responding to theCAFE medication or indicated a desire to withdraw, he could do so. Dr. Schulz advised Ms.Weiss that Mr. Markingson had not asked to be removed from the Study, and that his medicatioappeared to be helping with his symptoms. Further, Dr. Schulz reiterated to Ms. Weiss that Mr.Markingson had the right to seek a second opinion, but that decision was Mr. Markingson'salone. Finally, Dr. Schulz addressed Mr. Markingson's living situation and indicated to her thata trial run in a local apartment would certainly be better than Mr. Markingson's desire to returnto California without supervision. The letter written by Dr. Schulz, in the opinion ofDr. Glick,was reasonable, appropriate and satisfied the standard of care. Dr. Glick will testify that in noway did Dr. Schulz's actions cause or contribute to Mr. Markingson's death.

Dr. Glick will testify that there was absolutely no evidence which would have indicatedto Dr. Schulz that Dr. Olson was an absent physician or principal investigator. To the contrary,in the opinion of Dr. Glick, Dr. Schulz investigated and appropriately reached the conclusion thMs. Markingson was receiving reasonable and appropriate care in the clinical trial. There wasabsolutely no basis for Dr. Schulz to intervene into the care of Mr. Markingson nor discontinuehis participation in the Study. Dr. Schulz satisfied the standard of care and did not cause orcontribute to Mr. Markingson's death.

25



The only concerns about Mr. Markingson's care and treatment in the CAFE Study camefrom Ms. Weiss. Federal requirements indicate that an Institutional Review Board is to receiveinformation about concerns received from investigators conducting the Study. However, thoseare the concerns that are registered by the participants. Ms. Weiss was not a participant in theCAFE Study. It was not required that either Dr. Olson or Dr. Schulz report this information tothe Institutional Review Board, Quintiles nor Astrazeneca. Mr. Markingson did not personallylodge any complaints about his participation in the CAFE Study, the medication, noreffect he may have been experiencing. The standard of care did not call for Dr. Olson nor Dr.Schulz to advise the Institutional Review Board, Q uintiles, nor Astrazeneca Pharmac

Dr. Glick will also opine that Dr. Schulz did no t have a duty to disclose to Ms.he was a co-investigator on the CAFE Study in his response to her. That information hadnothing to do with Mr. Markingson's care. Further, there is no proof it would have changed thecare Mr. Markingson received. The standard of care did not require Dr. Schulz to disclose thatinformation to her. Ms. Weiss was not a participant in the CAFE Study, was not a monitor of thCAFE Study, and was simply a person presenting concerns about a patient. Thus, Dr. Schulz's

care and treatment did not cause or con tribute to Mr. Markingson's death.Dr. Glick will also opine that the fact that the Office of the Ombudsman, the D

of Health and Hum an Services, and the FDA all conducted investigations and studieoutcome of this case. In the opinion of Dr. Glick, each one of these investigating entities foundthat the standard of care had been satisfied and in no way did the care and treatment Dr. Olson, Dr. Schulz, or any person affiliated with the CAFE S tudy cause or contribMarkingson's death.

Instead, each of these entities found that the care and treatment provided to MrMarkingson was reasonable and appropriate. Dr. Glick will also point out that in each one of

these investigations conducted, Dr. Schulz was not named nor was he indicated as a pwhose actions were being investigated. Dr. Glick will indicate that this information is strikingbecause it demonstratively shows Dr. Schulz's role as both a co-investigator and the head of thDepartment of Psychiatry was not at any point in time questioned by these institutions. Furthernot one en tity believed that Dr. Schulz's role as a co-investigator, nor as the head of tDepartment of Psychiatry, caused or contributed to Mr. Markingson's death.

In the opinion of Dr. Glick, Dr. Schulz satisfied the standard of care both as a cinvestigator of the CAFE Study and as the head of the Department of Psychiatry at thUniversity of Minnesota. Dr. Schulz's activities in each of those roles, was reasonable andappropriate. There is not any evidence, in the opinion of Dr. Glick, as either a co-investigator o

as the head of the Department of Psychiatry Dr. Schulz in any way caused or contribMarkingson's death.

Dr. Glick will also opine that there was no ev idence of bias or unethical judgmOlson or Dr. Schulz as a result of Astrazenca's sponsorship of the study. According to Dr.Glick, there is absolutely no evidence of un lawful payment to Dr. Olson or D r. Schulby Astrazeneca. The method of payment to the University of Minnesota was reasonable andappropriate. Further, there was nothing that violated the standard of care by having payments

26



Ira D.Glick, .D.

m.acle lo the University even if a portion of these payments went to support Dr. Olson's or Dr.Schulz's salaries.

Dr_ Glick will also offer opinions about the emplo

schizophrenia. In his opinion, schizophrenia is a life longschizophrenia must be medioine compliant throughout thstability. As a result of the disease process, the majorityhave difficulty remaining medication compliant. Further,schizophrenia often experience several relapses throughohospitalized on at least one occasion in their life, All of thwith schizophrenia from the ability to obtain aad retain staexperience,, regardless of ideation level, most Will be unabreliant upon social security disability benefits as their sole

bility of a patient sufferin.g from

isease. People diagnosed withlife in order to maintain mentalpeople diagnosed with schizophreniaMODS with a diagnosis oftheir life, and most are re-se factors inhibit persons diagnosedlc, fun - ime employment. In histo maintain employment and arecans of support.

CERTIFICATIO

I certify that the tbregoing statements and opinions are true and correct to the best of myknowledge and belief. I further certify that the above opi ons are rendered to a reasonabledegree of m edical and psychiatriccertainty. These opinio i may be supplemented or revisedshould there be additional discovery and/or information su m inedor brought to my attention forTeVieW.

Subscribed and sworn to before me-this day of 2007.

Notary Public

MPLJB305611, I

(- David D.Angela MGISLASAttorneys

Charles701 XeniMinneapoPbone: 7

sop #120434- 'Nelson #03 066l 7

N flt HUNTER L LPfor Stephen Olson, M.D ., andSchulz, MD .Avenue South, Suite 500s, M N 55416

3-225-6000

Dated:

27



See Attached Document (Notary to cross out lines 1-6 belo0 See Statement Below (Lines 1-5 to be completed only by curnent signer[s], not Notary)

Signature of Document Signer N. 1 Signature ot Doodment Signer No. 2 II arty)

• Subscribed a

tC11 daDate

(1 )

"y(Proved toto be the

(2)

E PersonallyProved toto be th

d ewerft-te-ior affirmed) before me on this

of 206 , byMonth ea r

me on the basis of satisfactory evidencerson who appeared before me (.) (7)-

-fend"of Signer

known to meme asis of satisfactory

on who appeared before me.)

Signature or Notary Pub

Place Notary Seal Above

OPTIONALThough the information below Is not required by law, it may provevaluable to persons relying on the document and could prevent

fraudulent removal and reattachment of this form to another documentFurther Description of Any Attached Docurnzs ,t ,

r i) isaoS we -42- ,>c- u ic ot_ Title or Type of Doeurnentk-P11 / 4 1 '10 c • tArtk k c - ,

Decurneni Date: 1\3 0 Dafre-- umber of Pages: 7

Signer(s) Other Than Named Above: 10 Y 1/14 2Ar- S.7131 A,f2.ArS

30ZAMOINC2004 National NotaryAssocialion • 9350 De Soto Ave., P.O. Box 2402 • Chatsrvorth, OA 91313-2402*

RIGHT TI1UM BPRitIT IGHT T IqUIVIEPRINTOF SIGNER , t1 F. SIGNER' a2

NationelNoteryiorg Item #5910 Reorder: call Toll -Freet -Soo-876-e827

< 7 .Mame of Signer

NANCY CHEUNGCOMM. *1644065 Pt

Notary Pubit-caltorris e5AN,FRANascocouKrrMY Cann.E s p . F e t i9 , 2 4 1 0 I

•••• s •••• ••• ••• s •rrt

CALIFORNIA JURAT WITH AFFIANT STATEMENT2&SitiGM=

State of California

County of c,0



Ira D. Glick, M.D.

Curriculum Vitae

Ira David Glick, MD

Professor of P sychiatry, De pt. of Psych iatry & Behavioral SciencesStanford University Schoo l of M edicine;

401 Qu arry Road, #2122Stanford, CA 94305-5546

(650) 723-3519<[email protected]>

Date of Birth: October 15, 1935 lace of Birth: Brooklyn, New York S# 161-32-7428

Education:

1957 .S., Dickinson College, Carlisle, Pennsylvania

1961 .D., New Yo rk Me dical Co llegePostgraduate Education:

1961-19621962-1966

1965-1966

Rotating Internship, Beth Israel Hospital, New Y ork, NYPsych iatry Residency

1962-63 - First Year Resident, Hillside Hospital, Glen Oaks, New York1963-64 - Second Year Resident, Mt. Zion Hospital, San Francisco, California1964-65 - Chief Resident, Hillside Hospital

Ca ndidate, New Yo rk Psychoa nalytic Institute, New York, NY

Licensure & Certification:

1962 ew Yo rk State Me dical License1963 iplomate of the N ational Board of M edical Examiners1963 alifornia State M edical License - (G 9084)1968 iploma te of the Ame rican Boa rd of Psychiatry and Neuro logy1980 ental Hea lth A dministrator, Com mission on C ertification in Administrative Psych iatry of

the A merican P sychiatric Association1988 aryland M edical License

Academic Appointments:

1965-1968 nstructor & A ssistant Atten ding Psych iatrist, New York State P sychiatric Institute,C ollege of Physicians and Su rgeons, Co lumbia University

1966-1968 ssistant C linical Professor of P sychiatry, Medical Co llege o f Georgia

1968-1978

1978-1993

Schoo l of M edicine, Un iversity of Ca lifornia, San Francisco (UC SF):1968-72 Assistant Clinical Professor of Psychiatry and of Obstetrics & Gynecology1971-73 Career Teacher in Psychiatry of the National Institute of Mental Health at

Langley P orter N europsychiatric Institute1972-76 Associate Clinical Professor1976-78 Professor of Psychiatry in Residence, School of Medicine

Profe ssor of Psychiatry, Corne ll University M edical C ollege, New Y ork, NY



Ira D. Glick, M.D.

1993-

Positions:

1965-1966

1966-1968

1968-1978

1978-1993

Professor of Psychiatry & Behavioral Sciences, Stanford University Schoo l of M edicine

Staff Psych iatrist and Research Associate, Hillside Ho spital, Glen Oak s, New Y ork

Service Record: Captain, Army of the United States, Chief, Psychiatry Service,U.S.Army Hospital Specialized Treatmen t Ce nter, Fort Gordon, Ge orgia

Langley Po rter Neuropsychiatric Institute and De pt. of P sychiatry, Schoo l of M edicine,University of California, San Francisco

1968-78 Chief, Clinical Research Ward (renamed the In patient Treatment & ResearchService, 5/1/75)

1975-78 Director, Medical Student Education

Associate M edical Director, Payne Whitney C linic, De pt. of Psych iatry, The New Y ork HoCo rnell M edical Center

1978-88 - Director, Inpatient Services1978-93 - Director of the Family Therapy Program1990-93 - Director, Outpatient Dept.

1988-1990 enior Science A dvisor to the D irector, National Institute of M ental Health, Rockville, MD

1993- tanford Un iversity Schoo l of M edicine & Stanford Un iversity Ho spital1 993 - 2000 - Director o f Inpatient & Pa rtial Hospitalization Se rvices,1 995 - 96 - Acting Deputy C hief of Staff and Ch ief of Psychiatry, Palo A lto Veterans

Administration Hospital1993 — present - Director, Schizophrenia Research C linic

Other Training:

1965-1966 ept. of Research, Hillside Hospital: Seminar on Research Methods in Psychiatry, D. Klein, MD

1968-1969 . Starkweather, PhD, Dept. of Information Systems, UCSF: An Introduction to ComputerProgramming PL-1

1968-1969 ept. of Psychiatry, UCS F: Seminar on Supervision , R. Wallerstein, MD

1968-1969 ept. of Psychiatry, UCSF: Seminars on Models in Psychiatry, J. Ruesch, MD

1969-1970 ept. of Psych ology, Langley Porter Neu ropsychiatric Institute: Co urse on A dvancedStatistics, W. Hargreaves, Ph D

1971-1972 ept. of Psychology, Langley Porter Neuropsychiatric Institute: Advanced Statistics226- A & B, R. Elashoff, Ph D a nd W. Hargreaves, PhD

1971-1972 C SF: Health Sciences Edu cation Seminar, E. Rosinski, PhD

1972 ept. of An atomy , UCSF: Cou rse on C ell Structure & Function, R. Long, PhD

1972 ept. of Ph ysiology, UC SF: C ourse, Endocrinology 1 01 , C. Kragt, PhD

1972 ept. of Business Administration, Philosophy of M ana gemen t University of C alifornia,Berkeley Science, C. Churchm an, PhD

2



Ira D. Glick, M.D.

1973 ardiovascular Research Institute, UCSF: Group Practice in the Art of Teaching, N. Staub, MD

1978-1979 ept. of Psychiatry, Albert Einstein C ollege of M edicine: A dministrative Psych iatry &M ental Health Planning, S. R. Kaplan, MD

Honors and Awards:

1953-1954 kull & Key Award: Dickinson College. Given yearly to College's most outstanding freshman

1959 ational Foundation Medical Student Fellowship, De pt. of P hysical Medicine & Reha bilitationNew Yo rk Medical Co llege (Summer)

1960 ational Institute of Mental Health Research Training Grant , Dept. of Psychiatry, New Y orkM edical Co llege (Summer)

1961 tephen P. Jewett Award : Dept. of Psychiatry, New York Medical College. One award giveneach y ear for proficiency in psychiatry to a fo urth yea r medical student

1968 rmy Commendation Medal : U.S. Army H ospital, Ft. Gordo n, Geo rgia

1971-1973 areer Teacher in Psychiatry: National Institute of Mental Health, MH-12450

1974-1975 ept. of Psych iatry No minee for theKaiser Award for Excellence in Teaching, andth e UCSF Budget Committee Award for Special Recognition of Distinction in Teaching

1979 merican Journal of Nursing, 1979, Books of the Year Award, presented for "PsychiatricHospital Treatment for the 1 980's"

1974-1978 onsultant, Psych iatric Education Bran ch of the N ational Institute of Me ntal Health

1979-1980 d Hoc Reviewer for the Psych osocial & Biobe havioral Treatmen ts Subcomm ittee of theTreatment D evelopment an d A ssessment Research Review Co mmittee, NIMH

1982 ember, Special Review C ommittee o n D epression, AD AM HA, NIM H (July)

1987 ulbright Research Scholar, Japan, (Janu ary through July).

1987 esearch Fellowship, the Japane se National Institute of M ental Health, Itchikawa, Japan,(January through July)

1987 he American Psychiatric Association and PIA Award for Hospital Psychiatric Research, awardedann ually for research in the field of h ospital psychiatric treatmen t.

1986-1997 he Best Doctors in America

1990 he Seymour D. Vestermark Award, awarded annually "to recognize leadership & creativity inpsychiatric education, "by the American Psychiatric Association, (given to the ACNP for a ModelCurriculum in Psychopharmacology developed by a su bcom mittee wh ich I co-chaired with DaJanowsky, MD )

1990 irector's Award, National Institute of M ental Health

1991 he Association for Academic Psychiatry Psychiatric Education Award, Honorable Mention,

3



Ira D. Glick, M.D.

awarded biannually for Innovative Educational Materials and Techniques, for the ModelCurriculum in Psychobharmacology

1991 ne of three recipients of Alumni Achievement Awards from New York Medical College

1991 unner-up for The American Academy of Clinical Psychiatrists Clinical Research Award

1991-1994 acArthur Foundation Research Network on Depression

1993 he Van Ameringen Award in Psychiatric Rehabilitation, awarded annually by American PsychiatricAssociation, in recognition of outstanding and sustained contributions to field of psychiatricrehabilitation in areas of research, service and education (in 1992, I was given "Honorable Mention"for this same award)

1994 he Gralnick Award, given annually by the American Psychological Foundation to a researcher"whose work covers the psychosocial aspects of schizophrenia with an emphasis on the early

stages of the disorder"

1996 ssociation for Academic Psychiatry Annual 1997 Education Award for "outstanding

contributions as an educator, both in curriculum development and in presentation"

2000 nnual Outstanding Achievement Award of the Northern California Psychiatric Society (NCPS) ofthe APA, "recognizes a member of NCPS who has made significant and exceptional contributionsto the field of psychiatry."

2001 istinguished Contribution to Family Systems Research Award. This annual AFTA awardrecognizes an individual for outstanding research on subjects central to the field of family therapy.

2002 ockefeller Foundation Award for Residence at Bellagio, Italy, Summer 2002.

2003 etzger-Conway Fellow, Clarke Center, Dickinson College, Carlisle, PA

2003 ulbright Lecturing Award, India

2004 xcellence in Teaching Award, Stanford University School of Medicine, Stanford, CA. Inrecognition of contributions to the educational mission of the school.

2004 ominee for Franklin G. Ebaugh, Jr. Award for excellence in teaching, SUSM

2005 irst Annual Irma Bland Award for Excellence in Teaching Residents, given annually by theAmerican Psychiatric Association to Departments of Psychiatry for outstanding and sustainingcontributions made as a faculty.

2006 ickinson College Distinguished Alumni Award for Professional Achievement. This yearly awardnames alumni who have demonstrated outstanding accomplishment, as well as strength ofcharacter, in their professional and civic lives.

2005-2009 ember, NIMH Review Committee concerned with clinical trials of pharmacotherapeutic,psychotherapeutic and combination treatments.

Visiting Professorships (VP) & Endowed Lectures:

1972 P: Dept. of Psychiatry, School of Medicine, University of San Marcos, Lima, Peru, (August)1 ) Teaching of Psychiatry to Medical Students2) Family Therapy Today

4



Ira D. Glick, M.D.

1978-1988 istinguished Lecturer, Lederle Pharmaceutical Co

1979 P: Dept. of Psychiatry, College of Medicine, University of Arizona, Health Science Center,Tucson, Arizona

1980 ary N. Spero Community Mental Health Memorial Lecture Series, "The Family Model inInpatient an d D ay Ho spital Settings," Maimonides M edical Center, Brooklyn

1980 P: Dept. of Psychiatry, University of Connecticut Health Center, Farmington, Connecticut

1981 P: Maudsley Hospital, Tavistock Clinic and Hospital for Sick Children, London1 ) "The Family Mo del in an Inpatient Setting", Seminar on Ho spital Psychiatry,

M ental Health Wo rkers, Great Britain2) "Family Therapy and Hospitalization", Ta vistock Clinic3) "Family Research", M arlborough H ospital4) "Family Resea rch", Grand Rou nds, Hospital for Sick Ch ildren5) "Indications and Co ntraindications for Fam ily The rapy", The Family Institute of Lo

1982 eynote Address, "Guidelines for Fam ily The rapy," as part of a con tinuing education cou rseentitled "Clinical Techn iques for the Practice of Family Therapy," spon sored by the De pt. oPsychiatry, Long Island Jewish- Hillside M edical Cen ter

1982-1989 isiting Faculty Program, M ead Johnson Pharmaceutical Co .

1983 P: Dept. of Psychiatry, University of California, San Diego

1983 P: Dept. of Psychiatry, College of Medicine, University of Arizona Health Sciences Center,Tucson

1984 chweppes Visiting Professor, The Menninger Clinic, Topeka

1985 P: Dept. of Psychiatry, University of Wisconsin Medical School, Madison, "The Shrinking ofHospital Psychiatry"

1985 P, De pt. of Psych iatry, Me dical University of Sou th C arolina, Charleston1) Grand Rou nds, "Inpatient Family Intervention - A C ontrolled Study"2) Inge Taylor Memorial Lecture, "Why Don't Patients Receive Appropriate Psychiatric

Treatment?"3) All Day Se minar with Psychiatry Residents, "Theo ry & Practice of Integrative Psyc

1985 P: Western Psychiatric Institute and Clinic, University of Pittsburgh School of Medicine,De pt. of Psych iatry, "The Family Mo del: Do es It Have A nything to O ffer for the TreatmenAffective D isorders?"

1985 P: Fairfield Hills Hospital, Newtown, Connecticut, "Treating the Hospitalized Patient andTheir Family"

1986 P: Dept. of Psychiatry, School of Medicine, University of Verona, Italy, Jan-Jun

1990 isiting Lecturer Series, "Effectiveness in Psychiatric Care," New Jersey College of Medicineand De ntistry, Newa rk

5



Ira D. Glick, M.D.

1990 nvited Speaker, "What a Psychiatric Hospital Can and Cannot Do: A Review of EfficacyStudies." at a conference , "The Ro le of the M ental Hospital in the 21 st Cen tury," sponsoredby the Lo ndon Psychiatric Hospital, Ontario, C anada

1990 nvited Lecture, "New Wine in New Bottles: The Changing Role of Psychiatric Hospitals forPatients and The ir Families," at The She ppard Pratt Nationa l Symposium on Schizophrenia,Baltimore

1991 cademic Lecture: "New Models for the Treatment of the Chronically Mentally III," AnnualM eeting of the O ntario Psychiatric Association, Toron to (February)

1991 nvited Lecture: "A S urvival Guide for the Family of the Bo rderline Pa tient (and Vice VersaNew A pproaches to the "Borderline Sy ndrome ," Sixth Tokyo Institute of PsychiatryInternationa l Symposium, Tokyo , Japan (November)

1993 P & Invited Lecture: University Institutions of Psychiatry, Geneva, Schoo l of Medicine,University of Gene va, Switzerland an d Invited Lecture, "Effectiveness in Psych iatric C are:Followup Study of the Treatmen t of Hospitalized Pa tients with M ajor Affective D isorder sein Euro pe, Asia and th e U.S. United States" (April)

1993 P: Institute of Clinical Psychiatry, School of Medicine, University of Pisa, Pisa, Italy, withInvited Lecture, "Effectiveness in P sychiatric Ca re: A Followup Study of the Treatment Hospitalized Pa tients with M ajor Affective Disorder in Europe, A sia and the United Stat

1993 nvited Lecture, "Effectivene ss in P sychiatric C are: A Followup Study o f the Treatmen t ofHospitalized Pa tients with M ajor Affective Disorder in Europe, A sia and the United States,Dept. of P sychiatry, Secon d Scho ol of M edicine, N aples, Italy (April)

1993 nvited Lecture, "Effectivene ss in P sychiatric C are: A Followup Study o f the Treatmen t ofHospitalized P atients with M ajor Affective Disorder in Europe, A sia an d the Un ited States,Institute of C linical Psychiatry an d the D ept. of Psychiatry, School of M edicine, Veron a, Ita

1994 cademic Lecture: "Combining Medications with Psychosocial and Rehabilitation Strategiesfor the 1990's," 2nd Annu al Psychopha rmacology C linical Da y, Department of Psych iatry,

University of Toronto, Toron to (October).

1995 istinguished Lectu rer, Professors of P sychiatry Series: New Strategies of Trea tment forAxis IDisorders, 1995.

1995 P, D epartment o f Psychiatry, Schoo l of Me dicine a nd Su rgery, University of Ba ri, Italy, JuKeyno te Speaker, Strategies of Intervention in Family Psych otherapy, First NationalC ongress, Italian So ciety for Research and Interventions on th e Family, Subsection o f theItalian Psych iatric Society..

1996eynote Address, Combination Therapy for the Treatment of Psychosis, Third Annual STEPSymposium, Improving the Progn osis of Psycho tic Disorders (Schizophren ia Treatment &

Evaluation Program ), University of No rth Ca rolina a t Ch apel Hill, June, 1 996,

1996 eynote Address, Combination Therapy for the Treatment of Axis I Disorders, 1996 TaipaiM ental Health C onferen ce, Taipai, Taiwan, December 1 996.

1997 P, D epartment of P sychiatry, University of Iowa H ospital and C linics, Iowa C ity, M arch 1

1997 ward Lecture, Through the Golden Chalkboard: Reflections on the Teaching-Learning Processin Psychiatry, 1997 An nual M eeting of the Association o f Academic Psychiatry, March, 19



Ira D. Glick, M.D.

1998 P, De partment of Psych iatry & Internal Me dicine, St. Francis Me dical C enter, Pittsburgh, 1998.

1998 rincipal Speaker, "Lone Star : Society, The Familly and Individual Identity," as part of the filmseries of the New Orleans Museum of Art and Department of Psychiatry LSU, entitled: Lights,

Ca mera - An alysis, " New Orleans, October, 1998.

1998 eynote Speaker, "New Treatmen ts for Schizophrenia and Othe r Psychoses," at the Na tionaSatellite Symposium for the A rgentine Psych iatric Society, "Time for C han ge in the TreatmPsychosis, " Buenos Aires, Argentina, November, 1998.

1998 rincipal Speaker, at the Na tional C onference o rganized by the Uruguayan M inistry of HealUruguay an Society of Psych iatry and the Psychiatric Departmen t of the School of M edicinthe National University, Mon tevideo, Uruguay, Novem ber 1998:

"New Atypical Antipsychotics and Their Indications"'Com bining Medication and Psych otherapy for Axis I Disorders"

1999 isiting Professor, University Hospital Utrecht, The N etherlands, Summ er 1 999.

1999 lenary lectures at the Schizophrenia Symposium, Eastern Idaho R egional Me dical Ce nter, Falls, ID, June, 1999:• "New Strategies for the Treatmen t of Axis I Disorders"• "New Treatments for Sch izophrenia"

1999 lenary Lecture, "New Diagnositic Methods and Treatments for Schizophrenia: Turning theTreatment C orner" at the An nual M eeting of the C anadian Psychopharmacologic AssociatHalifax, June, 1 999

2000 uest Lecture, "The New A typical Antipsychotics for New Indications," An nua l Meeting, KPsycho pharmacology A ssociation, Korea, April, 2000.

2000 isiting Professor, EPP IC Program , University of Melbou rne, Melbou rne, Australia, August

2002 nvited Lecture, "Novel Antipsychotics: What We've Learned; What We Need to Know." CMEcourse on N ovel Antipsycho tics, C ase Western Reserve University Schoo l of Medicine,Cleveland, September, 2002.

2004 isiting Professor, Family Studies Unit, Nationa l Institute M ental Health an d Health Se ries(NIMHA NS), Bangalore, India• "Combining Medication and Psychotherapy"• "The New M odel of Inpatient Psychiatry"

2004 naugural Lecture, "Gary N. Spero Memorial Lectureship, "Schizophrenia and Psychosis: NewDa ta, New (Com bined) Treatments & New Co ntroversies." Department of P sychiatry, WeilM edical C ollege of C ornell University, New Yo rk, March, 2004.

2004 isiting Professor, Scho ol of M edicine, University of Iowa• Co mbining Me dication an d Psychoth erapy for Axis I Disorders• Schizophrenia: New Data and N ew C ontroversies

2005 t the Indonesian Society for Biological Psychiatry, Psychopharmacology and Sleep Medicine,Jakarta, Indonesia, February, 2005.• Educational Symposia, "The Teaching of Psychopharmacology: Circa 2005"

7



Ira D. Glick, M.D.

• Opening Plenary Lecture: "Developing a Curriculum in Psychopharmacology"

2005 ecture: "Developing a Curriculum in Psychopharmacology." Teaching PsychopharmacologSubstance , Meth ods, Science. Pre-M eeting: American Association of Directors of PsychiatResidency Training, Tucson , AZ, March, 2005

2005 nvited Lecture, "Co llabo ration W ith Big Pha rma," as part of the Stanford Sum mer ResearchInstitute, entitled C areers in Geriatric Psych opharm acology. Stanford, C A, July, 2005

Funded Research Activities:

1965-66 .D. Searle Research Grant for the studyPseudopregnancy Treatment of Periodic Psychiatric Illness

1971-75 ational Institute of M ental Health Grant for the project MH-20593Short vs. Long Psychiatric Hospitalization: A Controlled Study 133,000

Supplement 25,484

1975-77 ederle Research Grant for the studyLoxitane Treatment in Schizophrenia

1977-1978 ndo Research Gran t for the studyMolidone Hydrochloride vs. Haloperiodol:Double Blind Investigation of the Treatment of Acute Schizophrenia

1977-1982 ational Institute o f M ental Health Grant forMedical Student Psychiatric Education, MH-10569 395,280

1977-1978 ice Ch ancellor's Advisory Co mmittee o n InstructionalImprovements Grant, UC SF, for projectEffectiveness andEfficiency in Small Group Teaching with Mary Malloy, MD

1,400

1982-1983 ational Institute of M ental Health - Biomedical Research Su pportGrant for the studyInpatient Family Intervention: A Controlled Study 15,000

1982-1983 ational Institute of M ental Health Co ntract -to develop aModelPsychopharmacology Curriculum for Psychiatric Residency TrainingPrograms 83K055987501D (with David Janowsky MD) under theauspices of the American College of Neuropsychopharmacology. 4,290

1984-1986 ational Institute of M ental Health Grant for projectInpatient Family Intervention: Evaluation of Practice, MH-34466 180,000

1984-1993 ational Institute of M ental Health, Co operative C linical Agreement A wardfor the project,Treatment Strategies in Schizophrenia, MH-40007 863,000

1987-89 upplement 104,0001989-92 ompetitive Renewal 688,5811992-93 upplement 30,000

1987 ulbright Research A ward for the project,

8



Ira D. Glick, M.D.

Delivery and Compliance to Good Medical Treatment 20,000

1991 anssen Resea rch Grant for the study,Risperidone in theTreatment of the Negative Symptoms of Schizophrenia

1992-1995 ational Institute o f M ental Health Grant,Marital Treatmentfor Bipolar Disorder Patients, MH-45528-01A3,C o-Principal Investigator with Joh n C larkin, Ph D, P .I. 520,000

1992 (Cornell) Abbott Laboratories Research Grant for the study: Depakote in thePrevention of Mania

1993 (Stanford)

1992 fizer Research Gran t for the study:CP-88 for the Treatmentof Schizophrenia and Schizoaffective Disorder

1992 (Cornell) Abbott Laboratories Research Grant for the study: The Safetyand Efficacy of Sertindole in Schizophrenic Patients:

1993 (Stanford) A Double-Blind, HaIdol-Referenced, Placebo-Controlled Study

1993 harmacoloqic Medication Discovery & Development Project (PMDDP) 10,000Supported by Sm ithKline Beecha m, Lilly & Ab bott Laboratories

1993 fizer Research Gran t for the study,Treatment of Adolescent Depressionwith Sertraline

1993 bbott Laboratories Research Grant for the study,Safety and Efficacyof Depakote in the Prevention of Mania in Patients With Bipolar Disorder

1995 li Lily un restricted gran t to develop aModel PsychopharmacoloqyCurriculum for Residents (Com mittee C hair) under the auspices ofthe Ame rican Society of Clinical Psychopha rmacology

1995 li Lily Resea rch Gran t for the study,Olanzapine versus Risperidonein the Treatment of Schizophrenia and other Psychotic Disorders

1995 pjohn Research Grant for the study,Dose-response Study in theTreatment of Negative Symptoms of Schizophrenia with Pramipexole

1995 bbott Laboratories Research Grant for the study,A Comparative CostEffectiveness Study of Depakote and Usual Care versus Lithium andUsual Care in the Treatment of Bipolar Disorder

1996 ene ca Pha rmaceuticals Research Grant for the study,A Multicenter,Open, Randomized Comparison of Seroquel and Usual Care on HealthOutcomes in Subjects with Schizophrenia and Schizoaffective Disorder

1997 oechst M arion Roussel Research Grant for the study,A Multicenter,Randomized, Double-Blind, Placebo and Active Controlled Study of

MDL 100,907 in Schizophrenic and Schizoaffective Patients

1997 tsuka Am erica Ph armaceutical, Inc. Research Grant for the study,A Phase III Double-Blind Placebo-Controlled Study of Aripiprazole

$50,000

9



Ira D. Glick, M.D.

in the Treatment of Psychosis, with Risperidone as Active Control

1998 ovartis Ph armaceuticals C orporation,A Prospective, Randomized, International ,Parallel-group Comparison of Clozaril/Leponex vs. Zyprexa in the Reduction ofSuicidality in Patients with Schizophrenia or Schizoaffective Disorder Who Are AtRisk for Suicide

1998 ene ca Ph armaceu ticals Research Grant for the investigator initiatedstudy, Quetiapine vs Haloperidol Decanoate for the Long-TermTreatment of Schizophrenia and Schizoaffective Disorderwith M arder S.

1998 illy Research La bs,The Acute and Long-Term Efficacy of Olanzapinein First-Episode Psychotic Disorders: A Randomized Double-BlindComparison w/Haloperidol

$100,000

1998 fizer Ph armaceuticals,A Multi-Center, Placebo Controlled Double BlindStudy Comparing the Safety and Efficacy of Ziprasidone and Olanzapine inSubjects with Schizophrenia or Schizoaffective Disorder Needing Inpatient Care.

1999 anssen Pharmaceutica,Risperidone Depot vs. Placebo in the Treatment ofSubjects with Schizophrenia or Schizoaffective Disorder

1999 evelopment of a Model Psychopharmacology Curriculum for PsychiatricResidents. (through the Am erican Society of Clinical Psycho pharmaco logy)

Supported in part by Lilly, Janssen a nd Ze neca Pha rmaceuticals.

2000 ristol-Myers Squibb,Aripiprazole vs. Perphenazine in the Treatment ofPatients with Acute Schizophrenia.

$15,000

2000 Nationa l Institute of M ental Health, sub-con tract (MH9000 1 ),Comparative 550,000Effectiveness of Antipsychotic Medications in Patients with Schizophrenia

CATIE.• Human Gen etics Initiative

2001 ristol-Myers Squibb,A Multicenter , Randomized, Double-Blind, PlaceboControlled Study of Flexible Doses of Aripiprazole Versus PerphenazineIn the Treatment of Patients with Treatment-Resistant Schizophrenia.

2003 fizer, Zodiac International Schizophrenia Study to Compare the CardiovascularSafety of Ziprasidone and Olanzapine.

2003 fizer, A 12 Week Multicenter, Randomized, Double-Blind, Placebo ControlledEvaluation of Donepezil Hydrochloride as Adjunctive Therapy in the Treatmentof C ognitive Impairment in Patient with Schizophrenia or Schizoeffective Disorder

2004 shima Education Fun d 30,000

2004 stra-Zeneca, Comparison of Atypicals for First Episode (CAFE)

2004 ristol-Myers Squibb,The Treatment of Schizophrenia and OCD 80,000Symptomatology with Aripirazole (investigator initiated study).

2004 ristol-Myers Squibb,Efficacy and Weight Reduction Effects ofAripiprazole in Stabilized Patients with Schizophrenia and Weight Associated 105,000

1 0



Ira D. Glick, M.D.

with Atypical An tipsychotics (investigator initiated study).

2005 mericanCo llege of Neuropsycopharmacology, AC NP Public Outreach 5,000Program

2005 laxoSmithKline, Lamictal vs D epakote Do uble Blind. (investigator initiated 120,000

study)

2005 olvay Ph armaceu ticals, Parallel-Group Efficacy and Sa fety Studyof Two Fixed Doses of Bifeprunox in the Treatmen t of Schizophrenia.

2005 o-Investigator of a Harma n C linic Endowme nt Grant for a project$145,000

Fostering C ollaboration Th rough C linical Education: A ClinicalNeurosciences Seminar, C linic and C urriculum Series in Ch ildPsychiatry and Pe diatric Neu rology (with Joshi SV, C han g KD andHahn J).

Regional and National Professional Societies:

1965-1970 merican M edical Association

1965- merican P sychiatric A ssociation1971 Fellow1985-92 oun dations' Fund Boa rd for Research in Psychiatry

(Chair, 1985-92)1999 Life Fellow1999 M ember, Com mittee on Research on P sychiatric Treatments2003 ub-comm ittee on A ntipsychotic Drugs & Diabetes M ellitus2004 C ommittee on Awards, Northern C alifornia Psychiatric Society

1970-1974 & merican C ollege of Psychiatrists1990- 990 Fellow

1996 C ommittee on Hono rary Fellowships

1970- ociety of Biological Psychiatry1991-93 esource Development Committee1997Task Force on the Future of SBP2001 eorge N. Thompson Award Committee, Society of Biological Psychiatry

1973- merican Co llege o f Ne uropsychopharmacology1973Scientific Associate1978 Member1980-84 ducation an d Training C ommittee, (Chair, 1982-84)1984 Fellow1984-90 o-Chair, Committee to Develop a M odel Cu rriculum in Psychopharmacolo1987-89 ommittee on Problems of Public Co ncern1989-91 ask Force on C oordinating Academic — Industry & Government Efforts

in Psychopharmacology1989 & '96-98 ask Force o n P sychotropic Drug P rescribing Privileges for Non -physici1988-92 ask Force on Scientific Misconduct1994- entor, NIMH/Mead Johnson Minority Award Program1995-97 inance C ommittee (Cha ir, 1997-98)

11



Ira D. Glick, M.D.

2000-03 onstitution an d Rules Comm ittee (Ch air, 2002-2004)2006-07 o-Ch air of the Education and Training Comm ittee

1973 ssociation for Academic Psychiatry, Charter Member1978-80 ecretary1983 C o-Ch airman and Founder, Section on Re sidency Training

1983-84 ellowship C ommittee

1978 he Hastings Cen ter-Institute o f Society, Ethics and the Life Sciences

1978 merican Family Therapy Acade my1982-84 oard of Trustees1985 Co mmittee on History of AFTA

1980 merican A ssociation of P sychiatric Adm inistrators

1982 ssociation for C linical Psych osocial Research, Foun ding Mem ber1982-85 teering C ommittee1988 Fellow

1984-94 roup for the A dvancement of P sychiatry, Committee o n the Family1991 rogram Com mittee1992 d hoc C omm ittee to De velop Practice Guidelines

1989 sychiatric Research Society

1990 ollegium Internationa le Neuro-Psych opharma cologicum (C.I.N.P.)2002 CINP Regional Comm ittee for North America

1992- cademia, M edicine & P sychiatria Fou ndation1992 ellow

1993- merican Society of C linical Psychopharmacology, Founding M ember1993 - odel Curriculum C ommittee, Chair1995Work Group,Interface with Governme nt & Industry, C linical Trials Com mittee1998 - cientific Advisory Boa rd2001-04 reasurer2005Co-chair, Joint ASC P-AAD PRT C urriculum Project

(with D avid Goldberg, MD )

1993- nternationa l Society for Sports Psychiatry, Foun ding Mem ber1993C hair, Scientific Program1993 - xecutive Board2004 - hair, Nomination C ommittee

1997 est Co ast C ollege of Biological Psychiatry, Fellow1998 Program Ch air

1998 acific Rim C ollege of P sychiatrists, Fellow

2006-2007 CN P, Co -Chair of he Education an d Training Comm ittee

Editor ia l a n d Adviso ry Boa rds :

12



Ira D. Glick, M.D.

1970-1981 amily P rocess

1981 ournal of Clinical Psychopharmacology

1981 ontemporary Family Therapy - An International Journal

1982 - he Jou rnal of Family Therapy (England)

1982-1995 oard of Advisors, Dickinson Co llege

1984-1997 he Journ al of Family Psych otherapy

1984-1987 ational Cou ncil of Advisors on D evelopment and External Affairs, UCS F

1989 rogress in N europsychology and Biological Psychiatry

1990 -2 dvisory Bo ard, Mu ltiM edia Reviews in Psychiatry,, Ma ssachusetts General Hospital.

1993 oard M ember, The National Men tal Health Project

1993 ertindole Advisory Board„ Neuroscience Venture, Abbott Laboratories

1995-1997 ralnick Foun dation A wards Comm ittee

1996 NS Science Advisory Board, Wyeth A yerst Pharmaceutical

1997- 9 dvisory Board, Janssen Pharma ceutica and Research Foun dation

1997- 9 dvisory Bo ard, Institute for H ealthcare Qu ality, M inneapolis

1997 dvisory Board, Zeneca P harma ceuticals

1998 dvisory Board, Otsuka P harma ceuticals

1 999Advisory Board, Hoech st Marion Rou ssel (Aventis)

1 999Advisory Board, NPSP P harma ceuticals Bipolar Clinical Advisory Board, Boca Raton

2001, 5 dvisory Boa rd, Pfizer (Geodon) P harmaceu ticals

2001 oard o f D irectors, National Foun dation for Depressive Illness, Inc.

2002, 4,5 dvisory Bo ard, Shire P harmaceu ticals

2002, 3,4,5 dvisory Boa rd, Bristol-Myers Squibb C alifornia Ne uroscience A dvisory Boa rd

2005 - ditorial Board, The Journal of Clinical Psychiatry

PUBLICATIONS

Books, Monographs, Bibliographies:

1 . aley J, Glick ID: Psychiatry and the Fa mily, An An notated Bibliography o f Articles Pu blished1 960-64. Palo A lto, C alifornia, Family Process, 1 965.

13



Ira D. Glick, M.D.

2. Glick ID, Haley J: Family Therapy and Research: An Annotated Bibliography of Articles and BooksPublished 1 960-1970. New Y ork, Grune and Strat ton, 1971.

3. Glick ID, Kessler DR: Marital and Family Therapy. New Yo rk, Grune an d Stratton, 19741976 - Summa rized in Foote C , Levy RJ, Sande r FEA, Cases an d materials on family law,

second e dition, Boston, Little, Brown, 1 976, pp. 11 53-11 451980 - Seco nd Edition.1985 - Translated into Japanese by Koji Suzuki, M D; 2nd printing, 19891986 - Translated into C hinese by Xiang De-Zha o, MD1987 - Third Edition, with Clarkin JF & Kessler DR. Published by American Psychiatric

Press, Inc., Washington, D .C.2000 - Fou rth Edition, with Berman E, Clarkin JF & Raft D . American P sychiatric Press, In

Washington, D.C.2002 Spanish Edition, translated by Raquel M artin Lana s, Madrid, Grupo M edica

4. Glick ID, Hargreaves WA: Psychiatric Hospital Treatment for the 1980s: A Controlled Study of ShortVersus Long Hospitalization. Lexington, Mass., Lexington Press, 1979.

5. Glick ID, Weber D, Rubinstein D, Patten J: Family Therapy and Research: An Annotated Bibliography ofArticles, Books, Videotapes and Films Published 1950-1 979, 2nd Edition, New Yo rk, rune and Stratton,1982.

6, lick ID, Janowsky DS, Salzman C, Shader RI: A Model Psychopharmacology Curriculum forPsychiatric Residents. Nashville, TN, The American College of Neuropsychopharmacology, 1984

a) Translated into Japane se, Japane se Journal of Psycho pharmaco logy, 6:335-452, 1 986b) Reprinted in Psych opharma cology: The Third Gene ration o f Progress,

edited by Herbert Y. Meltzer. Raven Press, New York, 1313-1321, 1987c) Translated into Japanese for the Lectures o n C linical Psychiatric Issues, Part II,

edited by Yamaguchi T, Tajima S. C hugoku -shikoku Psychotherapy Workshops,Hiroshima an d Nichidai Seishin-shinkeika W orkshops, Tokyo 1 994

7. Grunebaum H, Beavers WR, Berman E, Combrinck-Graham L, Glick ID, et al: (Formulated by theCo mmittee on the Family, Group for the Advan cemen t of Psychiatry), The Family, the Pa tient, andthe P sychiatric Hospital: Toward a Ne w M odel. New York, Brunn er/Ma zel, 1 985.

8. Clarkin JF, Haas GL, Glick ID (eds): Affective Disorders and the Family: Assessment and Treatment,New York, Guilford Press, 1988.

9. Glick ID (ed): Treating De pression, Sa n Fran cisco, Jossey-Bass, 1995.

10. DeBattista C, Glick ID (ed.). The Medical Management of Depression. Essential Medical InformationSystems, Inc. Durant, OK: 1996.

1998 - Second Edition2002 — Third Edition

11. Glick ID, D oraiswarmy P M , Halper J, et al:2001 - Second Edition2004- Th ird Edition

• Glick ID, Ellison J, Halper J, et al: The ASC P M odel Psych opharma cology C urriculum, for PsResidency Programs, Training Directors, and Teach ers of Psychoph armaco logy. The A mericanSociety of Clinical Psychopharmacology, Inc. New York, 2004.

12. Ritvo EC , Glick ID: The C oncise Guide to M arriage an d Family Therapy. American P sychiatric PreWashington, DC , 2002.

14



Ira D. Glick, M.D.

2005 panish Edition translated by Jose Luis Nunez Herrejon, Ma drid, Man ual Mo derno pubs.

1 3. andon R, Glick ID, Goldman M , Jibson M D, M arder SR, Mel!man TA: Ma naging Schizophrenia, Comprehensive Primer 2005. McMahon Publishing Group, New York, 2005.

Journal Articles:

1 . Glick ID, Singer B: Follow-up of patients discharged from the rehabilitation service of a hospital fortreatment of ch ronic disease.Arch Phys Med Rehab 44:29-36, 1 963.

2. Greenb erg IM, Glick ID, M atch S, Riback SS: Family therapy: Indications an d rationa le.Arch GenPsychiat 10:7-24, 1964.

3. Glick ID, Grauber D N: Kartagener's syndrome and schizophrenia: Report of a case with chrom osomstudies, Am J Psychiatry 121:603-605, 1954

4. Glick ID, Salerno LF, Royce JR: Psych ophysiologic factors in etiology o f preeclampsia.Arch GenPsychiat 12:260-266, 1965.

5. Glick ID: Mood and behavioral changes associated with the use of the oral contraceptive agents: Areview of the literature.Psychopharmacol 10 :363-374, 1967.

6. Glick ID, Setleis H, Woerner MH, Pollack M: Schizophrenia in siblings reared apart: A casereport. Am J Psychiatry 124:236-240, 1967.

7. Glick ID: The "sick" family and schizophrenia - cause and effect? Supplement, Dis New Syst 29:129-132, May 1 968.

8. Hauptman B, Glick ID: Auditory hallucinations with imipramine.J Hillside Hosp 17:32-34, 1968

9. Mardikian B, Glick ID: Patient-staff meetings: A study of some aspects of content, tone andspeakers. Ment Hygiene 53:303-305, 1969.

10. Glick ID, Sternberg D: Performance IQ as a predictor of hospital treatment Comprehen Psychiat 10:365-368, 1969.

11. Goldfield M D, Glick ID: Self-mutilation o f the female ge nitalia.J Nerv Ment Dis 31 :843-845, 1970.

12. Glick ID, Ha uptman B, Klein D F: Pseudo pregnancy treatment o f periodic psychiatric illness: A pilostudy. Psychiat Quart 44:403-407, 1 970.

1 3, hastko HE, Glick ID, Gould E, Hargreaves WA: Patients' posthospital evaluation of psychiatric nursingtreatment. Nurs Res 20:333-338, 1971 .

1 4. lick ID, Winstead D : Ch ildhoo d a sociality in the differential diagno sis of schizophrenia with drugvs. psycho sis with drug intoxication .Psychiat Quart 47:208-217, 1 973.

1 5. 'Hanrahan T, Glick ID: Drug a buse an d function in graduate students.Comprehen Psychiat 14:235-240, 1973.

16. angee H, Glick ID, Hoffma n B, Silver LB, Morrison AP : The requirements of a residency trainingprogram, circa 1 972.Am J Psychiatry 130:1151-1152, 1973.

17. lick ID, Goldfield MD, Kovnat P: Recognition and management of psychosis associated withhemodialysis. Calif Med 11 9:56-59, 1973.

15



Ira D. Glick, M.D.

35. Braff D, Stone C, C allaway E , Geyer M , Glick ID, Bali L: Prestimulus effects on hum an startle reflnormals an d schizophrenics.Psychophysiology 15:339-343, 1978.

36. Drues J, Hargreaves WA, Glick ID, Klein DF: Premorbid asocial adjustment and outcome inschizophrenia.J Nerv & Ment Dis 166:881-884, 1978.

37. Braff DL, Bachman J, Glick ID, Jones R: The therapeutic community as a research ward: Myths andfacts. Arch Gen Psychiat 36:355-360, 1 979.

38. Kessler D R, Glick ID : Brief fam ily th erapy. Psych iatric C linics of N orth A merica, 2:75-84, 1979. (Rin Adva nces in Fa mily Psych iatry, Vol. III, Howells J (Ed), NY Int. Pre ss).

39. Glick ID, Hargreaves WA: Hospitals in the 1980s: Service, training and research. Hosp & CommPsychiatr 30:125-128, 1979.

40. Da vis C, Glick ID, Ro sow I: The architectural design o f a psycho therapeutic milieu.Hosp & CommPsychiatr 30:453-460, 1 979.

41. Glick ID, Kessler DR: Family Therapy, in the American Psychiatric Association's Syllabus for Self-Assessment P rogram (PKSAP=IV), 1979, pp 131 -1.

42. Glick ID, Stewart D: A new drug treatment for premenstrual exacerbation of schizophrenia.Comprehensive Psychiatry 21:281-287, 1980

43. Glick ID, M arcotte D B: Psychiatric aspects of baske tball.Psychiatric Annals 10:3, 1980.

44. C larkin JF, Glick ID: D uration o f hospitalization as a variable in ou tcome.The Psychiatric Hospital 13:50-54, 1982.

45. Young RC, Gould E, Glick ID, Hargreaves WA: Personality inventory correlates of outcome in a followup

study of psych iatric ho spitalization .Psychological Reports 46:903-906, 1 980.46. Binder R, Glick ID, Rice M: A comparative study of parenteral molindone and haloperidol in the acutely

psychotic patient.J Clin Psychol 42:203-206, 1981 .

47. Johnson GR, Glick ID, Young R: Length of stay of patients in sheltered care and physical space: Acomparative study.Psychological Reports 47:703-708, 1980.

48. Glick ID, Braff DL, Johnson J, Showstack JA: Outcome of irregularly discharged psychiatric patients. AmJ Psychiatry 13 8:1472-1476, 1981 , (French translation, Mede cine et Hygiene, 44:3320-3328, 1 986)

49. Glick ID: A family the rapist in the P eople's Republic of Ch ina.Intl J Family Therapy, 4:177-183, 1982

50. Pyn oos RS , Glick ID: The use o f joint consultations in inpatient psychiatry.Am J Psychiatry, 140:596-5981983.

51. Clarkin JF, Glick ID: Recent developments in family therapy: A review. Hosp Comm Psychiatry, 33:550-556, 1982. Reprinted inPsychotherapies (French).

52. Glick ID, Showstack JA, Klar HM: Toward the definition and delivery of appropriate care. Am J Psychiatry13 9:908-909, 1982.

53. Braff DL, Glick ID, Griffin P : Thou ght disorder and de pression in psychiatric patients.Comp Psychiatry,24:57-64, 1 983.

17



Ira D. Glick, M.D.

54. Frosch WA, Glick ID, Talbott JA: The teacher as impediment to learning: The problem of focalconviction.Arch Gen Psychiatry, 40:1257, 1983.

55. Glick ID, Borus JF: Marital and family therapy for troubled physicians and their families. JAMA, 251:1855-1858, 1984.

1. Translated into Japanese, JAMA,pp 27-32, 1984

56. Brown R, Kocsis J, Glick ID : Efficacy and feasibility o f high dose tricyclic an tidepressant treatmen telderly delusional depressives.J Clin Psychopharm, 4:311 -315, 1984.

57. Glick ID, Klar HM, Braff DL: Guidelines for hospitalization of chronic psychiatric patients. Hosp & CommPsychiatry, 35:934-936, 1 984.

58. Ch en C , Glick ID: C ore tasks in the resident's mastery of psychiatric administration.Admin in MentalHealth, 12:207-211, 1985.

59. Glick ID, C larkin JF, Spen cer JH, et al: Inpatient fam ily intervention. A controlled evaluation o f praPreliminary results of the six-months follow-up.Arch Gen P sychiatry, 42:882-886, 1985. Reprinted in theSixth Edition o f the P sychiatric Knowledge a nd Skills Self-Assessment P rogram VI of the A mericanPsychiatric Association

60. Roy-Byrne P, P yno os RS, Glick ID: The inpatient psychiatric unit as consultation service.Can JPsychiatry, 31:54-58, 1986.

61. Glick ID, Spencer J: Inpatient family therapy: On the boundary between past and present. Fam Proc,24:349-352, 1985.61.

62. Janowsky DS, Glick ID, Lash L, et al: Psychobiology and psychopharmacology: Issues inclinical research training.J C lin Psychopharmacol, 6:1-7, 1986.

63. Gruenke LD, Craig JC, Klein FK, Glick ID, et al: Determination of chlorpromazine and its majormetabolites by gas chromatography/mass spectrometry: Application to biological fluids. Biomedical MassSpectrometry, 12:707-713, 1 985.

64. Glick ID, Fleming L, D eC hillo N , et al: A co ntrolled study of transitiona l day care for no n-chronicapatients. Am J Psychiatry, 143:1551-1556, 1 986.

65. Glick ID: Treating the new American couple. J of Sex & Marital Therapy, 12:297-306, 1986. Translatedinto Japanese for the Journal of the Japanese Association of Group Psychotherapy, 1988.

66. Haas GL, Glick ID, Spencer JH: The patient, the family, and compliance with posthospital treatment foraffective disorders. Psychopharmacology Bulletin,22:999-1005, 1986.

67.Talbott JA, Glick ID: The inpatient care of the chronically mentally ill. Schizophrenia Bulletin, 12:129-1401986.

68. Haas GL, Glick ID, Clarkin JF, et al: Inpatient family intervention: A randomized clinical trial II. Results athospital discharge. Arch Gen Psychiatry, 45:217-225, 1988.

69. Braff DL, Glick ID, Johnson MH, Zisook S: The clinical significance of thought disorder across time inpsychiatric patients. J Nerv M ent Dis, 176:213-220, 1988.

70. Glick ID, Marcotte DB: Psychiatric aspects of basketball. JSports Medicine & P hysical Fitness,29:104-11 2, 1989.

18



Ira D. Glick, M.D.

71. Greenberg L, Fine SB, Cohen C, Larson K, Michaelson A, Rubinton P, Glick, ID: An interdisciplinarypsychoedu cation program fo r schizophrenic patients an d their families in an acute ca re setting.Hospital &Comm unity Psychiatry, 39:277-282, 1988.

72. An dreason NC , Glick ID: Bipolar affective disorder and crea tivity: Implications and clinical mana ge

Com prehensive Psychiatry, 29:207-217, 1 988.

73. Spencer JH, Glick ID, Haas GL: A randomized clinical trial of inpatient family intervention, Ill. Overalleffects at followup for the entire sample.Am J Psychiatry, 145:1115-1121, 1988.

74. Burti L, Glick ID, Tansella M : Mea suring the Treatment En vironm ent of a Psychiatric Ward and aCo mmun ity M ental Health C enter After the Italian Reform.Comm unity Mental Health Journal,26:193-201, 1990.

75. Glick ID, Showstack JA, Co hen C , Klar HM : Between P atient and Do ctor: Improving the Qu ality oSerious M ental Illness.Bulletin of the Menn inger Clinic,53:193-202, 1989.

76. Glick ID , Spencer JH, C larkin JF, et a l: A Ran domized C linical Trial of Inpatient Fam ily InterventioFollowup Results for Subjects with Schizophrenia.Schizophrenia Research, 3:187-200, 1990.

77. Glick ID, Jacobs M , Lieberma n J, et al: Prediction o f Sho rt Term Outcom e in Schizophrenia: DepreSymptoms, Ne gative Sy mptoms, and Extrapyramidal Signs.Psychopharm acology Bulletin,25:344-347,1989.

78. C larkin JF, Glick ID, Ha as GL, et al: A ran domized clinical trial of inpatient fa mily intervention, V. for affective disorders.J Affective Disorders,18:17-28, 1990.

79. Glick ID, Burti L, Suzuk i K, Sack s WI: Effectiven ess in psychiatric care: I. A cross-nation al study ofprocess of treatment an d outcom es of major depressive disorder.J Nerv Ment Disease, 179:55-63, 1991

80. Glick ID , C larkin JF, Haas G, e t al: A ran domized clinical trial of inpatient family intervention: VI. Mvariables and ou tcome.Family Process, 30:85-99, 1991 .

81. Haas GL, Glick ID, Clarkin JF, et al: Gender and schizophrenia outcome: A clinical trial of an inpatientfamily intervention.Schizophr Bull, 16:277-292, 1990.

82. Glick ID : Improving treatment fo r the severely men tally ill: Implications of th e de cade-long Italianpsychiatric reform.Psychiatry, 53:316-323, 1990.

83. Glick ID, Burti L, Minakawa K, Maehara K, Sacks M: Effectiveness in psychiatric care: II. Outcome for thefamily after hospital treatmen t for major affective disorder.Annals of Clinical Psychiatry,3:187-198, 1 991

84. Glick ID, Janowsky DS, Salzman C, Shader RI: A proposal for a model psychopharmacology curriculumfor psych iatric residents.Neuropsychopharmacology, 8:1-5, 1993.

85. Glick ID , Burti L, Suzuki K, Sack s M : Effectiveness in psychiatric care: IV. Ach ieving effective m edmana gement for major affective disorder.Psychopharm acology Bulletin28:257-259, 1 992.

86. Glick ID: M edication a nd family therapy for schizophrenia and m ood disorder.PsychopharmacologyBulletin, 28:223-225, 1992.

87. Olfson M, Glick ID and Mechanic D: Inpatient treatment of schizophrenia in general hospitals. Hospital &Comm unity Psychiatry, 44:40-44, 1993.

19



I ra D. Gl ick , M.D .

88. Glick ID, Burti L, Okonogi K, Sacks M: Effectiveness in psychiatric care: Ill. Psychoeducation andoutco me fo r patients with m ajor affective disorder an d their families.British Journal of Psychiatry, 164:104-106, 1994.

89. Glick ID , C larkin JF, Ha as GL, Spen cer JH: C linical significance of inpatient fam ily intervention: VConclusions from the clinical trial.Hospital and Com munity Psychiatry, 44:869-873, 1993.

90. Glick ID , Du lit RA, W achter E, C larkin JF: The family, family the rapy & b orderline personality disoJPsychotherapy Practice and Research , 4:237-246,1995.

91. Carpenter D, Clarkin JF, Wilner PJ, Glick ID: Personality pathology among married adults with bipolardisorder. Journal of Affective Disorders,34:269-274, 1995.

92. Guttman HA, Beavers WR, Berman E, Combrinck-Graham L, Glick ID, et al: A model for theclassification an d diagnosis of relationa l disorders.J Psychiatric Services, 46:926-932, 1995.

93. Hanrahan M, Glick ID: Improving outpatient treatment for severely mentally ill persons: doing the rightthing. Administration Policy in Mental Health,23:459-463, 1 996.

94 . Scho oler NR, Severe JB, Glick ID, Hargreaves WA, Keith SJ: Transition From Acu te To M aintenanTreatment: Prediction of Stabilization.Internat'l Clin Psychopharm, 1 1 (suppl2):85-91, 1 996.

95 . Glick ID, Lecrubier Y, Montgomery S, Vinar 0, Klein DF: Efficacious and safe psychotropics not availablein the Un ited States.Psych Annals, 26:354-361, 1 996.

96. Schoo ler NR, Keith SJ, Severe JB, Matthe ws SM , Bellack A S, Glick ID: Relapse an d rehospitalizatiduring maintenan ce treatment of schizophrenia: The effects of dose reduction and fam ily treatmentArchives of Gen Psych, 54:453-463, 1 997.

97. Guttman HA , Beavers WR, Berman E, Co mbrinck-Graham L, Glick ID, et al: (Group for the Advanof Psych iatry Com mittee on the Family): Global assessment of relational functioning scale (GARF)Background and Rationale,Family Proc, 35:155-172, 1996.

98. Clarkin JF, Ca rpenter D, Hu ll J, Winer P, Glick ID: Effects of psychoeduca tional intervention fo r mbipolar patients and their spouses.Psychiatric Services, 49:531 -533, 1998.

99. Glick ID : The inpatient family intervention (IFI) experience.Italian J Psych Behav S ci, 1:1-9, 1997.

100. Pea rsall R, Glick ID, Pickar D , Suppes T, Tauscher J, Jobson KO: A n ew algorithm for treatingschizophrenia.Psychopharmacology Bulletin, 34:349-353, 1998.

101. Schu ltz SC, Thompson P, Jacobs M , Ninnan P T, Robinson D, Weiden P , Yadalam K, Glick ID: Lithaugme ntation fails to redu ce symptoms in po orly responsive schizophren ic outpatients.J Clin Psychiatry,60:366-372, 199 9.

102. M ordaca i D, Glick ID: Divalproex for the treatm en t of geriatric bipolar disorder.In JGeriatric Psychiatry, 14:494-496, 1999.

103. Amb rosini PJ, Wagner KD , Biederman J, Glick I: M ulticenter ope n-label sertraline study in adolescoupatients with ma jor depression.J Am Child Adolesc Psychiatry,38:566-572, 1999.

104. Jeste D V, Glick ID : Editors' Introduction: "Intervention research in psychosis: past, present, and futuSchizophrenia Bulletin,26:527-531, 2000 .

20



Ira D. Glick, M.D.

105. M ueser KT, Sengu pta A, Schoo ler NR, Bellack A S, Xie H, Glick ID, Keith SJ: Family treatmen t anmedication dosage redu ction in schizophrenia: effects on patient so cial functioning, fam ily a ttitudeburden. J Consulting & Clinical Psychology; 69:3-12, 2001 .

106. Glick ID, Su ppes T, DeBattista C , Hu R, M arder S: Clinical update: psychopha rmacological treatmestrategies fo r depression, bipolar disorder an d schizophrenia.Annals Internal Medicine 134:47-60, 2001 .

107. Glick ID, Jano wsky D S, Zisook S, Lydiard RB, Oe sterheld J, Ward NG , Ellison J, Shea r MK, D oraiPM , Preven D W, Ross P, Klein D F: Teaching psychopharmaco logy in the 1990s: the first year expewith The Am erican Society of Clinical Psych opharma cology model psychopharma cology curriculuAcademic Psychiatry, 25:1-8, 2001.

108. Glick ID, Horsfall JL: Psy chiatric con dition s in sports: diagno sis, treatm en t, and qua lity of life.Th ePhysician and Sportsmedicine, 29: 45-55, 2001 .

109. Glick ID, Lemme ns P, Vester-Blokland E: Treatmen t of the symptom s of schizophrenia: a combinedana lysis of do uble-blind studies comparing risperidone with haloperidol and o ther an tipsychotic ageInternational Clinical Psychopharmacology, 16:265-274, 2001 .

110, lein DF, Glick ID et al: Improving clinical trials: American Society of Clinical Psychopharmacologyrecommendations.Archives of General Psychiatry, 59:72-278, 2002.

111. Glick ID, M urray SF, Vasudevan P M arder SR, Hu RJ: Treatment with atypical antipsychotics: newindications and n ew populations.J Psychiatric Research 35:187-191, 2001.

112. Glick ID, Berg P H: Time to study discontinuation, relapse and com pliance with atypical or con ventiantipsychotics in schizophrenia an d related disorders.International Clin Psychopharm 1 7:65-68, 2002.

113. Glick ID, D ixon L: Patient and family support organization services shou ld be included as part of trfor chronic psychiatric illness.J Psychiatric Practice, 8:63-69, 2002.

114. Da vis JM, C hen N, Glick ID: A meta-ana lysis of the efficacy of second-gene ration antipsychotics.Archivesof General Psychiatry 60:553-564, 2003.

115. Stroup TS, M cEvoy JP , Swartz MS , Byerly M, Glick ID, et al: The NIM H an tipsychotic trials of inteffectivene ss (CA TIE) project: Schizophren ia trial design and protocol development.SchizophreniaBulletin 29:15-32, 2003.

116. Jibson M D, Glick ID, Tando n RT: Schizophrenia and o ther psychotic disorders.Focus 2:17-30, 2004.

117. Glick ID, C arter WG, Tando n R: A paradigm for treatment o f inpatient psychiatric disorders: from ato intensive care. J Psychiatric Practice 9:1-5, 2003.

118. Glick ID, Zan inelli R, Hsu C , et al: Patterns o f conco mitant psychotropic medication use du ring a twstudy comparing clozapine a nd olanza pine fo r the prevention of suicidal beh avior.J Clinical Psychiatry65:679-685, 2004 .

119. Glick ID: Adding psychotherapy to pharmacotherapy: data, benefits, and guidelines for integration. Am JPsychotherapy 58:186-208, 2004.

120. Zisook S, Benjamin S, Balon R, Glick ID, et al: Alternate metho ds of teaching psycho pharmaco logyAcademic Psychiatry 29:141-154, 2005.

121. Glick ID: Undiagnosed b ipolar disorder: new syndrom es and n ew treatmen ts.The Primary CareCompanion to the J Clin Psychiatry 6:27-33, 2004.

21



Ira D. Glick, M.D.

122. Glick ID, Zisook S: The challenge of teaching psycho pharmaco logy in the new millenn ium: the rolecurricula.Academic Psychiatry 29: 134-140, 2005.

123. Green A l, Tohe n M F, Hamer RM , et al: First episode schizophrenia-related psycho sis and sub stancedisorders: acute response to olanzapine and haloperidol.Schizophrenia Research 66:12 5-135, 2004.

124. Glick ID : Psych osis: new pe rspectives and strategies:l'Encephale 37:49-50, 2001.

125. Glick ID: A typical antipsychotics: new data an d ne w con troversies.Japanese J Clin Psychopharmacology6:500-512, 2003.

126. Simpson GM , Glick ID, Weiden P J, Romano SJ, Siu C O: Rando mized, controlled, doub le-blindmulticenter co mparison of the e fficacy and to lerability o f ziprasidone an d olanzapine in acutely ill iwith schizophrenia or schizoaffective disorder.Am J Psychiatry 161:1837-1847, 2004.

127. Glick ID, M arder SR: Long-term maintenan ce therapy with quetiapine versus haloperidol decano atepatients with schizophrenia o r schizoaffective disorder.J Clinical Psychiatry 66:638-641, 200 5.

128. Ritvo EC, Glick ID: Fa mily problems a nd sports performance.Physician & Sportsmedicine 33:37-41, 2005

129. Glick ID, D uggal V, Hodu lik C : Aripiprazole as a dopamine partial agon ist: positive and n egative efClinical P sychopharmacology (in press).

Book Chapters & Columns:

1 . Glick ID, Bennett SE. Psychiatric effects of progesterone and oral contraceptives. In: Shader R (ed)Psych iatric Complications of M edical Dru gs. New Y ork, Raven P ress, 1972, pp 295-331 .

2. Glick ID. Psychotropic action of oral contraceptives. In: RH TM (ed), Psychotropic Action of Hormones.Wh ite Lake , NY, Spectrum P ublications, Inc., 1976, pp 155-167.

3. Glick ID. The quality of delivery of mental health services to the community. In: Serban G (ed) NewTrends of P sychiatry in the C omm unity. Cam bridge, Ballinger Pub lishing Co ., 1977, pp 203-206.

4. Kessler DR, Glick ID. Family therapy. In: Ostwald P, Ruesch J (eds) Communication and HumanInteraction. Ne w Yo rk, Grune an d Stratton, Inc., 1977.

5. Glick ID. Practical considerations (Discussions of "The effects of social class on parental values andpractices" by Kohn M L and of "The developmen t of children in mothe r-headed families" by HetherEM, Cox M, Cox R), In: Reiss D, Hoffman H (eds) The American Family: Dying or Developing. NewYo rk, Plenum P ress, 1979, pp 73-78, 14 7-150.

6. Glick ID, Kessler DR, Clarkin JF. Approaches to family therapy. In: Arieti S, Brodie HKH (eds),

Am erican Handbo ok o f Psychiatry, Volume VII, New Y ork, Basic Book s, 1981, pp 388-407.7. Glick ID, Clarkin JF. The effects of family presence and brief family intervention for hospitalized

schizophrenic patients: A review, In: Harbin HT (ed) The Psychiatric Hospital and the Family. Spectrum,Inc., 1982, pp 157-171 .

8. Clarkin JF, Frances AJ, Glick ID. The decision to treat the family: Selection criteria and enabling factors.In: Aronson ML, Wolberg LW (eds) Group and Family Therapy. New York, Brunner/Mazel, 1981, pp 149-167.

22



Ira D. Glick, M.D.

9. Glick ID , C larkin JF.Family therapy when an affective disorder is diagnosed. In: Gurman AS (ed)Que stions & A nswers in the Practice of Family Therapy, New Y ork, Brunne r/Mazel, 1981 , pp 250-

10. Glick ID, Bennett SE.Oral contraceptives and the menstrual cycle. In: Friedman RD (ed) Behavior andthe M enstrual Cycle. New York, M arcel Dekke r, Inc, 1982, pp 345-365.

11. Glick ID, Borus J.Family therapy for the impaired physician. In: Scheiber SC, Doyle BD (eds) TheImpaired Ph ysician. New Yo rk, Plenum Press, 1983, pp 97-108.

12. C larkin JF, Glick ID.Supervision of family therapy. In: Blumenfield M (ed) Applied Supervision inPsycho therapy. Grune and Stratton, 1 982, pp 87-106.

13. Gruneba um H, Glick ID.The basics of family treatment. In: Grinspoon L (Ed): Psychiatry Update, VolII. Washington AP A P ress, 1 983, pp 185-203.

14. M agaro P A, Talbott JA, Glick ID.The inpatient care of chronic schizophrenia. In: Bellack AS (ed),Schizophrenia - Treatment, Man ageme nt, and Reha bilitation. Orlando, FI, Grune and Stratton, 1 98193-218.

15. Haa s GL, Clarkin JF, Glick ID.Marital and family treatment of depression. In: Beckham EE, Leber WR(eds), Handbook of Depression: Treatment, Assessment, and Research. Homewood Illinois, TheDo rsey Press, 1985, pp 151 -183.

16. Glick ID. Treatment of premenstrual syndrome in psychiatric practice. In: Osofsky HJ, Blumenthal SJ(eds) Premenstrual Syndrome: Current Findings & Future Directions, Progress inPsychiatry. Washington , D.C., Ame rican P sychiatric Press, 1985, pp 57-65.

17. Glick ID, Clarkin JF.The family model of intervention. In: Sederer L (ed) Inpatient Psychiatry: Diagnosisand Treatment, Seco nd e dition. Baltimore, W illiams an d Wilkins, 1986, pp 296 -307 (third edition, 1255-276).

18. Stewart TJ, Bjorksten OJ, Glick ID .Sociodemographic aspects of contemporary American marriage. In:Bjorksten OJ (ed) New C linical Con cepts in M arital Therapy. Washington , D.C., American P sychiaPress, Inc. 1985.

19. Glick ID, Ha as GL, C larkin JF:The family and posthospital treatment compliance among affectivedisorders. In: Halbreich U, Feinberg SS (eds) Psychosocial Aspects of Nonresponse to AntidepressantDrugs, Washington, D ,C., American Psychiatric Press, 1986.

20. Glick ID, Quitkin FM, Benn ettSE: The influence of estrogens, progestins and oral contraceptives ondepression, In: Halbreich U, Rose R, (eds) Hormones and Depression, New York, Raven Press, 1987,pp 339-356.

21. Talbott JA, Glick ID:The inpatient care of the chronic mentally ill. In: Lion JR, Adler WN, Webb WL

(eds) M odern Ho spital Psychiatry. New Y ork, Norton & C ompan y, 1988, pp 352-370.22. C raig JC , Gruenke LD, Klein FD , Glick ID, etal. Development of a method for the determination of

chlorpromazine and its major metabolites by gas chromatography/mass spectrometry, and application tobiological fluids, Perspectives in Psychopharmacology: A Collection of Papers in Honor of Earl Usdin,Edited by W. Bun ney and R. Barcha s, New Y ork, Alan R. Liss, Inc., 1988, pp 375-389.

23. Glick ID, C larkin JF, Haa s GL.Family and Couple Therapies, in Treatments of Psychiatric Disorders(Karasu, T. Byram, (ed) A Task Force Report of the American Psychiatric Association, Washington, D.C.APP I, 1989.

23



Ira D. Glick, M.D.

24. Clarkin JF, Glick ID , Haas GL, Spen cer, JH Jr.Inpatient Family Intervention for Affective Disorders . In:Keitner, GI (ed) Depression and Families: Impact and Treatme nt, Progress in P sychiatry Series,Am erican Psychiatric Press, Wash. DC , 1990.

25. C larkin JF, Haas GL, and Glick ID:Inpatient Family Intervention. In: Clarkin JF, Haas GL and Glick ID(eds) Affective D isorders and the Fam ily: Assessment an d Treatmen t, New Y ork, Guilford Press, 19

134-152.

26. Clarkin JF and Glick ID:Instruments for the Assessment of Family Malfunction. In: Wetzler S, (ed),M easuring M ental Illness: Psych ome tric Assessment fo r Clinicians, American P sychiatric Press,Washington , D.C . 1 989, pp 211 -227.

27. Glick I D , Du lit RA, Wa chter E, Clarkin JF:A Survival Guide for Patients with Borderline PersonalityDisorder and Their Families. In: Minakawa K (ed) New Approaches to the Borderline Syndrome, Toyko,Iwasaki Gakujutsu Shuppan , 1991, pp 158-168.

28. Glick ID, Freund NY a nd Olfson M :What a Psychiatric Hospitalization Can and Cannot Do: A Review ofEfficacy Studies. In: Persad E, Kazarian SS and Joseph LW (eds) The Mental Hospital in the 21stC entury. Toronto , Cana da, Wall & Emerson, Inc., 1992, pp 191 -204.

29. C larkin JF, Haas GL an d Glick ID:Family and Marital Therapy. In: Paykel, ES. (ed) Handbook ofAffective Disorders, 2nd edition. N ew Y ork, C hurch ill Livingstone , 1992, pp 487-500.

30. Glick ID, C larkin JF and Goldsmith SJ:Combining Medication with Family Psychotherapy. In: Beitman B(ed), C omb ined Treatments, the Ame rican P sychiatric Press Review of Psychiatry, Vol. 1 2. WashingD.C . American Psychiatric P ress, Inc., 1993, pp 585-610.

31. Klerman GL, Weissman M W, M arkowitz J, Glick ID, Wilner PJ, Mason B, Shear M K:Medication andPsychotherapy. In: Bergen, AE and Garfield, SL (eds), Handbook of Psychotherapy and BehavioralC hange, 1 994, John Wiley, New Y ork. fourth edition, pp 734-781.

32. Glick ID, Braff D, Janowsky D :Short and Long-Term Psychopharmacological Treatment Strategies. In:Psychopharmacology: The Fourth Generation of Progress, Bloom FE, Kupfer DJ (eds). Raven Press,New York, 1 995, pp 839-848.

Revised: Glick ID, M arder S, Janowsky D , Suppes T, DeBattista C :New short- and long-termpsychopharmacologic treatment strategies for schizophrenia, bipolar disorder and depressivedisorder. In: Watson SJ, Deutch A (eds), Psychopharmacology: The Fourth Generation of ProgressCD-ROM, Philadelphia, PA, Lippincott-Raven, 1998.

33. DeBattista C, Glick ID:The applicability of pharmacotherapy for neurosis and personality disorder: In:C urrent Opinion in Psychiatry, 1995, pp. 102-105.

34. Glick ID : Unbundling the Function of an Inpatient Unit: In: JP Docherty (ed), Inpatient Psychiatry in the1990's: New Directions in Mental Health Services. San Francisco: Josey Bass, 1994, pp. 35-43.

35. Glick ID : Neuroleptic-psychosocial interactions and prediction of outcome. In: Gaebel W, Awad AG(eds): Prediction of Neuroleptic Treatment Outcome in Schizophrenia - Concepts and Methods. NewYo rk, Springer-Verlag, 1994: pp 65-70.

36. Thase M E, Glick ID:Combined Treatment. In: Glick ID (ed), Treating Depression. San Francisco,Jossey-Bass, 1995, pp 183-208.

37. Sholevar GP, Glick ID, Sholevar EH:Family Intervention and Psychiatric Hospitalization. In: Textbook ofFamily and Cou ples Therapy. Edited by GP Sho levar and LD Sch woeri. Wash ington, DC , AmericanPsy chiatric Pub lishing, Inc., 2003, pp 637-655.

24



Ira D. Glick, M.D.

38. Glick ID, Lecrubier Y, Mon tgomery SA , Vinar0, Klein D. Promising Psychopharmacological Agents*Available in Europe. In: Schatzberg AF, Nemeroff CB (eds), Textbook of Psychopharmacology.Wash ington, DC , American P sychiatric Press,1995: pp 839-846.

39. Glick ID, Clarkin JF: Family In: Sacks MFI, Sledge WH, Waren C (Eds) Core Readings in Psychiatry: An

An notated Gu ide to the Literature, Washington, AP PI, 1995: pp. 63-70.

40. Clarkin JK, Glick ID: Family and Marital Therapy In: Sacks MH, Sledge WH, Waren C (Eds) CoreReadings in Psychiatry: An An notated Gu ide to the Literature, Washington, AP PI, 1995: pp. 553-56

41. Glick ID, Clarkin JF: Family Support and Intervention. In: Sederer LI and Rothschild AJ, Acute CarePsychiatry: D iagnosis and Treatment, Ba ltimore, Williams & Wilkins, 1 997: pp. 337-354.

42. Glick ID: Familiy Associations and Family Therapy: from Conflict to Collaboration. In: Clerici M,Bertrando P (Eds) Psychoedu cation an d Self-Help in M ajor Psychiatric Disorders, Torino, Italy,Boringhieri Editore, (in press)

43. Belanoff JK, Glick ID: New P sychotropic Drugs for Axis I Disorders: Recently Arrived, in DevelopNever Arrived. In: Schatzberg AF, Nemeroff C B (eds), Textboo k of Psych opha rmacology, Secon d EWash ington, DC , American Psychiatric Press, 1 998, pp 101 5-1026.

44. Glick ID: Family therapies: efficacy, indications a nd treatmen t outcom es. In: Jano wsky D F (ed),Psycho therapy: Indications and Ou tcomes, Ame rican P sychiatric Press, 1999, pp 303-321 .

45. Jeste D V, Glick ID : Editors' introduction: intervention research in psychosis: past, present, and futurNIM H Sch izophrenia Bulletin, 26:527-531, 2000.

46. Belanoff JK, Glick ID: New Psychotropic Drugs for Axis I Disorders. In: The Essentials of ClinicalPsychopharmacology. Edited by AF Schatzberg and CB Nemeroff. Washington, DC, AmericanPsychiatric P ress, 2001, pp 701-714.

47. Tandon R, Glick ID: Introduction. In: Managing Schizophrenia: A Comprehensive Primer. New York,M cMa hon Pub lishing, 2002, pp. 6-9.

48. Glick ID, Loraas EL: Family Treatmen t of Borderline P ersonality Disorder, In: Family The rapy and Health. Edited by M acFarlane M M . New York, NY, The Haworth Press, 2001, pp 135-150.

49. Ritvo EC , Glick ID: Co uples Therapy, for the text, Textboo k of P sychiatry, Second Edition, Edited Tasman A, Lieberman J, Kay J. England, John Wiley & Sons, Ltd, 2003, pp 1792-1806.

50. Glick ID, M ullen B: Family Intervention in the Treatme nt of P ersonality Disorder and Issues of C oIn: Person ality Disorder and the Fa mily (in press).

51. Liberman RP , Glick ID: D rug an d psychosocial curriculum fo r psychiatric residents in the treatme nschizophrenia. Psychiatric Services 55:1217-1219, 2004

52. Glick ID , Horsfall JL: Diagnosis and Psychiatric Treatment o f Ath letes. In: C linics in Sports M ediciEdited by Tofler IR and M orse ED , Elsevier, NY, 2005, pp. 771-781.

53. Glick ID, M ullen B: Family Intervention in the Treatmen t of Pe rsonality D isorder and Issues of C oIn: Personality Disorder: Current Research and Treatments. Edited by Reich J, Routledge, Taylor &Francis Group, New York, 2005, pp.1 85-201.

Editorials:

25



Ira D. Glick, M.D.

1 . Glick ID, Showstack JA, Klar HM: Toward the definition and delivery of appropriate care. Am J Psychiatry13 9:908-909, 1982.

2. GAP C omm ittee on the Family: The cha llenge o f relational diagno ses: Applying the biopsycho sociin DSM -IV.Am J P sychiat, 146:1492-1494, 1989.

3. Judd LL, Glick ID: The N ational Institute of M ental Health: prospects and promises.Biol Psychiatry,26:545-546, 1989.

4. Glick ID, Zisook S, Schader RI: The challenge o f teaching psychopharm acology an d improvingC linical practice.J C lin Psychopharmacology, 25:203-205, 2005

5, isook S, Glick ID, Goldberg DA : Cha llenges an d opportunities in teaching psychopharma cology dresidency training.J Clin Psychiatry 66:948, 2005.

Book Reviews:

1 . Glick ID: Treating the Treatmen t Failures by A rnold M . Ludwig, Grune & Stratton, Inc. 1971 , 235 pCalifornia Medicine177: 104, July 1972.

2. Glick ID: M om's House, D ad's House by Isola Ricci, Ma cmillan Pu blishing Co . 1980, 270 pp.J PsychiatryLaw, Federal Legal Publications, Inc.,1982.

3. Glick ID, Clarkin KC: Handboo k of Family Therapy edited by Gurman AS an d Kniskern DP , Brunn1981 , 796 pp. Hospital and Comm unity Psychiatry33: 490-491, June 1 982.

4. Glick ID: Inpatient Psychiatry: Diagnosis and Treatment edited by Sederer LI, Williams and Wilkins, 1983,337 pp. New E ngland J Medicine309:619, 1983.

5. Glick ID, Clarkin KC : The Strength of Family Therapy: Selected papers of Nathan W. Ackerma n,Brunner/M azel, 1982, 460 pp.J Marital and Family Therapy329-330, July 1 985.

6. Perry S, Glick ID: M assachusetts Gene ral Hospital Handboo k of Ge neral Hospital Psychiatry editedThomas Hackett and Ned C assem, PSC 1 987, 658 pp.NEJM 317:1609, 1987.

7 l ick ID: The C reat ive Process of Psychotherapy by A rnold Rothenberg, WW Norton & C o, 1987,Am J P sychiatry 146:675, 1989.

8. Glick ID: Bringing Up Baby — Without D estroying Mo mmy a nd D addy by Jerry Lewis, Brunner/Mxii + 201 pp.Contem porary Psychiatry9:96, 1990.

9. Glick ID: Evaluating Family Me ntal Health by John Schwab , J Stephen son, John Ice, Plenu m, 1993

pp. Psychiatric Times, p. 41, Novemb er 1 994.10. Glick ID: The Sorrow of War: A Novel of North Vietnam (1994) by Bao N inh, New Yo rk Riverhea d

1 996, 235 pp. Am J Psychiatry 157:12, December 2000

Films and Videotapes:

1 . Glick ID, Marshall G: Videotape Playback in Family Therapy. 16mm, B & W, Sound 45 min., 1968

2. Glick ID, Marshall G: Family Therapy: An Introduction. 16 mm, B & W, Sound 45 min., 1970

26



Ira D. Glick, M.D.

Commentaries:

1 . Practice Guidelines for the Treatment of Bipolar Disorders. In Abstracts of Clinical Care Guidelines, 7:5,19 95, pp 3-4,

2. Glick ID: Introduction to the C lassic Article Section. J Psycho therapy P ractice Research 6:151-1 53

27



Ira D. Glick, M.D.

CURRICULUM VITAE - PART II

Teaching Services

University of California, San Francisco 1968-78:

1975-1978 irector of M edical Studen t Education, De pt. of Psych iatry:

First Year Medical Students

1969-1970 a) Behavioral Science and Psychopathology, Seminar Leader, Winter, 2 hrs/wk. Lecture,"Psycho physiologic D isorders," given to e ntire class

1970 b) Basic Clerkship 1-A. Supervisor, 2 hrs/wk, Spring

Second Ye ar M edical Students

1968-1969 a) Psych iatry 1 21 , Basic Psychiatry. Seminar Leader, 3 hrs/wk, Spring, Fall, Winter

1969-1970 b) Psych iatry 1 8, Behavioral Science and P sychopatho logy. Seminar Leader, 3 hrs/wk,Fall Quarter; 2 hrs/wk, Spring Quarter, 1969-70. Course Coordinator, Spring, 1970

1972 c) Psychiatry 100, Psychopathology Co urse Com mittee, Course C oordinator andLecturer, 6 hrs/wk, Winter, 1972

1972 d) Psychiatry 101 , Psychopathology C ourse Co mmittee, Course Co ordinator andLecturer, 6 hrs/wk, Winter, 1972

1973-1977 e) Psychiatry 100-1 01, Introduction to C linical Psychiatry:

1972-73 Course Committee and Lecturer, 6 hrs/wk, Fall-Winter1973-74 Course Coordinator and Lecturer, 6 hrs/wk, Fall-Winter1974-77 Course Supervisor and Lecturer, 6 hrs/wk, Winter-Spring; Lecturer

Third Year Medical Students

1968- ) sychiatry 1 10 , Clinical C lerkship in Psychiatry. I hour/week, 1 968-present;Acting D irector, Fall, 1977-78

Fourth Year Me dical Students

1968-1978 ) sychiatry 1 10 , Clinical Clerkship in P sychiatry. 1 hou r/week

1970-1975 ) ehavioral Specialist Path way, C linical Subpathwa y, Individual an d FamilyTherapy. C oordinator, 1 h our/week , Summe r, Fall, Winter, Spring, 1970-75

Residents, De partment of Psych iatry

1968-1978 a) Basic P sychiatry 1 . Seminar Series P articipant

1968-1978 b) Supervisor, 1st, 2nd, 3rd, and 4th Yea r Psychiatry Residents

1968-1978 c) Seminar on Hospital Psychiatry to P sychiatric Residents. 1 hou r/week

28



Ira D. Glick, M.D.

1970-1972 d) Sem inar, Family Dy na mics and Th erapy . 3 hrs/wk, Fall, '70; Spring, '71; Spring, '72

1969-1970 e) Clinical Psychiatry fo r No n-Psych iatrists. 2 h rs/wk, Fall-Winter

1968-1970 f) Pa ramed ical Staff. 5 hrs/wk

1970 g) Co mmittee to condu ct qualifying examinations for admission to can didacy for PhDdegree , B. Teshe r, Nursing, in the field of family therapy

1972-1973 h) The Teaching-Learning P rocess in P sychiatry. To Psych iatric Residents, Fall-Winter,2 hrs/wk.

1973-1978 i) C oordinator, Basic Psychiatry II, to all Second Y ear P sychiatric Residents

1974-1977 j) C ore semina r, Theory & P ractice of Family Therapy, as part of Basic Psychiatry II, toall second y ear psychiatric residents, 1 974-75, 1975-76,1976-77 with D avid Kessler, M

1976-1977 k) Seminar o n C linical Research D esign, Elective, Third Year P sychiatric Residents

Cornell University Medical College - 1978-1993:

First Year M edical Studen ts

1979 a) Understanding Huma n Beha vior, Preceptor, 10 wee ks, Fall

1980 b) Understanding Hum an Be havior, Lecturer and Pan elist, Fall

1982 c) Investigative A pproaches of Human Behavior, Preceptor, Spring

Third Year Me dical Students

1978 a)Psychological Assessment of M edicine, P receptor, Spring

1978 b) Core Clerkship, Preceptor, Summer

Other

1980-1993 a) Faculty Advisor

1980-1981 b) Internship Advisor

Faculty and Staff -- De partment of Psych iatry

1978 a) Family Therapy Supervisory Sem inar for Payn e Wh itney Fa culty, 9 weeks, Spring

1978 b) Family Therapy Su pervisory Sem inar for We stchester Division Faculty, 9 weeks, Fall

1978 c) Seminar on Intro to Psychiatric Research fo r Payn e Wh itney S taff, 2 weeks, Fall

Residents: Department. of Psychiatry

Research Courses:

29



Ira D. Glick M.D.

General Psychiatry Courses

1993-94- a) Psychopathology course, PGY II , Treatment Mo dules on Schizophrenia & Bipolar Diso

1994-95- b) PGY IV Board Review Course, Schizophrenia Module

1993-98 c) Chairman's Rounds

Hospital Psychiatry Courses

1993- ) Inpatient Medical Student and Resident Supervision

1994-98 ) Inpatient Psychiatry, Course Coordinator and Lecturer, PGY II

1. Overview

2 . Wo rk u p a n d Tre atm en t P la n nin g

3 . Tre atm en t o f Psy ch osis

Psychopharmacology Courses

1994-95 Introduction to Psychopharmacolopy, PG II,

2002 -Person ality Disorder

2003 - Bipolar Disorder, Me dication and C ompliance Issues

1995-96-- trategies of Outpatient Psychopharmacoloov, PG III, Course Coordinator and lecturer

1. Schizophrenia

2. Combining & In tegra ting Psychotherapeutic In te rvention with M edica tion

2004 euroscience, PG III

Lecture, Me tabolic Side Effects o f A ntipsychotics

2005-- ntroduction to Psychophatholody and Psychopharmacology, PG II, 4 quarters/year, CourseDirector (with Sara M ueller, MD )

Medical School Courses

Winter, 2001-02, Me dical Scho ol Clerkship, Psych otic Disorder and Neuroleptic Treatmen t.

Outside UCSF, Cornell University Medical College & Stanford University

1965-1966 olumbia Un iversity, College of P hysicians and Su rgeons. Basic Clinical Psychiatry, to ThiYear Medical Students, Fall-Winter, 3 hrs/wk.

1964-1966 illside Ho spital. Supervision an d Tea ching, First an d Seco nd Year Psych iatric Residents,15 hrs/wk, all year.

1966-1968 .S. Army Hospital Specialized Treatment Center. Ft. Gordon, Georgia. Basic Psychiatry I,to M edical and Pa ramedical Staff, I hr/wk, all year.

1966-1968 edical College of Georgia. Family Therapy, to Psychiatry Dept. Staff, Residents, and MedicalStudents, 2 hrs/wk, 20 wks/yr

31



Ira D. Glick, M.D.

1 970-1 978 t . Zion Hospital and M edical C enter. Seminar in Psych opharma cology, Psycho somaticConference, to Second and Third Year Psychiatry Residents, two 90-minute sessions yearly

1986 chool of Medicine, University of Verona. Seminar on Recent Developments in AmericanPsychiatry, to P sychiatric Residents and Fa culty, January-June, six 90 minute sessions

32



Ira D. Glick, M.D.

1990-1993 ormulary Comm ittee1990-1993 ppointments and Promotions C ommittee

Stanford University School Of Medicine:

Departmental Committees

1993 - xecutive C ommittee1993 - esidency Training C omm itte1993 - 95 redentials Co mmittee, Chairman1996 - 2005 ppointment & Promotions

Ch air, 1999 — 2005

Hospital C ommittees

1993 - 20001993 - 20001993 - 20001993 - 20001998 - 2000

Inpatient Management CommitteeOperations Improvement CommitteePsych iatry Business Plan C omm itteeClinic Executive C omm itteeUCSF/Stanford Merger -

Brown & Toland Medical Group Mental Health Executive Committee

34



Ira D. Glick, M.D.

COM M UNITY AND PUBLIC SER VICE

Presentation of paper "Psychophysiologic Factors in the Etiology of Preeclampsia," American PsychosomaticSociety, April 1964.

Grand Rounds, "Psychophysiologic Factors in the Etiology of Schizophrenia," to the Dept. of Psychiatry, Mt. ZionHospital, San Francisco 1964.

Grand Rounds, "Psychophysiologic Factors in the Etiology of Schizophrenia," to the Dept. of Obstetrics andGyneco logy, Mt. Zion Ho spital, 1964.

Presen tation of paper, "Mo od and Beh avioral Ch anges A ssociated with the Use of the O ral Contraceptive A Review of the Literature," Eighth Ann ual Psychiatric Research So ciety Mee ting, 1 965.

Presentation of paper, "The 'Sick' Family and Schizophrenia - Cause and Effect?" to the Tenth Annual PsychiatricResearch Society M eeting, Cincinnati, 1967.

Institute Leader, "Family Dynamics and Treatment," Annual Meeting, Georgia Branch, National Association ofSocial Workers, February 1 967.

Invited Lecture, "The Place of Occupational Therapy in Clinical Psychiatric Treatment," Georgia OccupationalTherapy A ssociation, 1967.

Institute Leader on "Family Therapy and Ho spital Psychiatry," at C olumbia, S.C., VA Hospital September 1

Invited Lecture, on "The School and the Family," to the Annual Meeting of the Georgia Association of VisitingTeache rs, Au gusta, Georgia, Novembe r 1967.

Seminar Leader on "Family Therapy," at Ma con, Ga., Men tal Health Clinic, M acon , Ga., Novembe r 1967.

Invited Address, "The Ch anging Ro le of the Fam ily," Unitarian Fellowship, Au gusta, Ga., De cembe r 1967,

Invited Lecture, "Basic C linical Psychiatry" to Psycho logy Studen ts, Paine C ollege, Augusta, Ga., (Jan)1 96

Lecture and Panel Discussion, "The Role of the Clergy in Family Counseling, at a seminar on Family Counseling,Au gusta, Ga., February 1 968,

Address, "The Family and Sou thern So ciety," to First Mt. Mo riah Ba ptist Chu rch, Augu sta, Ga., April 1 968

Film Presentation: Videotape Playback in Family Therapy (with G. Marshall) 16mm. B & W 10 min. Presented atthe 1 968 annua l meeting, American Psych iatric Association, Boston, Mass. May 1 6, 1968

Grand Rou nds, "Moo d and Beha viorial Cha nges A ssociated with Use of Oral C ontraceptives," OBGYN , U

of C alifornia, San Francisco, September 1968.Participant, panel on Training of Family Therapists, Don D. Jackson M emo rial Family C onfe rence, AsilomCa lifornia, February 1969.

Lecture on "Cu rrent Status of Fa mily The rapy," given to Association of Fam ily The rapists, San Francisco,

Film an d Seminar D iscussion on "An Introdu ction to Family Therapy," given at the C linical Seminar SeriesPo rter Neuropsychiatric Institute, Psycho logy Dept., March 1 969.

35



Ira D. Glick, M.D.

Two-Da y Seminar on C urrent De velopments in Psychiatry given at De pt. of Psych iatry, Medical College oGeorgia, M ay 1 969.

Film "Family Therapy: An Introduction," presented at the An nua l Meeting, American P sychiatric AssociatiBeach, Fla., May 1969.

Discussion of paper entitled "Psycho sexual Responses to Ileostomy and C olostomy" at Am erican PsychiatrAssociation M eeting, Miami Beach, Fla., 1 969.

Film "Family Therapy: An Introduction," shown at Staff Mee ting, M ental Research at Ninth W estern DivisM eeting 1969, of Westen P sychiatric Association, Sea ttle, Augu st 1969.

M oderator of Pan el on Family Therapy: Rationa le, M ethods, Teaching and Research at Ninth Western DivM eeting 1969, of Western P sychiatric Association, Seattle, August 1 969.

Discussion o f Paper, "The Psych iatrist as Co unselor an d Friend to the Fa mily," by Herbert C. Wimberger, MNinth W estern D ivisional M eeting, Western Psychiatric Association, Seattle, August 1 969.

Ab stracts Editor, Family P rocess, July 1 964-78.

Participant in C BS News Reports Program titled "The Pill," KPIX, February 1 970.

Participant on Pan el: "Therapists and Fam ilies," American O rthopsychiatric Association 47th An nua l Mee tSan Francisco, M arch 1 970.

Lecture on "Issues in Fam ily Th erapy Training," presented to Interdisciplinary Training Pro gram Se minar, NState Hospital, May 1 970.

M oderator of P anel, "Issues in Training of Fam ily The rapists," American P sychiatric Association An nua l MMay 1 970.

Discussion Leade r, NIM H Caree r Teachers in Psych iatry Me eting, Boston, Octobe r, 1 971

Participant In Pa nel, "Emotional Problems o f Psychiatric Residents," American Psych iatric Association AnM eeting, May, 1972.

Presen tation o f paper entitled "Man ageme nt of Psych oses Associated with Dialysis," Ame rican P sychiatricAssociat ion A nnua l Meeting, M ay 1 972.

Regional Co ordinator, "The P sychiatrist as Teache r," for the National Co nferen ce on Teach ing Psychiatry,regional meeting held at San Francisco, May 1 972.

Presen tation of P aper and Pa rticipant on P ane l, "Stress Events & Psychiatric Illness," at theSymposium"Stress: Its Impact on Th ou ght and Em otion," University of C alifornia at San Fran cisco, June 1

Group Leade r, Regiona l Coo rdinator, and P resentation at "Free University" of film on Family Therapy at thnationa l conference, "The P sychiatrist as a Teacher." Airlie House, O ctober 3-6, 1972.

Lecture "Transference and Countertransference," to Graduate Psychiatric Nursing Students, University ofC alifornia, San Francisco, Novembe r 1972.

Resou rce Teacher in Section on "University D ept. of Psych iatry" at the First National Co nferen ce on TrainFamily Therapy, Philadelphia, Novembe r 30 - De cembe r 2, 1972.

36



Ira D. Glick, M.D.

Lecture, "Depression," presented as part of a section en titled "Dilemmas in Therapy" as part of the 23rd AnCo urse for Physicians in Gene ral Practice, M t. Zion Hospital and M edical Ce nter, February 1973.

Presen tation of paper, "Short vs. Long Hospitalization: A Prospective Co ntrolled Study -- Preliminary ResuOn e-Year Fo llow-up o f Schizophrenics," Research Seminar, De pt. of P sychiatry, Mt. Zion Ho spital, April 1

Presen tation of paper, "Short vs. Long Hospitalization: A Prospective Co ntrolled Study -- Preliminary ResuOn e-Year Follow-up of Schizophren ics," at the Ann ual Me eting, Am erican Psychiatric Association, Hon olHawaii, May , 1973.

Presen tation of paper, "Indications an d Relative C ontraindications for Fam ily Treatmen t, Circa 1973," at thFrancisco Family Forum, San Francisco General Hospital, Janua ry 10, 1 974.

Presen tation of paper, "Treatment and Ou tcome in Schizophren ia," at the Me rger Celebration in Hon or of of Lan gley Po rter Neuro psychiatric Institute with Un iversity of C alifornia, San Francisco, February, 1974.

Presen tation o f paper, "Indications and C on traindications for Family Therapy," at the N athan W . AckermanM emorial Conference, Venezuela, February, 1974.

Film presentation, "Family Therapy: A n Introdu ction:" 971: 12 showings 972: 8 showings1973: 8 showings 974: 6 showings

Discussant, Co nferen ce, "Lithium: Its Role in M anic-Depressive Illness," Chief's Con ference, D ept. of PsyM t. Zion Hospital, San Francisco, March 1 2, 1974.

Presen tation of paper, "Short Versus Lon g Psych iatric Hospitalization for Schizophrenia - P reliminary Re suYea r Followu p," Noo n C onfe rence, Langley Po rter Neuropsychiatric Institute, San Francisco, 3/74.

Presen tation o f paper, "Mo od and Beh avioral Ch anges Associated with the Use of Oral C ontraceptives," 1C ongress of Biological Psychiatry, Buenos A ires, Argentina, September, 1974.

Presen tation of paper, "Short Versus Lon g Psych iatric Hospitalization: A C ontrolled Study," Dept. of PsychGrand Rou nds, Corne ll University Me dical Co llege, New Yo rk, NY, Novembe r 1974.

Presen tation of paper, "Short Versus Long P sychiatric Hospitalization: A C ontrolled Study," SUNY, Do wnsM edical Center, New York, NY, November 1974.

C oordinator, "The Role of the Fam ily in M edical Practice," Third National Worksho p on P sychiatric EducaAssociation for Aca demic Psychiatry, Ch icago, Illinios, Novem ber 1 974.

Presen tation of paper, "Short Versus Long Ho spitalization - A Pro spective C ontrolled Study: One Y ear FolResults,' Section o n Interaction of Dru gs and No nsoma tic Therapies, Ame rican C ollege ofNeuropsychopharmacology, Pu erto Rico, D ecember 1 974.

Presen tation of paper, "Short Versus Long Ho spitalization: A Prospective Co ntrolled Study. IV-A. One Y eaFollowu p Results for Schizophrenics," Research C onfe rence, De pt. of Psych iatry, Mt. Zion M edical C enteFrancisco, February 1 8, 1975.

Pan el Discussant, "The Treatment of Schizophrenia at Langley Porter Institute," Noo n C onfe rence, LangleInstitute, San Fran cisco, April 30, 1 975.

Pan el Mo derator, "Con trolled Studies of A lternative Lengths of Hospitalization for Psych iatric Illness," prethe 1975 An nua l M eeting, American Psychiatric Association, An ahe im, C alifornia, May 1 975.

37



Ira D. Glick, M.D.

Presen tation of paper, "Short Versus Long Ho spitalization: A Prospective Co ntrolled Study. IV. One Y ear FResults for Schizophrenics," Ame rican P sychiatric Association A nnu al Mee ting, Ana heim, CA , 5/75.

Radio presentation, "Loxitane in Schizophrenia," CBS Radio Netwo rk, July 12 a nd 1 3, 1975.

Discussant, "Con ceptual Approaches to S chizophrenic Disorder," Grand Ro unds, De pt. of P sychiatry, Univ

Ca lifornia, San Francisco, September 22, 1 975.

Discussant, "Depression in M edical Practice," Grand Rou nds, Dept. of M edicine, Un iversity of C alifornia, Francisco, September 23, 1 975.

Presen tation of paper, "Short Versus Lon g Hospitalization: A Prospective Co ntrolled Study. II. Results forSchizophrenic Inpatients," Langley P orter Institute weekly research staff conferen ce, October 1 0, 1975.

Pan elist, "Can a Psych iatric Hospital Survive M ental Health and M arijuan a?" Grand Rou nds, Dept. of PsycUC SF, Novemb er 18 and 25, 1975.

Seminar Leade r, "Issues in Family Therapy," Ca lifornia Branch District M eeting Am erican Psych iatric AssoCo nference, Palm Springs, November 1 975.

Presen tation of paper, "Sho rt VersusLon g Psychiatric Hospitalization: A C ontrolled Study. Medication and for Schizophrenics," Ame rican C ollege of Ne uropsychopharmaco logy, Puerto Rico, December 1 975.

Exhibit, entitled "A Tea ching Pa ckage for a Preclinical Psychiatry Co urse," 30th All-University Faculty C oUniversity o f C alifornia, Santa Barbara, M arch 25-27, 1976.

Discussant and Presentation of paper, "Short Versus Long Psychiatric Hospitalization," as part of asymposium: "A C ritical Appraisal of C omm unity P sychiatry," Kittay Scientific Fou ndation, N Y, 3/76.

Presen tation of paper, "Con troversial Premises of M arital and Fam ily The rapy," (with David R. Kessler, M DSan Fran cisco Family Forum, Family Health Ce nter, San Francisco Gen eral Hospital, April 15, 1 976.

Presen tation and D iscussion, "Short Versus Long P sychiatric Hospitalization: A C ontrolled Study, Two Ye aResults," Grand Ro unds, D ept. of Psychiatry, UCS F, April 20, 1976.

Pan elist, "Schizophrenia -- Which Treatmen t and For Whom ," 1 976 Annu al Mee ting, Am erican PsychiatricAssociation, Miami, M ay 1 976.

Pan elist, "What M akes M edical Studen ts So Difficult To Teach ?" 1976 Annu al Mee ting, Am erican PsychiaAssociation, Miami, M ay 1976.

Pan elist, "Co ntroversies in P sychiatric Education," 1976 An nua l Mee ting, Am erican Psychiatric AssociatioM ay 1976.

Presen tation of paper, "Increasing Learning D uring the P sychiatric Residency," (with Leon Epstein, MD ) 1An nua l M eeting, American Psychiatric Association, M iami, M ay 1 976.

Presen tation of paper, "Indications an d Co ntraindications for Family Therapy; Ch anging C once pts," PsychGrand Ro unds, Dept. of Psychiatry, School of M edicine, U.C. Davis, Septembe r 1976.

Presen tation of paper, "Short Versus Lon g Psych iatric Hospitalization: A C ontrolled Study: Two Y ear ResuDept. of Psychiatry, Mt. Sinai School of M edicine, New York, September 1 976.

Presen tation of paper, "Sho rt Versus Long Psych iatric Hospitalization: Final Resu lts and Treatment ImplicaDept. of Psychiatry, Mt. Zion Hospital and M edical C enter, San Francisco, October 1976.

38



Ira D. Glick, M.D.

Keynote Speaker, "Short-Term Intensive Psychiatric Hospital Treatment: Which Treatment and forWho m?" National Co nference o n Sh ort-Term Intensive P sychiatric Hospital Treatment, Scottsdale, AZ, 1 1

Panel Moderator, "Treating th e Impaired P hysician: C onfidentiality vs. Responsibility," presented a t the 197An nu al Meeting, Association of American M edical C olleges, San Francisco, November 1 976.

Examiner, Ame rican Boa rd of Psychiatry and Neuro logy, Seattle, February 1977.

Special Lecture, "A Teaching Package for a Preclinical Psychiatry Course," Dept. of Psychiatry, College ofPh ysicians and Su rgeons, Co lumbia University, New Y ork, February 1 977.

Presentation of paper, "Short Versus Lon g Psych iatric Hospitalization: A Co ntrolled Study," Grand R oun ds,of Psych iatry, University of New Me xico, Albuque rque, New M exico, M arch 1 977.

Presentation of paper, "Indication s and C ontraindications fo r Family Therapy," Grand Ro unds, VeteransAdministration H ospital, Albuque rque, New M exico, March 1 977.

Referee, Journal of Nervous and Mental Diseases, Archives of General Psychiatry, American Journal ofPsych iatry, and Family Process. Hospital and Co mmu nity Psychiatry.

Presentation of paper, "The A rchitectural Design of a Psycho therapeutic Milieu," 1977 Ann ual Me eting of American Psychiatric Association, Toronto, Canada, May 1977.

Panelist, "New D irections in Family Resea rch: Ritual, Real Time an d Images," 1977 Ann ual M eeting of theAmerican Psychiatric Association, Toronto, Canada, May 1977.

Panel Moderator, "Schizophrenia - W hich Treatment an d For Wh om?", 1977 Annu al Mee ting of the Am ericPsychiatric Association, Toronto, Canada, May 1977.

Panelist and Discussion Group Leader, at conference entitled "Families In Contemporary America: Varieties ofForm, Function an d Experience," jointly sponsored by the D ept. of Psych iatry and Behavioral Sciences of tGeorge Washington University School of M edicine a nd the Cen ter for Con tinuing Education in M ental Hethe P sychiatric Institute Foun dation, Washington, D .C., June 1 977.

Television Presentation, Role of C linical Psychiatry - on "The Hidden Un iverse" - ABC National TelevisionDocum entary, June 1 977.

Presentation of paper, "Sho rt Versus Long Psych iatric Hospitalization," W orld Psychiatric Association, H onAugust 1 977.

Presentation of paper, "Indications and C ontraindictions fo r Family The rapy," as part of an invited seminar oFamily Therapy, World Psychiatric Association, Hono lulu, August 1 977.

Advisory Editorial Board Member,International Journal of Family Therapy, as of September 1977. PsychiatricQua rterly, 1980.

Discussant, "The Premenstrum: A Psychological Investigation," Grand Rounds, Dept. of Psychiatry, University ofC alifornia, San Francisco, Novembe r 22, 1977.

Presentation of paper, "De velopment of a C urriculum an d of a Faculty for M edical Student Educa tion inPsych iatry," The An nua l M eeting of the Association of Aca demic Psychiatry, New O rleans, Janua ry 1978.

Presentation of paper, "A New D rug Treatment for Preme nstrual Psychosis," Po ster Session, The Ann ual Mof the A merican Psych iatric Association, Atlanta, Georgia, M ay 1 978.

39



Ira D. Glick, M.D.

Organ izer, Special Session, "Treating the Impaired P hysician: C onfidentiality an d Respon sibility," The A nnM eeting of the American Psych iatric Association, Atlanta, Georgia, M ay 1 978.

Presen tation of paper, "Hospitals in the 1980s: Service, Training and Re search," Presented a s part of the SpSession, "Hospital Treatmen t of Emotional Disorders: C irca, 1978, at the A nnu al Mee ting of the A merican

Psychiatric Association, A tlanta, Geo rgia, M ay 1 978.

Lecture and D iscussion, "Indications an d Co ntraindications for Family Therapy: Circa, 1978," at Grand RoDept. of P sychiatry, The N ew Yo rk Hospital-Cornell University M edical Co llege, M ay 1 7, 1978.

Presen tation o f paper, "Research in Occupationa l Therapy," at a Co nferen ce entitled, "A Revitalization M owithin Occu pational Therapy" sponsored by M etropolitan New Y ork D istrict, New Y ork State OccupationaAssociation. May 1978.

Presen tation and D iscussion, "Family The rapy & C risis/Loss,"Me morial Hospital, New Y ork, Novem ber 2,

Presen tation and D iscussion, "The Hospital Man ageme nt of the Su icidal Patient," at a Symposium: "The SuPatient: Identification a nd Treatmen t," sponsored by D ept. of Psych iatry, Albany M edical C ollege, M arch Albany, New York.

Presentation and Discussion, "Psychiatric Problems in General Practice," as part of a Symposium: "CommonM edical Prob lems in O ffice Practice," sponsored by the C ontinuing Educa tion C omm ittee of St. Vincen t's Santa Fe, N.M ., M arch 30, 1979.

Presen tation and D iscussion, "Effects of D ivorce on the Fa mily," as part of a Symposium, "Divorce and th ePatient," Sponsored by C ontinuing Edu cation C omm ittee of St. Vincent's Hospital, Santa Fe , N.M., 3/79.

Presen tation of paper, "Short Vesu s Long P sychiatric Hospitalization: A C ontrolled Study -- Final Results,"Rou nds, McLean Hospital, Boston, Ma ssachusetts, April 1979.

Presen tation of paper, "A New D rug Treatment for Preme nstrual Exacerbation o f Schizophrenia" at HarvarM edical School, Dept. of Psychiatry, Boston, M assachusetts, April 1979.

Presen tation of paper, "The P hysician's Family: Approach to Impairment," as part of a Sym posium, "The ImPh ysician: Prevention and Treatmen t," at the Annu al Meeting, American Psychiatric Association, Chicago1979.

Discussant, "Psychothe rapy Supervision," at the A merican Psych iatric Association's Annu al Mee ting, Ch icMay 1 979.

Presen tation, "Short Hospital Stay is Better than Lon g Hospital Stay?" "Pro P osition" a t the 31 st Institute oHospital and C ommu nity Psychiatry, September 3-6, 1979, New Orleans.

Presen tation, "Future Directions in Ho spital Psychiatry," keyn ote speech, D ept. of Psychiatry, at Alumni TDay , Long Island Jewish-Hillside Me dical Ce nter, Glen Oaks, Ne w Yo rk, September 1979.

Grand Ro unds, "The Family Mo del in an Inpatient Setting," De pt. of Psych iatry, North Sho re Hospital, M aNew York, October 1979.

Grand Ro unds, "The Family M odel in an Inpatient Setting," De pt. of P sychiatry, Albert Einstein Co llege o fM edicine, New Y ork, NY, October 1 979.

Grand Ro unds, "Family The rapy -- Indications a nd C ontraindications," Dept. of Psych iatry, City Hospital CElmhurst, October 1 979.

40



Ira D. Glick, M.D.

Grand Ro unds, "Psych iatric Hospitalization for the 1 980s: A C ontrolled Study of Short Versus Lo ng Ho spiFinal Results," De pt. of Psych iatry, C ornell University M edical College, April 1 980.

Invited Pa per, "Psych iatric Aspects of Basketball," Psych iatric Anna ls Volume 1 0, Numbe r 3:1 08-11 2, 198

Organ izer of C ontinuing M edical Education Sem inar, titled, "Hospital Treatmen t: Which Treatmen t and Hofor Wh ich Patients?" Corn ell University M edical College, Dept. of Psychiatry, /Nod 1 980.

Presen tation on "The Role of Psych oan alysis in Family Therapy," as part of a C ontinuing M edical EducatiC ourse en titled, "The Role of P sychoa nalysis in Co ntemporary P sychiatry," at Co rnell University M edical Spring, 1 980.

Discussant for Symposium, "Enha ncing Treatment Co mpliance," at the An nua l M eeting of the Am ericanPsych iatric Association, Sa n Fran cisco, 1 980.

Presen tation on "Leadership in the Ho spital," as part of a C ourse o n "Leadership," at the A nnu al Mee ting oAm erican Psychiatric Association, San Fran cisco, 1980,

Presen tation on "Family Therapy an d the Treatment of the C hild" at the weekly C hild-Adolescence Staff MDe pt. of C hild Psychiatry, M t. Sinai Hospital, November 1 980.

Participant, on Radio Program, "C onfe rence C all: Pa rents & C hildren, WABC , November 30, 1980, New Y

Grand Ro unds, "Psychiatric Hospitalization for the 80s," St. Joseph's Hospital and M edical Cen ter, PatersonJersey, February 1 981.

Keyn ote Spea ker, "Illness and the Impact on Fa mily Systems," at a Sy mposium en titled "Illness an d the Famsponsored by La Tortuga & Sherman Clinic, Santa Fe, March 1 981.

Presen tation of paper, "Thinking Disorder in D epression: Lon gitudinal Results" (with Braff D , Griffin P), a"Outcom e of Irregularly Discharged M ental Patients" (with Braff D, John son G), for the Ame rican P sychiaAssociat ion A nnual M eeting, New Orleans, M ay 1 981.

C onsu ltant for De partmental Planning, Dept. of Psychiatry, M t. Zion Hospital, San Francisco, CA , June 1

C hapter Co nsultant, Family Therapy, Ame rican P sychiatric Assn. Com mission o n Psych iatric Therapies, 1

Grand Rounds, "Short Vs Long Hospitalization: Final Results," State University of New York, Syracuse, NY, 9 /81.

Grand Ro unds, "Treating the H ospitalized Schizophrenic Patient and Fa mily," Rockland P sychiatric C enterOrangeberg, New York, October 1981.

Presen tation, "Short Versus Long Hospitalization fo r Schizophrenia," World Psychiatric Association/A PA RM eeting, New York City, November 1981 .

Ch airman, Education Co mmittee and session on the "Teaching of Psychopharmacology," Ann ual M eeting,American Co llege of N europsychopharmacology, San D iego, December 1981.

Presen tation, "The Fam ily M odel in an Inpatient Setting," Family Study Grou p, SUNY, Do wnstate M edicalJanuary 1 982.

Presen tation of paper, "Duration o f Hospitalization as a Variable in Outco me," (John F. Clarkin, PhD and ID. Glick, MD ), The Na tiona l Association of P rivate P sychiatric Hospitals, Scottsdale, Arizona, Janu ary 1 9

41



Ira D. Glick, M.D.

Pan elist, "Family The rapy of Suicidal Beha vior," Ann ual M eeting of A ssn. of Suicidology, New Y ork C ity,

Presen tation of paper, "Thought D isorder and D epression in P sychiatric Patients," (Da vid L. Braff, MD andD. Glick, MD ) for the Western P sychological Association Ann ual M eeting, Sacramento, CA , April 1982.

Pan elist, "The Widening Scope o f Family Therapy," Ann ual M eeting of the Am erican Psychiatric Associat

Toronto, Ca nada, May 1982.

Presen tation o f paper, "Which C hron ic Pa tients M ostly Need Readm ission," (with Braff D, MD , Klar H, MAnnu al Mee ting of the Am erican P sychiatr ic Association, Toronto, Canada, M ay 1 982.

Discussant, Con ference on "The C han ging American Family," The 67th Annu al Seymour Silverberg LectuIsland Jewish-Hillside Medical Center, June 1982.

Keyno te Address, "Co uples in the 1 980s: Emerging Trends," Worksh op on "Step-Parenting," and Pane lDiscussion - all at the Sym posium, "Marital and Sexual Therapy," The Fam ily an d Co uples Institute, The DPsych iatry, Tufts University Scho ol of M edicine, Boston, June 1982.

Presen tation o f Research P roject, "Inpatient Family Intervention: A C on trolled Study" and P resentation ofFamily Therapy Training Program at PW C " at the 1 982 Annu al Mee ting, American Family Therapy AssocBoston, June 1 982.

Invited Guest, Interviewed on topic of "Vacations & C ouples," on Travel Talk, Dena Ka ye, WM C A, NYC ,

Invited Lecturer, "The Changing American Family: Emerging Trends and Comparison with the Japanese Family,"De pt. of Psychiatry, Juntendo Un iversity, Tokyo , October 1982.

Grand Rou nds, "Toward the Definition an d Delivery of Me ntal Health Ca re," M assachusetts Men tal HealthBoston, October 1982.

Grand Ro unds, "Guidelines for Fam ily Therapy," De pt. of P sychiatry, Medical College of Geo rgia, 1/83.

Grand Ro unds, "Guidelines fo r Family Therapy," Dept. of Psych iatry, Tulane University and Louisiana StatUniversity, Februa ry 1 983.

Presen tation of paper, "Teaching Investigative Psych iatry to P sychiatric Residents, a Sequen tialC urriculum: Everything You W anted to Kno w Abo ut Research, But Were Afraid To Ask." Free UniversityPresentat ion, at the A nnual M eeting o f the Associat ion for Academic Psychiatry, Tampa, M arch 1 983.

Presen tation of paper, "A New D rug Treatment for Premenstrual Schizophrenia," at the Eleventh A nnu alCo nference on Psychosomatic Obstetr ics and Gy necology, Sugar Loaf, Temple Un iversity C onference C enPh iladelphia, March 1 983.

Visiting Scho lar, De pt. of P sychiatry, School of M edicine, University of Vermo nt, Burlington , March 1 983.

Grand Ro unds, "Psychiatric Hospitalization for the 1 980s," De pt. of P sychiatry, School of M edicine, UC LAHarbo r Hospital, Los An geles, April 1 983.

Grand Rou nds, "Toward the D efinition and D elivery of Me ntal Health Services: Who Sho uld Pay an d for WDe pt. of P sychiatry, UC SF, San Francisco, April 1983.

Invited Paper, "Treatmen t of Severe Premen strual Syndrom e (PM S) and Premen strual Exacerbation of PsyDisorder," Prem enstrual Syndrome W orksho p, co-sponsored by C enter for Studies of Affective Disorder,Psych obiological Processes & Beha vioral M edicine Se ction, C linical Research Branch, and the Intramu ralResearch P rogram, NIMH, April 1983.

42



Ira D. Glick, M.D.

Presentation,"Treatment of Dual Doctor Couples," as part of an APA Issue Workshop, "Dual Doctor Couples" atthe Annual Meeting of the American Psychiatric Association, New York, May 1983.

Co-Chair and Presentation,"Overview" for Component Presentation, "Obstacles to Quality Clinical Systems,"presented by APA Committee on Administrative Psychiatry, at the Annual Meeting of the American PsychiatricAssociation, New York, May 1983.

Presentation and Co-M oderator,APA Issue Workshop, "Family Therapy Training in Residency Programs," at theAnnual Meeting of the American Psychiatric Association, New York, May 1983.

Presentation,"The Basics of Family Treatment" (with Henry Grunebaum, MD), as part of "PsychiatryUpdate," at the Annual Meeting of the American Psychiatric Association, New York, May 1983.

Presentation,"Review of Length of Stay Research," as part of a course, "Inpatient Treatment Programs:Programs: Acute and Long-Term," at the Annual Meeting of the American Psychiatric Association, NY, 5/83.

Presentationof paper, "The Importance of Thought Disorder in Depressives" (with David Braff, MD), at the AnnualMeeting of the American Psychiatric Association, New York, May 1983.

Presentationof paper, "Inpatient Family Intervention: A Controlled Study," at the Annual Meeting of the AmericanPsychiatric Association, New York, May 1983.

Presentation of Research Project,"Inpatient Family Interventions: A Controlled Study" and Presentationof "TheFamily Therapy Training Program at PWC" at the 1983 Annual Meeting, American Family Therapy Association,San Francisco, California, June 1983.

Grand Rounds,"Psychiatric Hospitalization for the 1980s," Bergen Pines County Hospital, Paramus, NJ. 6/83.

Presentation,"Inpatient Family Intervention: A Controlled Study," at the Annual Meeting of the AmericanPsychological Association, Anaheim, California, August 1983.

Grand Rounds,"When Should the Chronic Patient be Hospitalized," Dept. of Psychiatry, St. Luke's/RooseveltHospital Center, New York, September 1983.

Distinguished Lecturer,"Doing Research Without Pain," University of Medicine and Dentistry of NJ, 101/83.

Lecture,"Diagnosis and Treatment of Depression," as part of a course, "Recent Advances in Medicine," TempleUniversity School of Medicine, Philadelphia, November 1983.

Co-Chairman,ACNP Training Session, "Issues in Clinical Psychobiologic-Psychopharmacologic ResearchTraining," Annual Meeting of the American College of Neuropsychopharmacology, San Juan, 1983,

Grand Rounds,"Toward the Definition of and Delivery of Mental Health Services - Who Should Pay and for

What?" The New York Hospital-Cornell University Medical College, January 1984.

Grand Rounds,"The Changing Role of the Hospital in Treatment of the Chronic Patient," Roosevelt Hospital, NewYork, February 1984.

Invited Lecturer,"Focus on Family Psychotherapy Advances" and "Practical Office Psychotherapy," WinterUpdate, Dept. of Psychiatry, University of South Dakota, February 1984.

Free Un iversity P resentation,"Teaching Integration of Psychiatric Models to Residents," at the Annual Meeting ofthe Association of Academic Psychiatrists, Tampa, March 1984.

43



Ira D. Glick, M.D.

Grand Rounds,"Diagnosis and Treatment of Depression" at Grand Rounds, in Dept. of Psychiatry in 5 settings,1983-84.

Grand Rounds,"Toward the Definition of and Delivery of Mental Health Services: Why Don't Patients ReceiveAppropriate Care?" Dept. of Psychiatry, Mt. Sinai, April 1984.

Invited Lecture ,"Towards the Definition of and Delivery of Mental Health Services: Why Don't Patients ReceiveAppropriate Care?" Dept. of Psychiatry," The University of New Mexico, April 1984.

Grand Rounds,"Toward the Definition of and Delivery of Mental Health Services," Dept. of Psychiatry, College ofPhysicians and Surgeons of Columbia University, April 1984.

Grand Rounds,"Psychiatric Hospital ization for the 1980s," Dept. of Psychiatry, New York Medical College,Valhalla, New York and Metropolitan Hospital, New York City, May 1984.

At the Annual Meeting of the American Psychiatric Association, Los Angeles, May 1984:

Presentation,"Treatment of the Premenstrual Syndromes," as part of a Symposium, "PremenstrualSyndrome: Current Findings and Future Directions."

Faculty,"Short-Term Psychosocial Inpatient Treatment," as part of a Course, "Short-TermPsychiatric reatment."

Leader of D iscussion Group,"Delivering State-of-the-Art Multimodality Treatment."

Co-Chair and Presentation,"New Demographic Trends in American Marriage," (with OliverBjorksten, MD and Thomas Stewart, PhD), as part of a Symposium, "New Clinical Concepts in MaritalTherapy."

Chairman and Presentation,"Inpatient Family Intervention: A Controlled Study, PreliminaryResults," (with J. Clarkin, PhD, G. Haas, PhD, J. Spencer , MD, et al), as part of a Symposium,"Results of Family Treatment: Second Generation Studies."

Grand Rounds,"Is There Any Future for Long-Term Hospitalization?" Silver Hill Foundation, New Canaan, CT,June 1984.

Grand Rounds,"Which Chronic Patients Most Need Readmission?" Norristown State Hospital, 9/94.

Visiting Lecture r,"Why Don't Patients Receive Appropriate Psychiatric Treatment?" Dept. of Psychiatry, Universityof Chicago School of Medicine, September 1984.

Invited Le cturer,"Creativity and Madness," Annual Meeting, Louisiana Psychiatric Society, New Orleans, 9/84.

Invited Lecture r,"Guidelines for Family Therapy," Departments of Psychiatry, Tulane University and LouisianaState University, October 1984.

Presentation,"The Family Model and the Treatment of Affective Disorders," at Albert Einstein Medical Center,Northern Division, Philadelphia, October 24, 1984.

Grand Rounds,"Indications and Contraindications," Dept. of Psychiatry, Bronx Lebanon Hospital Center, 11194,

Departmental C olloquia,"Why Don't Patients Receive Appropriate Psychiatric Treatment?" Dept. of Psychiatry,University of Pennsylvania, December 1984.

Guest Speaker, "Trends in Marriage & Marital Therapy," South Jersey Psychiatric Society, Cherry Hill, N J, 12/84.

44



Ira D. Glick, M.D.

Co -Chair, ACNP Study Group, "Psychotropic D rug and P sychotherapy Interact ion Research," Ann ual M ethe Am erican C ollege of Neuropsychopharmacology, San Juan , 1984.

Co -Chairman, AC NP Training Session, "Proposed C urriculum for Teaching P sychopharmacology," AnnuaM eeting of the American Co llege of N europsychopharmacology, San Juan 1984.

Grand Ro unds, "Guidelines fo r M arital and Fam ily The rapy," Detroit Psychiatric Institute an d Lafayette C lDe troit, Janu ary 1985.

C ontinuing Education W orksho p, "Family Therapy - Working with C ouples," De pt. of Co ntinuing EducatioHarvard Medical School at New Yo rk City, Janua ry 1985.

Grand Ro unds, "Why Do n't Patient Receive Appropriate P sychiatric Treatment?" D ept, of Psychiatry, UnivUtah, Salt Lake City, February 1 985.

Grand Rou nds, "Diagno sis and Treatmen t of Depression," Co ney Island Hospital, New Y ork, February 1 98

Grand Ro unds, "Inpatient Fam ily Intervention: A C ontrolled Study - Preliminary Results," University of C aSan Francisco, February 1 985.

Grand Ro unds, "New C once pts Abou t Inpatient Family Intervention for Psych iatric Disorders," Pen insula Hillsdale, California and San M ateo Ho spital, San M ateo, C alifornia, March 1 985.

Grand Rou nds, "New Co ncepts in Family Intervention in Ch ronic Me ntal Illness," Harlem Valley P sychiatrWingdale, New Yo rk, March 1 985.

Grand Ro unds, "Psychiatric Hospitalization for the 1 980s: A C on trolled Study o f Short-Term Versus Long-Hospitalization," Duke Un iversity M edical Ce nter, Durha m, North C arolina, M arch 1 985.

Invited Faculty, "The 'Shrinking' of Inpatient Psychiatry: What To D o A bou t Limited Hospital Stays" and W"Family Wo rk on a n Inpatient Unit," both as part of course at Harvard Me dical Schoo l, De pt. of C ontinuingEducation, Boston, M arch 1985.

Grand Ro unds, "Recent Trends in Ma rriage an d the Family: Effects on Therapy," Tufts-New En gland Me diC enter, Boston, April 1985.

Grand Ro unds, "The 'Shrinking' of Hospital Psychiatry," De pt. of P sychiatry and the Be havioral Sciences, UScho ol of M edicine, Los Ange les, April 1985.

Grand Ro unds, "Inpatient Family Intervention: A C ontrolled Study," The M edical Co llege of P enn sylvaniaPhiladelphia, April 1985.

Grand Ro unds, "The Family and Its Role in Diagno sis and Treatme nt of D epressive Disorder," Georgeto wn

University Schoo l of M edicine, Wa shington, D.C ., April 1985.Grand Rou nds, "Psych oedu cation in a Hospital Setting," Silver Hill Hospital, Silver Hill, Co nne cticut, 5/85.

Grand Ro unds, "Guidelines for M arital and Fam ily Therapy: C irca 1 985," De pt. of Psych iatry, Stanford M eScho ol, Palo Alto, California, M ay 1 985.

At the An nua l M eeting of the American Psychiatric Association, Da llas, M ay 1 985:

Workshop, Presentat ion of "A M odel Psychoharmacology C urriculum," (with D avid S. Janowsky, MRichard I. Shader, M D an d Carl Salzman, M D)

45



Ira D. Glick, M.D.

Presen tation, "The Family and Antidepressant Nonco mpliance" (with John Clarkin, PhD andGretchen Ha as, PhD ) as part of a Sym posium, "Resistance to An tidepressants: Psycho socialFactors"

Presen tation, "Qua lity Treatment an d Practitione r Co mpetence" as part of a Symposium, "Evaluatio

Knowledge a nd P ractice in Psych iatry - Joint Session w ith the Association for cademic Psychiatry"

Study G roup, "Residents with M arital Distress: The New Epidemic?"

C hairman an d Presentation, "Inpatient Family Intervention: A Con trolled Study," (with John C larkGretchen Ha as, PhD , James H. Spencer, MD , Alfred Lewis, M D an d Joann e Newm an, M .S.W.) as pof a symposium "Results of Family Therapy O utcome S tudies"

Faculty, "Short Term Psycho social Inpatient Treatment," as part of a C ourse, "Short-TermPsychiatric reatment"

Worksh op, "Family The rapy, Severe P sychiatric Pro blems and th e P sychiatric Hospital:C ritical Issues at the Interface," as part of a series of worksho ps, "Family Therapy: The M asterTherapists," sponsored b y D ept. of Psychiatry, University of C onn ecticut School of M edicine, 6/85

Grand Rou nds, "Diagno sis and Treatmen t of Depression," Dept. of Psychiatry, Bowma n Gray Scho ol of MeWinston-Salem, North Carolina, August 1985.

Invited Address, "Survival for the P hysician a nd the Family in the 1 980s," Ca pital M edical Society, TallahaFlorida, Au gust 1 985.

Grand Ro unds, "Indications and C ontraindications fo r Family Therapy," De pt. of P sychiatry, Emory UniverAtlanta, September, 1985.

Invited Presentation, "The Shrinking Of Ho spital Psychiatry And Wh at To Do Abo ut It," Ann ual M eeting, Co rporat ion of A merica, Orlando, De cember 1 985.

AC NP P oster Presentation, "Inpatient Family Intervention: The P atient, the Family and Co mpliance with DTreatmen t for Affective Disorders," Decemb er 1985.

Presen tation o f paper, "Inpatient Family Intervention: A C on trolled Study" at the An nua l Meeting of the APsych iatric Association, Washington, D .C., May, 1 986.

Invited Lecture, "The Family and R ecent D evelopments in P sychiatry," Family Institute of M ilan, Italy, 3/8

Visiting Professor, "Family Therapy: Indications and Contraindications," Dept. of Psychiatry, School of Medicineand S urgery, University of N aples, Italy, May, 1 986.

Grand Ro unds, "The P atient, the Fam ily an d Psychiatric Hospitalization," Dept. of Psychiatry, Jefferson MCo llege, P hiladelphia, O ctober, 1 986.

Grand Ro unds, "Psychiatric Hospitalization for the 1980's," Dept. of Psychiatry, Hahn eman n Un iversity,Ph iladelphia, O ctober, 1 986.

Grand Rounds, "Treating the Family of the Hospitalized Patient, Is it Worth It?" North Shore University Hospital,New Yo rk, October, 1986.

Grand Rounds, "Combination Therapy: A Study of Inpatient Family Intervention," Westwood Lodge Hospital andPem broke Ho spital, Boston, Octobe r, 1986.

46



Ira D. Glick, M.D.

Grand Ro unds, "Receiving Effective Psychiatric Treatment," Albert Einstein M edical Center, PA , 11 /86.

Grand Rounds, "Working With The Family - Is It Worth It? A Controlled Clinical Trial of Inpatient FamilyIntervention", De pt. of Psych iatry, Co rnell University M edical Co llege an d Pay ne W hitney C linic, The NeHospital, Novembe r, 1986.

Grand Rou nds, "New D evelopments in the Treatmen t of Schizophrenia: Comb ining Dru g and Family TheraDe pt. of P sychiatry, Lincoln Hospital, New Yo rk, Novemb er, 1986.

Grand Ro unds, "Psychoso cial Interaction in the Treatme nt of Schizophrenia," Dept. of Psychiatry, Con ey IHospital, Brooklyn, Novem ber, 1 986.

At the Ann ual M eeting of the Am erican C ollege of Neuropsychopharmacology, Washington, D.C. , 1986:

Co-Chair, ACNP Training Session, "Teaching Psychopharmacology in the 1990's"

C hair, Presen tation of Paper, "The Teaching of Psycho pharmaco logy in the United States"

AC NP P oster Presentation, "The Pa tient, the Family, and Co mpliance with Drug Treatment forAffective D isorders"

At the A nnu al Me eting of the Ame rican P sychiatric Association, C hicago, Illinois, May , 1987:

Presentation, "Inpatient Fa mily Intervention for A ffective D isorders" as part of a Sy mposium,"Depression an d Families: Recent Advan ces"

Presen tation, "Inpatient Family Intervention fo r Psycho tic Disorders" as part of a Sy mposium,"Advances in Family Psychiatry"

Presen tation, "Study De sign Influen ces Gen eralizability o f Result" as part of a Sym posium, "Long-Treatment Strategies in Schizophrenia"

In Japan, lectures an d oth er activities during sab batical year, 1987:

1) ew D irections in Family Therapy, Scho ol of M edicine, Kana zawa University, January.2) ndications an d Co ntraindications for Family Therapy, Kochi Me dical Schoo l, Kochi C ity,S3) he P sychoe ducational Approach , Psychoa nalytic Seminar, Keio University & Hospital4) ndications and C on traindications for Family Therapy, Tokyo C omm unity Co unseling Serv5) he Family on the Move: Family Function and Problems, International School of the

Sacred Heart, Tokyo, April.6) iagnosis and Therapy of D epression, D ept. of Psychiatry, Tokai University, April.7) sychoeducational Treatmen t in P sychiatry, Ok ayama Prefectorial Men tal Hospital, April.8) ndications an d Co ntraindications fo r Family The rapy, Psychiatric Research Institute of Tok

9) asaga wa Ho spital - April-Junea. New C oncepts in Treatment of Sch izophreniab . Psycho educational Treatment in a Ho spital Settingc. Diagnosis and Therapy o f Depression

10) he C han ging Ame rican Family, Continuing Education Cou rse, Japan NIMH11) ndications an d Co ntraindications for Family Therapy, D ept. of Psych iatry, Schoo l of Medi

Fukuo ka University12) ecen t Trends in Treatmen t of Me ntal Patients, Dept. of Social Administration , Tokyo

M etropolitan Hospital13) ndications an d Co ntraindications for Family Therapy, Toky o Family Therapy Association

47



Ira D. Glick, M.D.

Presen tation, "The Fam ily and Sch izophrenia" as part of a Symposium, "Psycho social Treatment ofSchizophrenia' ' with James Spence r, M D, Gretchen Ha as, PhD , Joh n C larkin, PhD , et al

Presentation, "Inpatient Family Intervention: Follow-up Results" as part of a Symposium, "Psychotherapy:Process and Outcome" with James Spencer, MD , Gretchen Haas, PhD , John larkin, hD , AlfredLewis, MD

Presen tation, "Predictors of Early Stabilization in Sch izophrenia" as part of a Symposium, "Long-teTreatment Issues in Schizophren ia" with Nina Scho oler, PhD , Sam Keith, M D, Alan Ba lleck, M D, e

The A nnual M eeting of the Association for C linical Psychosocial Research, Montreal , Canada, M ay, 1988Presen tation, "Family Therapy M anu als: Treatment in Search of a Man ual or Man uals in Search of a Treatas part of a Symposium on Psychotherapy Manuals, with John Clarkin, PhD and Gretchen Haas, PhD.

The A nnual M eeting of the Am erican Family Therapy A ssociat ion, M ontreal, Can ada, June, 1988:

Presentation, "Inpatient Family Intervention: Final Results for Schizophrenia and Affective Disorder"

Plenary Session, "NIMH Update"

The Region al Symposium of the W orld Psychiatric Association, Wa shington, D.C ., Octob er 1988:

Presentation: "Developing an Effective Treatment E quation"

Presentation: "The Family M odel and Schizophrenia"

Part icipant on Panel: "Mental Health an d the N ews M edia," The Fourth An nual Rosalynn C arter SymposiuM ental health Policy, Atlanta, October 1988.

Keyn ote Speak er, "Nationa l Priorities in M ental Health Research ," First Annu al Kansas Scientific SymposiKansas City, October 1 988.

Grand Ro unds, "Family Therapy: Indications an d Co ntraindications," Carrier Clinic, Princeton , NJ, 11 /88.

Presen tation: "The Nationa l Institute o f M ental Health P ublic Academic Liaison Initiative," National AssocSocial Workers 1988 Annual Conference, Philadelphia, Pennsylvania, November 1988.

Presen tation: "Fostering Collaborative Research that Impacts the A dminstration o f Pub lic Me ntal Health PThe Federal Perspective." American Pu blic Health Association, Boston , MA , Novembe r 1988.

The A merican C ollege of N europharmacology (AC NP) 27th An nual M eeting, San Juan, Pu erto Rico, 12/8

Presen tation o f paper for the TSS C ollaborative Study Grou p, "De pressive Symptoma tology,

Negative Symptoms and Extrapyramidal Symptoms (EPS) in Acute Treatmen t Response and Sho rtTerm Ou tcome," as part of a symposium, Acu te Treatment Response an d Short Term Outcom e inSchizophrenia"

Po ster with the IFI Research Group, "Working with the Fam ily to Improve M edication C ompliance"

Keyn ote Rema rks, "The NIM H Program for 1 989 and its Implications for Training." An nua l Meeting of AASan D iego, California, Janua ry 1989.

Keyn ote Address, "NIMH P rospects and Promises," C alifornia Co alition fo r Me ntal Health, Los An geles, CJanuary 1 989.

49



Ira D. Glick, M.D.

Symposia, "Family Intervention and Psychiatric Hospitalization" (with Sholevar, GP )

Po ster, "Improving Treatme nts for the Severely M entally III - Implications of the Italian P sychiatricReform"

Grand Rou nds, "The Effectiveness of Treatment for M ajor Depressive D isorder On e yea r Later," Jefferson

M edical Co llege, Ph iladelphia, Novemb er 1 989.

Wo rkshop, "Fundamen tals of M ental Illness Research," Nationa l Men tal Health A ssociation Scientific SymWashington, No vember 1989.

At the 1990 Annu al Meeting of the ACN P, Mau i, December 1 989.

Study Group, "Public/Acade mic Liaison to Gen erate Psychph armacology Re search: Can it Work?"(Co-cha ir with Schu lz S)

Open Session, "New Initiatives of the NIM H - the P AL Initiative"

Grand Rounds, "Working with the Family of the Hospitalized Patient: Is It Worth It Over the Long Run?"Holliswood Ho spital, Quee ns NY, D ecember 1 989.

Presentation of Pa per, "A Cross National Followup Study of the Treatment of M ajor Depressive Disorder,"M eeting Psychiatric Research Society, Park C ity, Utah, M arch 1990.

Grand Rounds, "Increasing the Effectiveness of Psychiatric Care: What Happens to Patients and Their FamiliesAfte r Hospitalization", Dept. of Psy chiatry, University of North C arolina, C hape l Hill, April 1 990.

At the 1 990 Annu al Meeting of the A merican P sychiatr ic Associat ion, New York, Ma y 1 990:

Vestermark Awa rd Session, "Overview of the M odel Cu rriculum an d a Follow Up Evaluation of itsUsefulness," as part of the session, "The Teaching and Learning of Psychopharmacology in the 1990's:How to Jum p in a Rapidly M oving Train"

A W orksho p, "Nationa l Plan Research on Severely M entally III" (with Burke, J)

Presen tation, "C ross-Nationa l Study of M ajor Depressive Disorders." as part of Symposium,"Cu ltural Aspects of Depression in Asia and Am erica"

Research Colloquia, "Drug and Family Treatment for Major Affective Disorder," Dept. of Psychiatry, University ofPen nsylvania Schoo l of Me dicine, M ay 1990.

Brief Presentation, "Making Inpatient Family Intervention Work," American Family Therapy Association,Ph iladelphia, June 1990.

Invited P resentation, "Implications o f the Italian Reform fo r the D elivery of M ental Health Se rvices in the C anada ," sponsored by British Co lumbia Me ntal Health Society, Vanco uver, July, 1990

At the 7th A nnu al Scientific Symposium, National M ental Health Association, "New Findings & PracticalApplications Of M ental Health Research" Houston, Texas, 1990:

Workshop, "Fundamentals of Mental Illness Research"

Workshop, "Increasing the Effectiveness of Psychiatric Treatment."

5 1



Ira D. Glick, M.D.

Poster, "Increasing the Effectiveness of Psychiatric Care: Achieving Effective Medication Management"(with three others)

Grand Rounds,''The Changing American Couple and Indications for Marital Therapy." Coney IslandHospital, Brooklyn, New York, January, 1992

At the Annual Meeting of the American Psychiatric Association, Washington, D.C., May 1992:

Debate:Resolved: For Most Psychiatric Inpatients, a Ten Day Hospitalization is as Effective as a LongerStay (with M. Herz, MD)

Paper: Increasing the Effectiveness of Treatment for Mood Disorder, as part of a symposium, The Familyand Mood Disorder.

New Research Poster:"Psychoeducation For Mood Disorder" with Lorenzo Burti, MD, KeigoOkonogi, MD and Michael Sacks, MD.

Poster: "Achieving Effective Medication Management" with Lorenzo Burti, MD, Koji Suzuki, MD and MichaelSacks, MD, NCDEU Annual Meeting, Boca Raton, Florida, June 1992.

Internationa l Seminar:"Revamping of the Uruguayan Mental Health System: New Patterns of Care, Methods ofDiagnosis and Treatment for Severe Mental Disorders" sponsored by the Uruguayan Psychiatric Association,World Association for Psychosocial Rehabilitation and the Republican National Bank, Director and Lecturer,Uruguay, June 1992 with John P. Docherty, MD.

Grand Rounds:"Alternative Treatments of Bipolar Disorder." Bronx State Psychiatric Cenmter. NY9192.

Grand Rounds:"Effectiveness in Psychiatric Care: A Follow-up Study of Hospitalized Patients with Major AffectiveDisorder." St. Vincent's Hospital and Medical Center. New York. September, 1992.

Grand Rounds,"Alternative Treatments of Bipolar Disorder." Bronx State Psychiatric Center, NY,9/92.

Invited P lenary Lectures:At the Fall Meeting, Louisiana Psychiatric Association, Destin, Florida, 1992:

a) "Theoretical Background and Literature Underlying Psychopharmacotherapy andMarital/Family Therapy Combinations"

b) "The New Algorithms for Combining Marital/Family Therapy with Drug and Other Psychotherapies"

Invited Lecture ,"The Role of Psychotherapy in Combination with Pharmacotherapy," as part of a symposium,"Bipolar Disorder: Current Progress and Future Directions in Diagnosis and Management," sponsored by StanfordUniversity School of Medicine, San Francisco, October, 1992.

Workshop,"The Millenium Has Arrived: Suggestions for a New Model of (and Research Questions about) HospitalTreatment of Psychiatric Disorders," Institute on H&CP, Toronto, October, 1992.

Grand Rounds,"Combining Medication and Psychosocial Strategies for the Treatment of the Major Psychoses."Stanford University Medical Center, Stanford, CA, November, 1992.

Grand Rounds,"Effectiveness in Psychiatric Care: What Happens to the Patient and Family After Hospitalization."Creedmoor Psychiatric Center, New York, December, 1992.

At the Annual Meeting of the American College of Neropharmacology (ACNP), Puerto Rico, December 1992:

53



Ira D. Glick, M.D.

Pa per, Treatmen t Strategies in Schizophrenia, (with 1 2 co-autho rs)

Invited Lecture: "C omb ining Treatmen ts to Improve Ou tcomes: A Followup Study of M ajor AffectiDisorders in Italy, Japan a nd the United States." Bronx D istrict Branch o f the A merican P sychiatricAssociat ion, Ne w Yo rk, March, 1 993.

At the Ann ual Me eting of the Am erican Psychiatric Association, San Francisco, M ay, 1993:

Invited Speaker for the A nnu al Review of P sychiatry Series, the C ombined Treatmen ts Symposium,Co mbining Me dications with Family Psych otherapy (with Scott Goldsmith and Joh n C larkin)

Workshop, Medication and the Italian Reform (with L. Mosher, G. Palermo and A. Bartolomeis)

Lecture: "Increasing Effectiveness of P sychiatric Inpatient Ca re." Medical Staff, Dept. of Psychiatry, StanfUniversity Hospital, September, 1993.

Grand Ro unds, "Effectiveness in Psych iatric Care." Dept. of Psychiatry, Bronx-Lebano n Ho spital Cen ter, BNY, November 1993.

At the A nnual M eeting of the American Co llege of N europharmacology (AC NP), Hawaii, December 1 993

Pape r, Promising Ne w M edications fo r Schizophrenia not A vailable in the U.S.A., (with five co-autas part of the European College of Neuropsychopharmacology panel, Are You Missing Anything?Recen t Psycho tropics Available in Europe, But Not in U.S.A. (Cha ir, Stuec M ontgom ery)

Po ster, Promising P sychoph armacologic M edications n ot Available in the U.S.A. (with five co-auth

Lecture: "Medication Combined With Couples Treatment" as part of a symposium, "Clinical Pharmaco logy: AnUpdate", Stanfo rd University School of M edicine, Janu ary, 1994.

Grand Ro unds: "The Ro le of the Psych iatric Hospital in the 1990's," Langley P orter Psych iatric Institute, U

San Francisco, M arch 1994.

Grand Rounds: "New Strategies for the Treatment of Acute and Chronic Schizophrenic." California MedicalFacility, Vaca ville, CA . April 1 994.

Grand Rounds: "Atypical Antipsychotic Medications," Sacred Heart General Hospital, Eugene OR, April 1994

Invited Presentation: "A C ross Cultural Study of Treatmen t of Mo od D isorders in Italy, Japan an d the UnitStates," The N orthern C alifornia Psychiatric Society 1 994 Ann ual M eeting, Olympic Valley, CA , April, 19

Lecture: "New Strategies for Treatment of Acute and Chronic Schizophrenia" as part of a symposium, NewApproach es to Treating Schizophrenia. Stanford University Scho ol of Medicine, May 1 994.

Pa per: Psychiatric Aspects of Basketball Ann ual M eeting, Internationa l Society of Sports Psychiatry, PhilaMay 1994.

Po ster: Efficacious an d Safe Psych otropics Not A vailable in the US., 1 994 Ann ual M eeting, Society of BioPsychiatry, Philadelphia, Ma y 1 994.

Training Seminar: The Legal - Psychiatric Interface, for San Francisco, Santa Clara & San Mateo judges andother legal mental health professionals, San Jose, CA , August, 1994.

54



Ira D. Glick, M.D.

Keynote A ddress,"Combining Medication with Psychosocial and Rehabilitation Strategies in the '90s": sponsored bythe Department of Psychiatry, University of Saskatchewan and the Department of Psychiatry, University of AlbertaHospitals, presented at Edmonton, Saskatchewan, and at Kingston,Canada, October, 1994.

Grand Rounds,"Combining Medications and Psychotherapy in the 1990's: Researching Clinical Issues". CaliforniaPacific Medical Center, San Francisco, October, 1994.

Grand Rounds,"Changing Models of Psychiatric Care: Psychiatric Hospitalization for the 90's." Chope Hospital &San Mateo Health Services Agency, San Mateo, CA, November, 1994.

Poster: "Current European Clinical Trials of Anti-Dementia Drugs," (with Shwartz GE, Montgomery S, Klein F) atthe 1994 Annual Meeting of the American College of Neuropsychopharmacology, San Juan, Puerto Rico,December, 1994.

Grand Rounds,"Combining Psychotherapy and Drugs in the 1990's." Department of Psychiatry, University ofArizona Health Sciences Center, Tucson, January, 1995.

Lecture:"Combining Psychotherapy & Pharmacotherapy" as part of the 1995 Annual Meeting of the AmericanCollege of Psychiatrists, Acapulco, Mexico, February, 1995.

Grand Rounds,"Diagnosis and Treatment of Psychotic Disorders Related to Parturition" Department of Ob/Gyn,Stanford University School of Medicine, March, 1995.

At the Biannual International Congress on Schizophrenia Research (ICSR), Warm Springs, VA, May, 1995

Poster: Lithium Augmentation Fails to Reduce Symptoms in Poorly Responsive SchizophrenicOutpatients, (withSchultz SC, TSS Collaborative Study Group).Poster: Promising Psychopharmacologic Medications Not Available in the USA, Glick, ID , (withLecrubier Y, Montgomery S, Vinar 0, Klein DF).

Clinical Update:"The Forces Forming Character," at the 1995 Annual Meeting of the Northern CaliforniaPsychiatric Society,Pacific Grove, CA, April,1995.

Keynote:"Combining Family Therapy with Medication for the Treatment of Axis I Disorders." as part of seminar,Effective Approaches: Working With Children, Adolescents and Their Families. Tender Lion Family Program,Family Service Agency of San Francisco, April 1995.

Grand Rounds:"New Strategies for Treating Schizophrenia," Eden Hospital, Castro Valley, CA, May, 1995.

Poster: "New Psychopharmacologic Strategies for Treatment," (with Braff D, Janowsky D) at the 1995 AnnualMeeting of the Society for Biological Psychiatry, Miami, FL, May, 1995.

Grand Rounds:"The Effectiveness of Family Therapy for inpatient Psychiatric Patients," Department ofPsychiatry, School of Medicine, UC Davis, and Sacramento County Mental Health, Sacramento, November, 1995.

Grand Rounds:"Psychiatric Hospitalization for the 90's," Napa State Hospital, Napa, CA, December,1995.

At the Annual Meeting of the American College of Neuropsychopharmacology (ACNP), Puerto Rico, December1995.

Mentor:Travel Awardee.Poster: New Treatment Strategies, (with Braff D, Janowsky D).Poster: Treatment Outcomes of First Episode & Chronic Multiepisode Schizophrenia, (with Lieberman J,et al).Study Group:A Psychopharmacologic Jam Session: A Dialogue on Tricks of the Trade, (with Janowsky

D, lein D, Schatzberg A)

55



Ira D. Glick, M.D.

• Flower Hospital, Toledo, OH, Septembe r, 1997.•International Hea lth C are, Salt Lake C ity, UT, September, 1997.• Napa State Ho spital, Napa, C A , 1 997.• Sacred Heart Medical Center, Spokane, WA , October, 1997.• John Ge orge Psychiatric Pavilion, San Lean dro, CA, Novem ber, 1997.• Tampa G eneral Ho spital, Tampa, FL, February, 1 998.• Florida Hospital, Orlando, FL, Februa ry, 1998.• Pen insula Hospital, Burlingame, C A, Janu ary, 1999.

At the An nual M eeting of the A merican C ollege of Neu ropsychopharmacology (AC NP), Puerto Rico, Dec1996.

• Study Group: "A Psychopharmacologic Jam Session:Tricks of the Trade," moderator and participant.• Po ster: "New P sychotropic Drugs for A xis I Disorders: Recen tly Arrived, In D evelopment, and N eArrived" (with Belano ff J, Golden W ).

Grand Ro unds: "Inpatient Fam ily Intervention: A C ontrolled Study," National University of Ta iwan, Taipai,December, 1996.

Grand Ro unds: "Com bining M edication w ith Fam ily Intervention for A xis I Disorders," Texas Tech Health Center, Amarillo, TX, January, , 1997.

M edical Students' Forum: "Working With Families of Se riously III Patients," Texas Tech Health Sciences CAm arillo, TX, Janu ary, 1 997.

Grand Ro unds: "Co mbined Th erapy for Treatme nt of A xis I Disorders," First Hospital Vallejo, Vallejo, CA ,February, 1997.

Research Se minar: "Treatmen t Strategies in Schizophrenia: Final Results," Departmen t of Psych iatry, Co lleM edicine, University of Iowa, Iowa C ity, IA, Ma rch, 1997.

Grand Rou nds: "C omb ining Medicine in Psych osocial Intervention," Department of Psych iatry, Co llege ofM edicine, University of Iowa, Iowa City, IA, Ma rch, 1997.

Keyno te: "New D evelopments in Antipsychotics," Western C olorado P sychiatric Me eting, C olorado Spring

April, 1997.International Co ngress on Schizophrenia Research, Co lorado Springs, CO, April 1 997.

Po ster: New P sychotropic Drugs for Schizophren ia (with Belanoff J).

Grand Ro unds: "Diagnosis and Treatmen t of Schizophrenia," St. Vincents Hospital, New Yo rk, NY, April 19

Invited Seminar: "New Trea tments for A gitation an d Aggression in A xis I Disorders," University of M ediciDe ntistry of N ew Jersey, Piscataway, N J, April, 1 997.

Lecture: "Cu rrent Con cepts in the Treatmen t of Schizophren ia," C onfe rence: Understanding and TreatingSchizophrenia: Progressing into the Ne xt Cen tury, Ann A rbor, MI, April, 1997.

At the Annual Meeting of the American Psychiatric Association, San Diego, CA, May, 1997:

Paper: "New Strategies and New Treatments for Schizophrenia," (with Belanoff J and DeBattista C).Paper: "The Professional Athlete as Role M odel."

Poster: "The Teaching of Psychopharmacology in the 1990's," (with Klein D, Doraiswamy M, Lydiard B). NCDEUAnn ual M eeting, Boca Raton, FL, June, 1997.

Lecture: "Combining New Antipsychotics with Psychosocial Intervention in the 1990's," St. Lawrence Hospital, E.Lansing, MI, September, 1997.

Lecture: "Comb ining New A ntipsycho tics with P sychoso cial Intervention in the 1 990's," as part of the progC ontem porary Issues in P sychiatry. Huran Valley C enter, Yipsilanti, M I, Septembe r, 1997.

57



Ira D. Glick, M.D.

Lecture:"New Treatment Approaches for Psychosis in the Elderly," McComb Hospital, Detroit, September, 1997.

Grand Rounds:"New Treatments for Schizophrenia," Department of Psychiatry and Behavioral Sciences,University of Washington, Seattle, WA, October, 1997.

Grand Rounds:"New Treatments for Schizophrenia,"Department of Psychiatry, School of Medicine, IndianaUniversity, Indianapolis, IN, November, 1997.

At the 36th Annual Meeting of the American College of Neuropsychopharmacology (ACNP), Waikoloa, HI,December, 1997.

Poster: "The Teaching of Psychopharmacology in the 1990's," (with ASCP Committee)).Poster: "Extrapyramidal Symptom Profile of Sertindole," (with L. Ramirez)

Continuing Education Update on Schizophrenia, for Neuroscience Regional Research Managers, Eli Lilly Co., atStanford University School of Medicine, February, 1998.

Expert Breakout Session (Schizophrenia). Second Stanford Psychopharmacology Review Course.Stanford, CA, March, 1998.

Lecture:"New Treatments and New Strategies for Schizophrenia: New Data," West Coast College of BiologicalPsychiatry, Palo Alto, California, 1998.

Lecture:"Progress in Psychoses: Improving Treatment and Evaluation, Enhancing Cognition," Continuing MedicalEducation Seminar, Los Angeles, April, 1998.

Grand Rounds:"Combining Medication with Psychotherapy," Weber County Mental Health Center, Ogden, Utah,April, 1998.

Grand Rounds:"New Treatments and New Strategies for Schizophrenia," University of California at Irvine, Irvine,California, April 1998.

Grand Rounds:"New Treatments and New Strategies for Schizophrenia," Department of Psychiatry andBehavioral Sciences, Stanford University School of Medicine, Stanford, California, May 1998.

Grand Rounds:"Combining Medication and Psychotherapy for Psychiatric Disorder," North Shore UniversityHospital, Great Neck, New York, May 1998.

Grand Rounds:"Combining Medication with Psychotherapy," Department of Psychiatry, Wright State UniversitySchool of Medicine, Dayton, Ohio, May, 1998.

Grand Rounds:"The Patient, the Family and Medication," Palo Alto and Menlo Park Veterans Administration,California, June , 1998.

At the Annual Meeting of the American Psychiatric Association, Toronto, May, 1998:Industry S ymposium:" New Atypical Antipsychotics: Data versus Clinical Experience,"Chair and lecturer:

Lecture 1 :"History of Somatic Therapy for Schizophrenia"Lecture 2:"Combining Medication with New Antipsychotics"

Grand Rounds:"An Overlooked Serotonin Dopamine Blocker; Loxapine Revisited," Atascadero Forensic Center,Atascadero, California, September, 1998,

Grand Rounds:"New Atypical Antipsychotics," Department of Psychiatry, Louisianna State University, NewOrleans, October, 1998.

Lecture:"Schizophrenia: Receptor Profiles & Efficacy," at the Continuing Education Seminar,Psychopharmacology 1998 Clinical and Research Update, sponsored by Department of Psychiatry, StanfordUniversity and West Coast College of Biological Psychiatry, San Francisco, California, October , 1998.

58



Ira D. Glick, M.D.

• A Followup Evaluation of a Model Curriculum in Psychopharmacology, 1999

Workshops:Northwest Medical Health Institute and Oregon Psychiatric Association, Gleneden Beach, Oregon,November, 1999.• New Treatments for Psychosis in the Year 2000• Combining Medication with Psychotherapy for Axis I Disorders

Grand Rounds:"Combining Medication with Psychotherapy for Axis I Disorders." Santa Barbara County CMHC,Santa Barbara, November, 1999.

Grand Rounds:"New Short and Long-term Strategies for Schizophrenia, Bipolar Disorder and DepressiveDisorder." Department of Medicine, Stanford University School of Medicine, December, 1999.

Grand Rounds:"Teaching Psychopharmacology in the New Millennium." Department of Psychiatry, University ofHawaii at Manoa, December, 1999.

Study Group Presentation:"Clozapine Treatment Resistance: What Does it Mean? New Methodological Issues inthe Study of Treatment Refractory Schizophrenia," at the Annual Meeting of the ACNP, Acapulco, Mexico,December, 1999.

Invited Lecture:"New Treatments and New Strategies for Psychosis for the Millennium," 2000 Annual Meeting ofthe Philippine Psychiatric Association, Hilo, Philippines, January, 2000.

Grand Rounds:"Combining Medical and Psychosocial Interventions for Schizophrenia." Grand RoundsPresentation at Nihon University and Keio University, Tokyo, Japan, February, 2000.

Workshop: Organizer and M oderator,"Introduction to Neuropsychopharmacology: Pathophysiology to ClinicalPractice." A Workshop for the Neurobiology Unit, Roche Bioscience. Palo Alto, CA, February, 2000.Lectures:

• Overview of New Medication Strategies for Axis I Disorders• Schizophrenia• Clinical Trials Design (with Alan Schatzberg)

Invited Lecture:"Long Term Maintenance: Risperidol versus Haldol." In the symposium, "Psychosis: NewPerspectives and Strategies," Monte Carlo, March, 2000.

Korea : April, 2000• Grand Rounds: "Indications for New Antipsychotics," Seoul National University, Seoul.• Invited Lecture: "New Treatments for Bipolar Disorders," Annual Meeting, Korean Psychopharmacology

Association.• "New Antipsychotics for Bipolar Disorder," Samsung Hospital, Seoul.• Regional Symposium, Kyong-Ju, "New Antipsychotics for Bipolar Disorder."• Regional Symposium, Kwang-Ju, "New Antipsychotics for Bipolar Disorder."

At the 2000 An nual M eeting of the Am erican P sychiatr ic Association, Chicago, May, 2000.• Industry-supported Symposium:New Antipsychotics: From Practice to Theory.

- Co-chair and Paper, "The Efficacy Spectrum for Atypicals in Clinical Practice."• Symposium:Psychopharmacological Approaches to the Athletic and Exercise Population.

- Paper, "Diagnosis and Psychiatric Treatment of Athletes."• M edia Session:- Cultural Identity on the Tex Mex Border: Impact on Relationships Past and Present,

discussion of movie, Lone Star, Chair and Presenter

Co -Chair, Forum,"The Future of Psychopharmacology: Generativity and Mentoring" at the NCDEU AnnualMeeting, Boca Raton, May, 2000.

Grand Rounds:"Combining Medication with Psychotherapeutic Intervention for Axis I Disorders." Department ofPsychiatry, University of California at San Diego, June, 2000.

Grand Rounds:"Atypical Antipsychotics." Alameda Center for Behavioral Healthcare, June, 2000.

60



Ira D. Glick, M.D.

Sabb atical, New Ze aland an d Au stralia, July-Augu st, 2000

New ZealandGrand Rounds, "New Treatments for Psychosis," Dept Psychiatry, School of Medicine, Otago University,Dunedin, July, 2000.

Australia(August, 2000)All "grand rounds" presentations or as "invited lecturer" for community mental health practitioners andstudents on 1) atypical antipsychotics, 2) combining medication with psychotherapy and/or 3) the teachingand learning of pharmacotherapy.

Brisbane• Royal Brisbane Hospital• Princess Alexandra Hospital• Prince Charles Hospital• Ipswich Hospital and Wolsten Park Hospital

Sydney• Royal North Shore Hospital• Macquarie Hospital• Hornsby Hospital and Manley Hospital

• Cumberland Hospital• Nepean Hospital• St. Vincents Hospital

Melbourne• Royal Melbourne Hospital• St. Vincents Hospital• Alford Hospital• Teleconference: Hallarat, Bendigo, Hobart, Warrnambool and Trarigan Hospitals• EPPIC Mental Health SKY Unit• Round Table with Professors of Psychiatry, Victoria• Plenary Lecture: New Trends in Treating Psychosis regional symposium

Adelaide• Royal Adelaide Hospital, Glenside Campus

• Lecture, Southern Australian PsychiatristsPerth

• Graylands Hospital• Lectures, Psychiatrists both Southern and Northern regions• Queen Elizabeth Hospital

Grand Rounds:"New Drugs for Brain Disorders." Department of Pharmacology and Toxicology, College ofPharmacy, University of Texas, Austin, September 2000.

Grand Rounds:"Combining Medication and Psychotherapy." Department of Psychiatry, University of Texas, SanAntonio, September 2000.

Invited Speaker:"New Drugs for the Treatment of Psychoses," Central California Psychiatric Society, Fresno,September 2000.

Workshop: "The Nuts and Bolts of Psychiatric Course Planning in the New Millennium." 2000 Annual Meeting ofthe Association of Academic Psychiatry, Vancouver, October, 2000 (with Rona Hu).

Grand Rounds:"The New Atypical Antipsychotics." Western State Psychiatric Hospital, Seattle, November, 2000.

Invited Lecturers:US Psychiatric and Mental Health Congress, San Diego, November 2000• "Combining Medication and Psychotherapeutic Intervention"• "Diagnosis and Psychiatric Treatment of the Elite Athlete"

61



Ira D. Glick, M.D.

Grand Rou nds: "Cu tting Edge Inpatient Ph armacoth erapy." San M ateo C omm unity Me ntal Health Service.Ma teo, November 2000.

Po stgraduate Education Sem inar, for Lilly Pharma ceutical Co. (Japan). "Treatmen t of Psycho sis in the NewMillennium," Dec. 2000.

At the 2000 Annu al Meeting of the AC NP, Pue rto Rico, December, 2000• Study Grou p: C omparing An tipsychotics: Wha t Do W e Really Know? C hair and Presen ter; (with Raji

Tandon, Moderator).• Poster, A M odel Psychopharmacology C urriculum (with the ASC P C ommittee)• Po ster, The Efficacy an d Extrapyramidal Side Effects o f the Atypical Antipsychotics (with J. Davis).

Grand Rou nds: "New A ntipsycho tics — C ontroversies and Que stions." Palo Alto Veterans A dministration, Alto, January 2001 .

Invited Lecture: "Psychosis and Atypical Antipsychotics," at the conference "Psychopharmacology in the Year2001," sponsored by the American Society of Clinical Psychopharmacology, Maui, February 2001.

Grand Rounds: "New Treatments for Psychosis." Maui Community Mental Health Center, Maui, February 2001.

Preceptor: "Update on Schizophrenia." Pfizer Preceptorship, Stanford, CA , February 2001 .

Invited Lectures: Japan, M arch 2001• "Combining Medication with Psychosocial Intervention for Treatment of Schizophrenia," at 1) Department

of Psychiatry for School of Medicine, Hiroshima University, 2) at Kita-Kyusyu University, Kyushu, and 3) atthe National Center of Ne urology and Psychiatry (NC NP), Tokyo.

• "Atypical An tipsychotics," for the D epartment of P sychiatry, School of M edicine, C hiba Un iversity,

Grand Rounds: "Long-term Treatment of Schizophrenia in the Community." Santa Maria County Mental HealthC enter, Santa Maria, CA, April 2001.

Lecture: "Treatmen t of Geriatric Psycho sis." St John s M edical C enter, Oxna rd, CA, A pril 2001.

Grand Rounds: "Atypical Antipsychotics." Santa Barbara College Hospital, Santa Barbara, CA, April 2001.

Invited Lecture: 'Diagnosis and Management of Treatment-Resistant Schizophrenia," at the symposium,"Psychiatric Care in Co mmu nity Residential Setting," sponso red by the Los Angeles Co unty of M eHealth and the S outh ern C alifornia Psych iatric Society, Los Angeles, CA , April 2001.

At the 2001 Annu al Meeting of the A merican P sychiatr ic Associat ion, New Orleans, Ma y, 2001.• C hair, Industry Sympo sium, A N ew Era for M ana ging Psychosis: Rebu ilding Lives for Patients an

Families.Paper, "Consum er Organizations M ay Improve Medication C ompliance."

• Po ster, "The Efficacy and Extrapyramidal Side Effects of the Atypical Antipsychotics," with D avis• Po ster, "Ziprasidone 's Benefits Versus O lanzapine on Weight an d Insulin Re sistance."• Presen tation, A M odel Cu rriculum in Psychopha rmacology, at the worksho p, "Teaching

Psycho pharmacology to Residents Using Evidence-based Algorithms."

NCD EU 2001 Ann ual Meeting, Phoenix, May, 2001• Poster, "The Efficacy and Extrapyramidal Side Effects of the Atypical Antipsychotics."• Co-Chair, Workshop, "Mentoring Throughout the Professional Life Cycle: Challenges and Lesson

(with A . Gelenberg)

7thWo rld C ongress of Biological Psychiatry, Berlin, Germany, July 2001• Po ster, "Ziprasidone vs Olanza pine: Weight, Lipids, Insulin."

62



Ira D. Glick, M.D.

Grand Ro unds: "New A ntipsycho tics: Ziprasidone ." Kaiser, Santa Te resa, San Jose, Au gust 2001 .

CM E Lecture: "Schizophrenia: New Treatme nt Dimen sions," at the program, "Psycho pharmaco logy CliResearch Update," sponsored by the W est Co ast Co llege of Biological Psychiatry, San Francisco,October 2001.

Grand Rounds: "New Antipsychotics: Current Controversies." Menlo Park Veteran's Administration Hospital,Men lo Park, December, 2001.

At the 2001 Annu al Meeting of the A merican C ollege of Ne uropsychopharmacology, Hawaii , Decembe• Chair, Special session, "Teaching Neuropsychopharmacology," and presentation, "The Teaching of

Psychopharmaclogy: Who Does It? With What Materials?)• Po ster, "Improving the Teaching of Psycho pharmaco logy: Circa 2001 ," (with D Jano wsky and S Z• Po ster, "The Efficacy of Atypical Antipsychotics C ompared to Ty pical Antipsychotics: A M eta-An

Revisited," (with N Ch en an d J Davis).

Lectures: "C urrent C ontroversies Aroun d the New A typical Antipsychotics," at the Nevada Adult M entaCen ter, and the Psychiatry D ept , Nevada D ept of C orrections, Reno, Nevada, Dec. 2001.

Grand Roun ds: "Advancements in the M anagement o f Schizophrenia." Spokane C ommun ity M ental HeCe nter, Janu ary, 2002.

Grand Ro unds: "Schizophren ia: The N ew Atypical Antipsycho tics." Dept of Psych iatry, Oregon Health University, Po rtland, Orego n, Janu ary, 2002.

Grand Rou nds: "New D ata and Ne w Indications for the Atypical An tipsychotics in Both Psych otic and Npsychotic Disorders." Department of Psychiatry and Behavioral Sciences, Stanford University School ofM edicine, Stanford, CA, M arch, 2002.

Invited Lecture: "The Use of N ew A ntipsycho tic Agen ts to Treat Bipolar Disorder," as part of a C M E cotreating Bipolar Disorder. Department of Psychiatry, UC Davis, Sacramento, CA, March, 2002.

Grand Rounds: "Clinical Management of Psychosis: The Short- and the Long-term." UCLA NeuropsychiatricInstitute, Los Ange les, C A, April, 2002.

Grand Ro un ds: "Fiscal Pha rmacology o f the A typical Antipsychotics." Napa S tate Hospital, Napa C A, A2002.

C M E Lecture: "Stabilizing the D opamine-Sero tonin System: A Ne w Era in the Treatment of P sychosis."Diego, CA June, 2002,

Grand Rounds: "The Efficacy of Atypical Antipsychotics: A Meta-analysis Revisited." Manhattan StateHospital, New Y ork, New Yo rk, June 2002.

Sabba tical, Japan, July 2002Plena ry Lectures: "The New A typicals: New D ata and C ontroversies" at the symposium "Cha llenOpportun ities in the M ana gemen t of Schizophrenia, "Osaka a nd Tokyo , July, 2002.

Grand Ro unds: "The New Atypicals: Cha llenges a nd O pportunities," 1) Kyoto Un iversity, 2) SappM edical Schoo l, 3) Tokushima M edical Scho ol and 4) Okayam a International Hospital.

CM E Lecture: "Borderline P ersonality Disorder, M edication a nd the Fam ily." Confe rence, on Bo rderlinPerson ality Disorder, Research and Treatmen t, Stanfo rd University Medical Cen ter, Septembe r, 2

63



Ira D. Glick, M.D.

Grand Rou nds: "The N ew Atypicals." Northwest Behavioral Healthcare, Department of M ental Health,Northfield, Oh io, September, 2002.

CM E Lecture: "Novel Antipsychotics: Wh at We've Learned; What We Nee d to Know." Case Western ResUniversity Sch ool o f M edicine, C leveland, September, 2002.

CM E Lecture: "New Steps in the Evolution of A ntipsycho tics: The R ole of P artial Agon ists," Sponsored Bristol-Mye rs Squibb a nd O tsuka Ph armaceutical:San D iego, June, 2002; San Francisco, Septembe r, 2002; New Y ork C ity, September, 2002;Seattle, March, 2003; Ph oen ix, April, 2003; Lon g Island, M ay, 2003.

Grand Ro unds: "The N ew A typicals." M etropolitan State Hospital, Los An geles, Sept 2002.

Grand Rou nds: "The New Atypicals." San Joaquin Co mmu nity Men tal Health Cen ter, Fresno, Septemb2002.

Lecture: "Mental Illness and the Workplace." Section on Labor Law, Annual Meeting of the State Bar ofCa lifornia, Monterey, Octobe r 2002.

Grand Rounds: "The New Atypicals." San Francisco Veterans Administration Hospital, San Francisco,October 2002.

Grand Ro unds: "Update on the Atypical Antipsychotics." Departmen t of Psych iatry, University of C alifSan D iego, San D iego, October 2002.

Grand Rounds: "Aripiprazole and the New Antipsychotics." Mood Disorders Program, UCSF, San Francisco,November 2002.

C M E Lecture: "The New A ntipsycho tics: Are The re Differences?" First West C oast ASC PPsychopharmacology Symposium, San Francisco, November, 2002.

Lecture: "Aripiprazole Efficacy an d Safety." Con tinuing Edu cation M eeting, BMS, Laguna Nigel, CA

November 2002.

Grand Rou nds: "Secon d Generation An tipsychotics: New D ata and Ne w Dilemmas." Napa State HospitNapa, CA, D ecember 2002.

At the 2002 A nnual M eeting of the American Co llege of N europsychopharmacology, Puerto Rico, Dec2002:• Ch air, Second A nnual Session on "Teaching N europsychopharmacology," and presentation of

"The ASC P M odel Psychopharmacology C urrticulum: New Scope and Ne w Au diences."• Po ster: "Co comitant Psycho tropic Medication Use in a Two-Year Study C omparing Clozapine

Olanzapine for the Prevention o f Suicidal Behavior."• Po ster: "A M eta-analysis of the Efficacy of Secon d-Generation A ntipsycho tics," (with John D a

National Teleconfe rence: "Improving Ou tcome in Sch izophren ia." Psychlink, Dallas, TX, January 2 003

Grand Ro un ds: "Update on M ood D isorders." C arlisle Hospital, C arlisle, PA , January 200 3.

Public Lecture: "The Changing American Family: New Roles, Opportunities and Challenges for Men, Womenand C hildren."Dickinson C ollege, Ca rlisle, PA, January 2003 .

Lecture: "The Ne w Atypicals and Treatment of Psych oses at the 2003 Biannua l C M E Co nferen ce." Unof Wisconsin Schoo l of M edicine an d Ma dison Institute of Medicine, Madison, WI, M arch 2003.

64



Ira D. Glick, M.D.

Plenary Lectures: Annual Meeting Central California Psychiatric Society, Monterey, CA , March 2003.• "Combined Treatment of Axis I Disorders"• "The New Atypicals"

Invited Lecture: "Recent Advances in Treatment of Schizophrenia." Stanford University School of MedicineSeventh Psychopharmacology Course, Update in Psychopharmacoloqy Clinical Case Conference,

Stanford, March, 2003.

Poster: "The Efficacy of Atypical Antipscychotics Compared to Typical Antipscychotics: A Meta-Analysis." (withN Chen and J Davis). International Congress of Schizophrenia Research, Colorado Springs, CO April,2003.

Presentation: "Effectiveness of Aripiprazole." Regional Advisory Council — Bristol Myers-Squibb, Phoenix, AZ,April, 2003.

Grand Rounds: "New Atypicals: New Medications and New Controversies."LSUHSC, Shreveport, LABaton Rouge CMHC, Baton Rouge, LA, April 2003

Grand Rounds: "Atypicals: New Drugs — New Controversies." St. Peter Regional Treatment Center, St. Peter,MN, May 2003.

Invited Lecture: "Combining Medication with Psychotherapy."St. Luke's Hospital, Dept of Psychiatry, Racine, WIRogers Memorial Hospital, Dept of Psychiatry, Milwaukee, MN, May 2003.

At the 2003 Annual Meeting of the American Psychiatric Association, San Francisco, May, 2003.• Lecture, "Clinical Considerations in the Management of First-Episode and Acute Exacerbation of

Schizophrenia," as part of the industry-supported symposium, Managing the Spectrum of PsychoticDisorders.

• Discussion, as part of an Issue Workshop: Psychiatric Perspectives on the Execution Process: AContinuing Conundrum, with HJ Osofsky, RK Bailey, AM Freedman, AL Halpern, DM Mancuso

• .Lecture: "Overview of the Efficacy of 2 n dand 1 s t Generation Antipsychotics," as part of an APAsymposium , Meta-Analyses of the Efficacy of 2 n dVS 1st-Generation Antipsychotics, chaired by ID Glickand JM Davis.

• Discussion, Efficacy of Atypicals in Acute Care Settings, as part of an industry-supported symposium,Best Practices in Antipsychotic Use.

Plenary Speaker: "Update on Care and Treatment of Schizophrenia."Southeast Regional Committee, NationalAlliance for the Mentally III, Pennsylvania Chapter, Norristown State Hospital, Norristown, PA, June2003.

Grand Rounds: "Atypicals: New Drugs and New Controversies," June 2003.• Milwaukee Veterans Administration• Milwaukee County Mental Health Clinic

• Winnebago Mental Health Clinic

Colloquium: "Recent Trends in the Development of Novel Antipsychotics." Atascadero State Hospital, CA, July2003.

Grand Rounds: "Combining Medication with Psychotherapy to Improve Compliance." Santa Clara ValleyMental Health Center, August 2003.

Invited Lecture: "A Meta-analysis of Antipsychotic Medications — Are the Second-generation Agents Betterthan the First-generation Agents?" 1) Westchester Medical Center and 2) Rockland State Hospital,August, 2003.

65



Ira D. Glick, M.D.

Lecture Tour: "First vs Second Generation Antipsychotics: Efficacy and Use of Polypharmacy Strategies."Asahiyama, Tottari, Osaka, Fukuoka and Saga, Japan, September, 2003.

Grand Rounds: The New Atypical Antipsychotics, Phoenix, October 2003,• Good Samaritan Hospital

• Phoenix V.A. Hospital

CME: "Management of Treatment Refractory Schizophrenia," UC Davis and Sacramento County, September2003.

Grand Rounds: "Use of Atypicals in Special Populations," at the Medical College of Georgia and at AugustaVA Psychiatric Hospital, Augusta, GA, October, 2003.

Grand Rounds: "New Treatments for Psychosis," at the Mayo Clinic, at the University of Minnesota MedicalSchool and at Minneapolis VA Medical Center, October, 2003.

Grand Rounds: "New Treatment for Treatment Resistant Schizophrenia," Kirby Forensic Psychiatric Center,New York City, November, 2003.

At the Annual Meeting of the American College of Neuropsychopharmacology, Puerto Rico, December 2003:• Study Group Co-Chair, "New Comparative Studies of Antipsychotics: Evidence from Controlled Trials

versus Clinical Practice" and presentation on Efficacy of Antipsychotics.• Chair, Third Annual Session on "Teaching of Neuropsychopharmacology."• Poster: "Maintenance Therapy with Haloperidol Decanoate or Quetiapine."• Poster: "Issues Which May Determine Outcome of Antipsychotic Trials: Populations, Sponsorship,

Design, etc."• Poster: "Update on Psychopharmacology Curriculums: Is There Any Relationship of Teaching to Clinical

Practice?"

Grand Rounds: "A Meta-analyses of the Efficacy of Antipsychotics," Harvard-Longwood Grand RoundsServices and Caritas St. Elizabeth's Hospital Series, Boston, January 2004.

Invited Lectures, New Data, Treatments and Controversies about Schizophrenia and Psychosis, India,February, 2004.

• Goa Psychiatric Society• Bombay .

• Kolcatta• Gowati• Dehli• Kochin-Kerola "

Grand Rounds: "Combining Psychotherapy with Medication: Is It Helpful?" Kern Medical Center, Bakersfield,CA, April, 2004.

Invited Lecture: "Antipsychotics for Bipolar Disorder: Monotherapy an Adjunct?" Central California PsychiatricSociety, Bakersfield, April, 2004.

At the Annual Meeting of the American Psychiatric Association, New York, May, 2004:• Issue Workshop participant : "Evidence-based treatment for schizophrenia in a correctional setting."• Symposium discussant : "Personality disorders in the workplace."• Master Educator Clinical Co nsultation: "Combining and integrating medication and psychotherapy for

schizophrenia and other Axis I disorders."

66



Ira D. Glick, M.D.

Grand Rounds:"Practical Management of Psychoses at South Nevada Adult Mental Health Center," LasVegas, May, 2004.

At the Annu al Meeting of NCD EU, Phoenix, June 2004• Poster: "Maintenance Therapy with Haloperidol Decanoate and Quetiapine: A Controlled Random

Assignment Study."

Lecture:"Families in the Treatment of Personality Disorders and Issues of Compliance." As part of thesymposium Personality D isorders: Research & Treatmen t — A n Update.Stanford University MedicalCenter, June, 2004.

Lecture:"Terrorism, Changing Family Roles and Functions — and Women's Wellness: Part II." Women'sWellness Rounds, Stanford University School of Medicine, June, 2004.

Grand Rounds:"What Does Psychotherapy Add to Medication Alone for Axis I Disorders." Dept Psychiatry &Behavioral Sciences, Stanford Univ School of Medicine, Sept, 2004

Grand Rounds:"Combining Medications and Psychotherapy." Dept of Psychiatry, University of Iowa School ofMedicine, September, 2004.

Grand Rounds:"Antipsychotic Use in Special Populations." Dept of Psychiatry, UCSF University MedicalCenter, Fresno, CA, October, 2004.

Lecture:"New Treatments for Schizophrenia." Univ of Oklahoma Health Sciences Center, Oklahoma City,October, 2004

Grand Rounds:"New Treatments for Psychosis." Fulton State Hospital, Fulton, MO, Oct, 2004.

Grand Rounds:"New Treatments for Psychosis." Dept of Psychiatry, University of Missouri, Columbia, MO,Oct, 2004.

Grand Rounds:"New Treatments for Schizophrenia." Dept of Psychiatry, Univ of Kansas School of Medicine,Wichita, KA, October, 2004.

Lecture:"New Treatments of Schizophrenia." North West Missouri State Hospital, Kansas City, KA, October,2004.

CM E Program:"A Workshop: Interpreting Mental Health Scales and Their Practical Application to YourPractice." 2004 US Psychiatric and Mental Health Congress, October, 2004.

• Chair• Lecture:"Assessment Scales: How Are They Useful?"

At the A nnual M eeting of the American Co llege of N europsychopharmacology, Puerto Rico, Decembe• Poster: "New Developments in Teaching of Psychopharmacology," with Sid Zisook.• Poster: "Second Generation Atypicals vs. First Generation Decanoate," with Stephen Marder.

• Poster: "Analysis of Industry vs Investigator Initiated Trials," with John Davis.• Chair:Fourth Annual ACNP "Teaching of Psychopharmacology" session.

Lecture:"Combination Drug Strategies in Schizophrenia." As part of the symposium StanfordPsycho pharmacology: Cou rse and Clinical Update.Stanford University Medical Center, March, 2005.

Lecture:"Metabolic Issues of Atypical Antipsychotics." Dominican Santa Cruz Hospital, March, 2005.

Consultant:"Antipsychotic Drugs." Smith Barney Citigroup 2005 Healthcare Conference, Washington, D.C.,March, 2005 (with John Kane, M.D. and Les Citrone, M.D.).

67



Ira D. Glick, M.D.

At the 2005 Annual Meeting of the American Psychiatric Association, Atlanta, GA, May, 2005.• De bate, Resolved: Seccon d Generation A ntipsycho tics are Uniformly Superior in Safety an d Effic

First Generation Antipsychotics.M oderator: Richard E. D 'Alli, MDAffirmative: Ira D G lick, MD , John M Da vis, MDNegative: Rajiv Tandon, M D, W illiam T Ca rpenter, Jr. , MD

• Ch air, Symposium, "Use of Co ncom itant or A djunctive M edications in Schizophrenia,"• Pape r presentation , "Efficacy of C onco mitant Me dications fo r Stabilized Patients withSchizoph renia," (with J D avis).

•Paper presentation, "The Challenge of Teaching Psychopharmacology in the New Millennium:The Ro le of Cu rriculum (with S Zisook) as part of Symposium "Teaching Psych opharma colthe 21 s tCentury."

• Ch air, Symposium, "Inpatient Psychiatry: Crisis and Re sponse."• Paper presentation, "Inpatient Psych iatry at the Turn o f the C entury" (with G C arter & R Tan

Lecture: "C areers in Geriatric Psycho pharmaco logy:" Co llabo ration with Big Pharma ," at the EleventhSumm er Resea rch Institute in Geriatric Psych iatry, Stanford University, July 2005

Grand Ro unds: "Update on Sch izophrenia and Bipolar Disorder." Sacred Heart Hospital, Spokane , WA,

October, 2005.

Grand Rou nds: "Update on Schizophren ia and Bipolar Disorder." American Lake VA, Tacom a, WA, Oc2005,

CM E Lecture: "Overcoming the Issues of No ncom pliance in Sch izophrenia," at the 2005 U.S. PsychiatM ental Health Co ngress, Las Vegas, October, 2005.

Grand Rou nds: "New A typicals." Shasta Com mun ity M ental Health, Redding, October 2005.

At the 2006 Annual Meeting of the American College of Neuropsychopharmacology Hawaii, December, 2005:C hair: Fifth An nua l "Teaching Neuro psycopharmaco logy" session: The Neglected Co nstituen cies:T eaching Abo ut Psychopharmacology C hange Att itudes and Pract ices?

• Paper: "The C hallenge of Teach ing at the Academ ic-Industry Interface" (with Terence Ke

Invited Lecture: "New Treatme nts in Schizophrenia," Psycho pharmaco logy Update for Visiting C linicaResearch P sychiatrists from S pain, Stanford University Schoo l of M edicine, Janu ary, 2006.

68



Ira D. Glick, M.D.

Photography

Training utorial - Mitch Heickin - 2001

Published Ph otos

1995 M useo de San Isledefonso, M exico City,in the New England J Medicine, Sept 7, 1995, p. 633.

2001 olden Gate Morning,in the New England J Medicine, Aug. 30, 2001, pg. 655.

2002 idnight, Fort Mason ,in the New England J Medicine, Aug. 1, 2002, pg. 313.

2003 Nocturne,in the New England J Medicine, July 24, 2003, pg 381

2004 South Ame rican Psychiatric Ho spital Series,cover Neuropsychopharmacology, Sept, Oct, Nov,2004

Prizes

1997 Third Place, Color, at the annual meeting of the Art Association of the APA (American Psychiatric

Association), for Toroko Go rge, Taiwan.

1999 Second Place, Black and White, at the annual meeting of the Art Association of the APA(American Psychiatric Associat ion), for Ca stel del M onte, Italy

2000 First Place, Color, at the annual meeting of the Art Association of the APA (American PsychiatricAssociation), for Argentinian Tango,(Argentina).

2004 Honorable Mention, Color, at the annual meeting of the Art Association of The American PsychiatricAssociation, for Golden Gate Morning.

Shows

2001-2 Group Show, Presidio Nocturnes,at the Presidio Alliance, San Francisco, Dec-Jan, 2002

2002 Group Show, Ft Mason an d Environs(an exhibition that explores the night landscape and featuresover a dozen established and emerging Bay Area photographers), at the San Francisco FortMason Center, Nov. 2002.

Ira D. Glick, MD

Documents

Transcript of Ira D. Glick, MD